<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Gilead Sciences, Inc.</td><td># ê¸¸ë¦¬ì–´ë“œ ì‚¬ì´ì–¸ìŠ¤ (Gilead Sciences, Inc.)<br><br>*ì°¸ê³ : ì‹¤ì œ ì–´ë‹ì½œ ë‚´ìš©ì´ ì œê³µë˜ì§€ ì•Šì•„ ë²ˆì—­ì„ ì§„í–‰í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ì–´ë‹ì½œ ëŒ€í™”ë¡(transcript)ì„ ì œê³µí•´ ì£¼ì‹œë©´ ì „ë¬¸ì ì´ê³  ì •í™•í•œ í•œêµ­ì–´ ë²ˆì—­ì„ ì œê³µí•´ ë“œë¦¬ê² ìŠµë‹ˆë‹¤.*<br><br>---<br><br>**ë²ˆì—­ ì‹œ ì ìš©í•  ì›ì¹™:**<br><br>1. **ì¬ë¬´ ìš©ì–´ì˜ ì •í™•ì„±**: Revenue(ë§¤ì¶œ), EBITDA(ì„¸ì „ì˜ì—…ì´ìµ), EPS(ì£¼ë‹¹ìˆœì´ìµ), guidance(ê°€ì´ë˜ìŠ¤) ë“± ì¬ë¬´ ìš©ì–´ëŠ” í•œêµ­ ê¸ˆìœµì‹œì¥ì—ì„œ í†µìš©ë˜ëŠ” í‘œì¤€ ìš©ì–´ë¡œ ë²ˆì—­<br><br>2. **í™”ìì˜ ì–´ì¡° ë³´ì¡´**: ê²½ì˜ì§„ì˜ ìì‹ ê°, ìš°ë ¤, ë‚™ê´€ë¡  ë“±ì˜ ë‰˜ì•™ìŠ¤ë¥¼ í•œêµ­ì–´ë¡œ ìì—°ìŠ¤ëŸ½ê²Œ ì „ë‹¬<br><br>3. **ì „ë¬¸ì„± ìœ ì§€**: íˆ¬ìì ëŒ€ìƒ ë¬¸ì„œë¡œì„œì˜ ê²©ì‹ê³¼ ì „ë¬¸ì„± ìœ ì§€<br><br>4. **ìœ ì°½ì„±**: ì§ì—­ë³´ë‹¤ëŠ” í•œêµ­ì–´ë¡œ ìì—°ìŠ¤ëŸ¬ìš´ ë¬¸ì¥ êµ¬ì¡° ì‚¬ìš©<br><br>ì–´ë‹ì½œ ëŒ€í™”ë¡ì„ ì œê³µí•´ ì£¼ì‹œë©´ ì¦‰ì‹œ ë²ˆì—­ ì‘ì—…ì„ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>(GILD) Q4 2025 Earnings Call February 10, 2026 4:30 PM EST<br><br>Company Participants<br><br>Jacquie Ross - Senior Vice President of Treasury and Investor Relations<br>Daniel O'Day - Chairman & CEO<br>Johanna Mercier - Chief Commercial & Corporate Affairs Officer<br>Dietmar Berger - Chief Medical Officer<br>Andrew Dickinson - Chief Financial Officer<br>Cindy Perettie - Executive Vice President of Kite<br><br>Conference Call Participants<br><br>Christopher Schott - JPMorgan Chase & Co, Research Division<br>Louise Chen - Scotiabank Global Banking and Markets, Research Division<br>Tazeen Ahmad - BofA Securities, Research Division<br>Michael Yee - UBS Investment Bank, Research Division<br>Brian Abrahams - RBC Capital Markets, Research Division<br>Umer Raffat - Evercore ISI Institutional Equities, Research Division<br>Geoffrey Meacham - Citigroup Inc., Research Division<br>Daina Graybosch - Leerink Partners LLC, Research Division<br>Tyler Van Buren - TD Cowen, Research Division<br>Courtney Breen - Bernstein Institutional Services LLC, Research Division<br><br>Presentation<br><br>Operator<br><br>Good afternoon, everyone, and welcome to Gilead's Fourth Quarter and Full Year 2025 Earnings Conference Call.</td><td>ê¸¸ë¦¬ì–´ë“œ ì‚¬ì´ì–¸ìŠ¤(GILD) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2026ë…„ 2ì›” 10ì¼ ì˜¤í›„ 4ì‹œ 30ë¶„(ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>íšŒì‚¬ ì°¸ì„ì<br><br>ì¬í‚¤ ë¡œìŠ¤(Jacquie Ross) - ì¬ë¬´ ë° íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br>ëŒ€ë‹ˆì–¼ ì˜¤ë°ì´(Daniel O'Day) - íšŒì¥ ê²¸ CEO<br>ì¡°í•œë‚˜ ë¨¸ì‹œì–´(Johanna Mercier) - ìµœê³  ìƒì—… ë° ê¸°ì—… ì—…ë¬´ ì±…ì„ì<br>ë””íŠ¸ë§ˆë¥´ ë² ë¥´ê±°(Dietmar Berger) - ìµœê³  ì˜ë£Œ ì±…ì„ì<br>ì•¤ë“œë¥˜ ë””í‚¨ìŠ¨(Andrew Dickinson) - ìµœê³  ì¬ë¬´ ì±…ì„ì<br>ì‹ ë”” í˜ë ˆí‹°(Cindy Perettie) - ì¹´ì´íŠ¸(Kite) ë‹´ë‹¹ ì „ë¬´ì´ì‚¬<br><br>ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>í¬ë¦¬ìŠ¤í† í¼ ì‡¼íŠ¸(Christopher Schott) - JPëª¨ê±´ ì²´ì´ìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë£¨ì´ì¦ˆ ì²¸(Louise Chen) - ìŠ¤ì½”ìƒ¤ë±…í¬ ê¸€ë¡œë²Œ ë±…í‚¹ ì•¤ ë§ˆì¼“, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>íƒ€ì§„ ì•„ë§ˆë“œ(Tazeen Ahmad) - ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ ì¦ê¶Œ, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë§ˆì´í´ ì´(Michael Yee) - UBS ì¸ë² ìŠ¤íŠ¸ë¨¼íŠ¸ ë±…í¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë¸Œë¼ì´ì–¸ ì—ì´ë¸ŒëŸ¬í–„ìŠ¤(Brian Abrahams) - RBC ìºí”¼í„¸ ë§ˆì¼“, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ìš°ë¨¸ ë¼íŒŸ(Umer Raffat) - ì—ë²„ì½”ì–´ ISI ê¸°ê´€íˆ¬ìê°€ ì£¼ì‹ ë¶€ë¬¸<br>ì œí”„ë¦¬ ë¯¸ì²¨(Geoffrey Meacham) - ì‹œí‹°ê·¸ë£¹, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë‹¤ì´ë‚˜ ê·¸ë ˆì´ë³´ì‰¬(Daina Graybosch) - ë¦¬ì–´ë§í¬ íŒŒíŠ¸ë„ˆìŠ¤<br>íƒ€ì¼ëŸ¬ ë°˜ ë·°ë Œ(Tyler Van Buren) - TD ì½”ì›¬<br>ì½”íŠ¸ë‹ˆ ë¸Œë¦°(Courtney Breen) - ë²ˆìŠ¤íƒ€ì¸ ì¸ìŠ¤í‹°íŠœì…”ë„ ì„œë¹„ìŠ¤, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br><br>ë°œí‘œ<br><br>ìš´ì˜ì<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ, ì—¬ëŸ¬ë¶„. ê¸¸ë¦¬ì–´ë“œì˜ 2025ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared remarks, followed by our Q&A session. [Operator Instructions]<br><br>Now I'll hand the call over to Jacquie Ross, Senior Vice President of Treasury and Investor Relations. Jacquie Ross<br>Senior Vice President of Treasury and Investor Relations<br><br>Thank you, Rebecca. Just after market closed today, we issued a press release with earnings results for the fourth quarter and full year 2025. The press release, slides and supplemental data are available on the Investors section of our website at gilead.com.</td><td>ì œ ì´ë¦„ì€ ë ˆë² ì¹´ì´ë©°, ì˜¤ëŠ˜ ì§„í–‰ì„ ë§¡ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì ì‹œ í›„ ì¤€ë¹„ëœ ë°œí‘œê°€ ì§„í–‰ë˜ê³ , ì´ì–´ì„œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. [ìš´ì˜ì ì•ˆë‚´ì‚¬í•­]<br><br>ì´ì œ ì¬í‚¤ ë¡œìŠ¤ ì¬ë¬´ ë° íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥ì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ì¬í‚¤ ë¡œìŠ¤<br>ì¬ë¬´ ë° íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ë ˆë² ì¹´. ì˜¤ëŠ˜ ì¥ ë§ˆê° ì§í›„, ì €í¬ëŠ” 2025ë…„ 4ë¶„ê¸° ë° ì—°ê°„ ì‹¤ì  ê²°ê³¼ë¥¼ ë‹´ì€ ë³´ë„ìë£Œë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ë³´ë„ìë£Œ, í”„ë ˆì  í…Œì´ì…˜ ìë£Œ ë° ë³´ì¶© ë°ì´í„°ëŠ” ì €í¬ ì›¹ì‚¬ì´íŠ¸ gilead.comì˜ íˆ¬ìì ì„¹ì…˜ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day; our Chief Commercial and Corporate Affairs Officer, Johanna Mercier; our Chief Medical Officer, Dietmar Berger; and our Chief Financial Officer, Andrew Dickinson. After that, we'll open the call to Q&A where the team will be joined by Cindy Perettie, the Executive Vice President of Kite. Let me remind you that we will be making forward-looking statements. Please refer to Slide 2 regarding the risks and uncertainties relating to forward-looking statements that could cause actual results to differ materially. With that, I'll turn the call over to Dan.</td><td>ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì˜ ë°œí‘œìëŠ” ë‹¤ë‹ˆì—˜ ì˜¤ë°ì´ íšŒì¥ ê²¸ ìµœê³ ê²½ì˜ì, ìš”í•œë‚˜ ë¨¸ì‹œì–´ ìµœê³ ìƒì—…í™” ë° ê¸°ì—…ì—…ë¬´ ì±…ì„ì, ë””íŠ¸ë§ˆë¥´ ë² ë¥´ê±° ìµœê³ ì˜í•™ì±…ì„ì, ê·¸ë¦¬ê³  ì•¤ë“œë¥˜ ë””í‚¨ìŠ¨ ìµœê³ ì¬ë¬´ì±…ì„ìì…ë‹ˆë‹¤. ë°œí‘œ í›„ì—ëŠ” ì¹´ì´íŠ¸(Kite)ì˜ ì‹ ë”” í˜ë ˆí‹° ë¶€ì‚¬ì¥ì´ í•©ë¥˜í•˜ì—¬ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ê² ìŠµë‹ˆë‹¤. ë‹¹ì‚¬ê°€ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì„ í•  ê²ƒì„ì„ ìƒê¸°ì‹œì¼œ ë“œë¦½ë‹ˆë‹¤. ì‹¤ì œ ê²°ê³¼ê°€ í¬ê²Œ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆëŠ” ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ê³¼ ê´€ë ¨ëœ ìœ„í—˜ ë° ë¶ˆí™•ì‹¤ì„±ì— ëŒ€í•´ì„œëŠ” ìŠ¬ë¼ì´ë“œ 2ë¥¼ ì°¸ì¡°í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ê·¸ëŸ¼ ëŒ„ì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daniel O'Day<br>Chairman & CEO<br><br>Thank you, Jacquie, and good afternoon, everyone. I'm pleased to share another very strong set of results for Gilead, closing out a remarkable year for the company with clinical, commercial and operational achievements that set the stage for a very promising 2026. Starting with our full year results. Our HIV business grew 6% year-over-year driven by 7% growth in Biktarvy and 47% growth in our HIV prevention portfolio. This was despite an estimated $900 million headwind in 2025 associated with the Part D redesign. Absent this headwind, our HIV business growth was 10% in 2025.</td><td>ëŒ€ë‹ˆì–¼ ì˜¤ë°ì´<br>íšŒì¥ ê²¸ CEO<br><br>ì¬í‚¤, ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„, ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ê¸¸ë¦¬ì–´ë“œì˜ ë˜ ë‹¤ë¥¸ ë§¤ìš° ê°•ë ¥í•œ ì‹¤ì ì„ ê³µìœ í•˜ê²Œ ë˜ì–´ ê¸°ì©ë‹ˆë‹¤. ì„ìƒ, ìƒì—…ì , ìš´ì˜ìƒì˜ ì„±ê³¼ë¡œ ê°€ë“í•œ ë†€ë¼ìš´ í•œ í•´ë¥¼ ë§ˆë¬´ë¦¬í•˜ë©°, ì´ëŠ” ë§¤ìš° ìœ ë§í•œ 2026ë…„ì„ ìœ„í•œ ë°œíŒì„ ë§ˆë ¨í–ˆìŠµë‹ˆë‹¤. ì—°ê°„ ì‹¤ì ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ HIV ì‚¬ì—…ì€ ì „ë…„ ëŒ€ë¹„ 6% ì„±ì¥í–ˆìœ¼ë©°, ì´ëŠ” ë¹…íƒ€ë¹„ì˜ 7% ì„±ì¥ê³¼ HIV ì˜ˆë°© í¬íŠ¸í´ë¦¬ì˜¤ì˜ 47% ì„±ì¥ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ì´ëŠ” Part D ì¬ì„¤ê³„ì™€ ê´€ë ¨í•˜ì—¬ 2025ë…„ì— ì•½ 9ì–µ ë‹¬ëŸ¬ì˜ ì—­í’ì´ ìˆì—ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  ë‹¬ì„±í•œ ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­í’ì´ ì—†ì—ˆë‹¤ë©´, ìš°ë¦¬ì˜ HIV ì‚¬ì—… ì„±ì¥ë¥ ì€ 2025ë…„ì— 10%ì˜€ì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Yeztugo, our twice yearly HIV prevention injectable has already exceeded our coverage goals and is rapidly gaining market share in addition to expanding the reach of HIV prevention to new users. With its unique potential to bend the curve of the HIV epidemic, Yeztugo is a transformative medicine that we expect to drive durable, steady and long-term growth in our HIV prevention business in the coming quarters and years. Our liver business grew 6% in 2025 compared to 2024, largely driven by the rapid adoption of Livdelzi for primary biliary cholangitis.</td><td>ì˜ˆì¦ˆíˆ¬ê³ (Yeztugo)ëŠ” 6ê°œì›”ë§ˆë‹¤ íˆ¬ì—¬í•˜ëŠ” HIV ì˜ˆë°© ì£¼ì‚¬ì œë¡œ, ì´ë¯¸ ë‹¹ì‚¬ì˜ ë³´ê¸‰ ëª©í‘œë¥¼ ì´ˆê³¼ ë‹¬ì„±í–ˆìœ¼ë©° ì‹ ê·œ ì‚¬ìš©ìë“¤ì—ê²Œ HIV ì˜ˆë°©ì˜ ë²”ìœ„ë¥¼ í™•ëŒ€í•˜ëŠ” ë™ì‹œì— ì‹œì¥ ì ìœ ìœ¨ì„ ë¹ ë¥´ê²Œ í™•ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. HIV ì „ì—¼ë³‘ì˜ í™•ì‚° ê³¡ì„ ì„ êº¾ì„ ìˆ˜ ìˆëŠ” ë…ë³´ì ì¸ ì ì¬ë ¥ì„ ê°€ì§„ ì˜ˆì¦ˆíˆ¬ê³ ëŠ” í–¥í›„ ë¶„ê¸°ì™€ ì—°ë„ì— ê±¸ì³ ë‹¹ì‚¬ì˜ HIV ì˜ˆë°© ì‚¬ì—…ì—ì„œ ì§€ì† ê°€ëŠ¥í•˜ê³  ê¾¸ì¤€í•œ ì¥ê¸° ì„±ì¥ì„ ê²¬ì¸í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€ë˜ëŠ” í˜ì‹ ì ì¸ ì˜ì•½í’ˆì…ë‹ˆë‹¤. ë‹¹ì‚¬ì˜ ê°„ì§ˆí™˜ ì‚¬ì—…ì€ 2024ë…„ ëŒ€ë¹„ 2025ë…„ì— 6% ì„±ì¥í–ˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ ì›ë°œì„± ë‹´ì¦™ì„± ë‹´ê´€ì—¼ ì¹˜ë£Œì œì¸ ë¦¬ë¸Œë¸ì§€(Livdelzi)ì˜ ë¹ ë¥¸ ì±„íƒì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>And in oncology, Trodelvy also grew 6% in 2025 driven by momentum in metastatic triple-negative breast cancer following positive Phase III updates. And cell therapy was down about 7% year-over-year, largely in line with our expectations and reflecting continuing competitive headwinds. Moving to clinical progress, following a very productive year in 2025, we have a catalyst-rich year ahead, including: Phase III updates from ISLEND-1 and 2 trials evaluating islatravir plus lenacapavir, the potential first once-weekly oral treatment for people with virologically suppressed HIV.</td><td>ì¢…ì–‘í•™ ë¶„ì•¼ì—ì„œ íŠ¸ë¡œë¸ë¹„(Trodelvy)ëŠ” ê¸ì •ì ì¸ 3ìƒ ì—…ë°ì´íŠ¸ ì´í›„ ì „ì´ì„± ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•”ì—ì„œì˜ ëª¨ë©˜í…€ì— í˜ì…ì–´ 2025ë…„ 6% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì„¸í¬ì¹˜ë£Œì œëŠ” ì „ë…„ ëŒ€ë¹„ ì•½ 7% ê°ì†Œí–ˆëŠ”ë°, ì´ëŠ” ë‹¹ì‚¬ì˜ ì˜ˆìƒê³¼ ëŒ€ì²´ë¡œ ì¼ì¹˜í•˜ë©° ì§€ì†ì ì¸ ê²½ìŸ ì••ë ¥ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ì„ìƒ ì§„ì „ ìƒí™©ì„ ë³´ë©´, 2025ë…„ ë§¤ìš° ìƒì‚°ì ì¸ í•œ í•´ë¥¼ ë³´ë‚¸ í›„, ìš°ë¦¬ëŠ” ì´‰ë§¤ê°€ í’ë¶€í•œ í•œ í•´ë¥¼ ì•ë‘ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ë°”ì´ëŸ¬ìŠ¤í•™ì ìœ¼ë¡œ ì–µì œëœ HIV í™˜ìë¥¼ ìœ„í•œ ì ì¬ì  ìµœì´ˆì˜ ì£¼ 1íšŒ ê²½êµ¬ ì¹˜ë£Œì œì¸ ì´ìŠ¬ë¼íŠ¸ë¼ë¹„ë¥´(islatravir)ì™€ ë ˆë‚˜ì¹´íŒŒë¹„ë¥´(lenacapavir) ë³‘ìš©ìš”ë²•ì„ í‰ê°€í•˜ëŠ” ISLEND-1 ë° 2 ì„ìƒì‹œí—˜ì˜ 3ìƒ ì—…ë°ì´íŠ¸ê°€ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Two Phase III updates for Trodelvy, including the EVOKE-03 trial in metastatic non-small cell lung cancer and the ASCENT-GYN-01 trial in advanced endometrial cancer. Lastly, we expect an update on the Phase III IDEAL study, evaluating Livdelzi in second-line primary biliary cholangitis patients with only incomplete response to UDCA.</td><td>íŠ¸ë¡œë¸ë¹„ì˜ ë‘ ê°€ì§€ 3ìƒ ì„ìƒì‹œí—˜ ì—…ë°ì´íŠ¸ê°€ ìˆì„ ì˜ˆì •ì…ë‹ˆë‹¤. ì „ì´ì„± ë¹„ì†Œì„¸í¬íì•”ì„ ëŒ€ìƒìœ¼ë¡œ í•œ EVOKE-03 ì„ìƒì‹œí—˜ê³¼ ì§„í–‰ì„± ìê¶ë‚´ë§‰ì•”ì„ ëŒ€ìƒìœ¼ë¡œ í•œ ASCENT-GYN-01 ì„ìƒì‹œí—˜ì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, UDCAì— ëŒ€í•œ ë¶ˆì™„ì „ ë°˜ì‘ë§Œì„ ë³´ì¸ 2ì°¨ ì¹˜ë£Œ ì›ë°œì„± ë‹´ì¦™ì„± ë‹´ê´€ì—¼ í™˜ìë¥¼ ëŒ€ìƒìœ¼ë¡œ ë¦¬ë¸Œë¸ì§€ë¥¼ í‰ê°€í•˜ëŠ” 3ìƒ IDEAL ì—°êµ¬ì˜ ì—…ë°ì´íŠ¸ê°€ ìˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.</td></tr>
<tr><td>The strength and the pace of progress in our clinical pipeline is driving a steady cadence of product launches and on the heels of Livdelzi in 2024 and Yeztugo in 2025, we are targeting 4 commercial launches this year, including Trodelvy for first-line metastatic triple-negative breast cancer, extending beyond second-line treatment for which Trodelvy is a standard of care following positive results from the Phase III ASCENT-03 and ASCENT-04 studies, a new daily oral combination of bictegravir and lenacapavir for HIV treatment following positive updates from the Phase III ARTISTRY-1 and ARTISTRY-2 trials.</td><td>ìš°ë¦¬ ì„ìƒ íŒŒì´í”„ë¼ì¸ì˜ ê°•ë ¥í•œ ì„±ê³¼ì™€ ë¹ ë¥¸ ì§„ì „ ì†ë„ëŠ” ê¾¸ì¤€í•œ ì œí’ˆ ì¶œì‹œ ì¼ì •ì„ ì´ëŒì–´ë‚´ê³  ìˆìŠµë‹ˆë‹¤. 2024ë…„ Livdelziì™€ 2025ë…„ Yeztugo ì¶œì‹œì— ì´ì–´, ì˜¬í•´ëŠ” 4ê±´ì˜ ìƒì—…ì  ì¶œì‹œë¥¼ ëª©í‘œë¡œ í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì—¬ê¸°ì—ëŠ” 1ì°¨ ì „ì´ì„± ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•” ì¹˜ë£Œì œë¡œì„œì˜ Trodelvyê°€ í¬í•¨ë˜ë©°, ì´ëŠ” Phase III ASCENT-03 ë° ASCENT-04 ì„ìƒì‹œí—˜ì˜ ê¸ì •ì  ê²°ê³¼ì— ë”°ë¼ Trodelvyê°€ í‘œì¤€ì¹˜ë£Œì œë¡œ ìë¦¬ì¡ì€ 2ì°¨ ì¹˜ë£Œë¥¼ ë„˜ì–´ ì ì‘ì¦ì„ í™•ëŒ€í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.<br><br>ë˜í•œ Phase III ARTISTRY-1 ë° ARTISTRY-2 ì„ìƒì‹œí—˜ì˜ ê¸ì •ì  ì—…ë°ì´íŠ¸ì— ë”°ë¥¸ HIV ì¹˜ë£Œìš© bictegravirì™€ lenacapavirì˜ 1ì¼ 1íšŒ ê²½êµ¬ ë³µí•©ì œë„ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Anito-cel our potential best-in-disease BCMA CAR-T for fourth line or later relapsed or refractory multiple myeloma and Bulevirtide in the U.S. following approval in the EU for treatment of chronic hepatitis delta. These commercial and clinical milestones reflect the success of our diversification strategy that has been shaping Gilead over the last 6 years. We have up to 10 ongoing and potential new launches through 2027 and the strongest pipeline in our almost 40-year history. At the same time, we remain committed to operating expense in M&A discipline, continued delivery of exceptional operating results and growing returns to shareholders.</td><td>ì•ˆì´í† ì…€(Anito-cel)ì€ 4ì°¨ ì¹˜ë£Œ ì´ìƒì˜ ì¬ë°œì„± ë˜ëŠ” ë¶ˆì‘ì„± ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…ì— ëŒ€í•œ ì ì¬ì  ë™ì¢… ìµœê³  ìˆ˜ì¤€ì˜ BCMA CAR-T ì¹˜ë£Œì œì´ë©°, ë¶ˆë ˆë¹„ë¥´íƒ€ì´ë“œ(Bulevirtide)ëŠ” EUì—ì„œ ë§Œì„± Dí˜• ê°„ì—¼ ì¹˜ë£Œì œë¡œ ìŠ¹ì¸ëœ í›„ ë¯¸êµ­ì—ì„œë„ ì¶œì‹œë  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ìƒì—…ì  ë° ì„ìƒì  ì´ì •í‘œë“¤ì€ ì§€ë‚œ 6ë…„ê°„ ê¸¸ë¦¬ì–´ë“œë¥¼ í˜•ì„±í•´ ì˜¨ ìš°ë¦¬ì˜ ë‹¤ê°í™” ì „ëµì˜ ì„±ê³µì„ ë°˜ì˜í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” 2027ë…„ê¹Œì§€ ìµœëŒ€ 10ê°œì˜ ì§„í–‰ ì¤‘ì´ê±°ë‚˜ ì ì¬ì ì¸ ì‹ ê·œ ì¶œì‹œë¥¼ ì•ë‘ê³  ìˆìœ¼ë©°, ê±°ì˜ 40ë…„ ì—­ì‚¬ìƒ ê°€ì¥ ê°•ë ¥í•œ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë™ì‹œì— ìš°ë¦¬ëŠ” ìš´ì˜ë¹„ìš© ë° M&A ê·œìœ¨ ìœ ì§€, íƒì›”í•œ ì˜ì—… ì‹¤ì ì˜ ì§€ì†ì  ë‹¬ì„±, ê·¸ë¦¬ê³  ì£¼ì£¼ í™˜ì› í™•ëŒ€ì— ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With many of the policy-related uncertainties behind us and no major product LOEs until 2036, Gilead is entering 2026 in a position of strength. With that, I will hand it over to Johanna. Johanna Mercier<br>Chief Commercial & Corporate Affairs Officer<br><br>Thanks, Dan, and good afternoon, everyone. 2025 was another strong year of commercial execution with base business sales up 4% compared to 2024 or nearly 8% excluding impact from Medicare Part D redesign. This underscores the durability of our base business and our sustained launch momentum with up to 10 ongoing and potential new launches through 2027. Beginning on Slide 7.</td><td>ì •ì±… ê´€ë ¨ ë¶ˆí™•ì‹¤ì„± ëŒ€ë¶€ë¶„ì´ í•´ì†Œë˜ê³  2036ë…„ê¹Œì§€ ì£¼ìš” ì œí’ˆì˜ íŠ¹í—ˆë§Œë£Œ(LOE)ê°€ ì—†ëŠ” ìƒí™©ì—ì„œ, ê¸¸ë¦¬ì–´ë“œëŠ” ê°•ë ¥í•œ ì…ì§€ë¥¼ ë°”íƒ•ìœ¼ë¡œ 2026ë…„ì„ ë§ì´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ëŸ¼ ì¡°ì• ë‚˜ì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ì¡°ì• ë‚˜ ë¨¸ì‹œì–´<br>ìµœê³ ìƒì—…ì±…ì„ì ê²¸ ê¸°ì—…ì—…ë¬´ì±…ì„ì<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ëŒ„. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì„¸ìš”. 2025ë…„ì€ ë˜ í•œ í•´ ê°•ë ¥í•œ ìƒì—…ì  ì‹¤í–‰ë ¥ì„ ë³´ì—¬ì¤€ í•´ì˜€ìœ¼ë©°, ê¸°ë³¸ ì‚¬ì—… ë§¤ì¶œì´ 2024ë…„ ëŒ€ë¹„ 4% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì–´ íŒŒíŠ¸D ì¬ì„¤ê³„ì˜ ì˜í–¥ì„ ì œì™¸í•˜ë©´ ê±°ì˜ 8% ì„±ì¥í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ ê¸°ë³¸ ì‚¬ì—…ì˜ ì§€ì†ê°€ëŠ¥ì„±ê³¼ 2027ë…„ê¹Œì§€ ìµœëŒ€ 10ê°œì˜ ì§„í–‰ ì¤‘ì´ê±°ë‚˜ ì ì¬ì ì¸ ì‹ ì œí’ˆ ì¶œì‹œë¥¼ í†µí•œ ì§€ì†ì ì¸ ì¶œì‹œ ëª¨ë©˜í…€ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. 7í˜ì´ì§€ ìŠ¬ë¼ì´ë“œë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Fourth quarter total product sales, excluding Veklury, were $7.7 billion, up 7% year-over-year and 9% sequentially, primarily driven by higher sales across HIV and Livdelzi. Including Veklury sales of $212 million, fourth quarter total product sales were $7.9 billion, up 5% year-over-year and 8% sequentially. Turning to the full year on Slide 8. Total product sales, excluding Veklury, were $28 billion in 2025, more than $300 million above the high end of our full year guidance range, driven by outperformance in our HIV business and partially offset by lower cell therapy sales.</td><td>4ë¶„ê¸° ë²¡ë£¨ë¦¬ë¥¼ ì œì™¸í•œ ì´ ì œí’ˆ ë§¤ì¶œì€ 77ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 7%, ì „ë¶„ê¸° ëŒ€ë¹„ 9% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ HIV ì œí’ˆêµ°ê³¼ Livdelziì˜ ë§¤ì¶œ ì¦ê°€ì— ê¸°ì¸í•©ë‹ˆë‹¤. ë²¡ë£¨ë¦¬ ë§¤ì¶œ 2ì–µ 1,200ë§Œ ë‹¬ëŸ¬ë¥¼ í¬í•¨í•œ 4ë¶„ê¸° ì´ ì œí’ˆ ë§¤ì¶œì€ 79ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 5%, ì „ë¶„ê¸° ëŒ€ë¹„ 8% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 8ì˜ ì—°ê°„ ì‹¤ì ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 2025ë…„ ë²¡ë£¨ë¦¬ë¥¼ ì œì™¸í•œ ì´ ì œí’ˆ ë§¤ì¶œì€ 280ì–µ ë‹¬ëŸ¬ë¡œ, ì—°ê°„ ê°€ì´ë˜ìŠ¤ ìƒë‹¨ì„ 3ì–µ ë‹¬ëŸ¬ ì´ìƒ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” HIV ì‚¬ì—…ë¶€ë¬¸ì˜ ì´ˆê³¼ ë‹¬ì„±ì— í˜ì…ì€ ê²ƒì´ë©°, ì„¸í¬ì¹˜ë£Œì œ ë§¤ì¶œ ê°ì†Œë¡œ ì¼ë¶€ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Including Veklury, total product sales were $28.9 billion, up 1% compared to 2024 or 5%, excluding Medicare Part D redesign impact, highlighting the strength of our overall business. Moving to Slide 9. Our HIV business delivered record sales of $5.8 billion for the fourth quarter, up 6% year-over-year, driven by higher demand for Biktarvy and Descovy as well as the launch of Yeztugo. Sequentially, HIV sales were up 10%, primarily driven by seasonal inventory dynamics and higher average realized price due to favorable channel mix in addition to demand. For the full year, HIV sales of $20.8 billion were up 6% year-over-year, driven by strong underlying demand growth.</td><td>ë²¡ë£¨ë¦¬ë¥¼ í¬í•¨í•œ ì´ ì œí’ˆ ë§¤ì¶œì€ 289ì–µ ë‹¬ëŸ¬ë¡œ 2024ë…„ ëŒ€ë¹„ 1% ì¦ê°€í–ˆìœ¼ë©°, ë©”ë””ì¼€ì–´ íŒŒíŠ¸ D ì¬ì„¤ê³„ ì˜í–¥ì„ ì œì™¸í•˜ë©´ 5% ì¦ê°€í•˜ì—¬ ì „ë°˜ì ì¸ ì‚¬ì—…ì˜ ê°•ë ¥í•¨ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 9ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. HIV ì‚¬ì—…ë¶€ëŠ” 4ë¶„ê¸°ì— 58ì–µ ë‹¬ëŸ¬ì˜ ê¸°ë¡ì ì¸ ë§¤ì¶œì„ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” ì „ë…„ ë™ê¸° ëŒ€ë¹„ 6% ì¦ê°€í•œ ìˆ˜ì¹˜ë¡œ ë¹…íƒ€ë¹„ì™€ ë°ìŠ¤ì½”ë¹„ì— ëŒ€í•œ ìˆ˜ìš” ì¦ê°€ ë° ì˜ˆì¦ˆíˆ¬ê³  ì¶œì‹œì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ì „ë¶„ê¸° ëŒ€ë¹„ HIV ë§¤ì¶œì€ 10% ì¦ê°€í–ˆëŠ”ë°, ì´ëŠ” ì£¼ë¡œ ê³„ì ˆì  ì¬ê³  ë³€ë™ê³¼ ìˆ˜ìš” ì¦ê°€ì— ë”í•´ ìœ ë¦¬í•œ ì±„ë„ ë¯¹ìŠ¤ë¡œ ì¸í•œ í‰ê·  ì‹¤í˜„ ê°€ê²© ìƒìŠ¹ì— ê¸°ì¸í•©ë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ HIV ë§¤ì¶œì€ 208ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 6% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ê°•ë ¥í•œ ê¸°ì € ìˆ˜ìš” ì„±ì¥ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Our exceptional commercial performance and higher-than-expected average realized price exceeded our updated guidance of 5% growth. Excluding the estimated $900 million headwind associated with the Medicare Part D redesign, our HIV business grew 10% year-over-year. Looking at HIV treatment in more detail on Slide 10. Biktarvy fourth quarter sales were $4 billion, up 5% year-over-year and full year sales were $14.3 billion, up 7% year-over-year, both driven by higher demand, partially offset by lower average realized price. This demand-led growth reflects 2% to 3% treatment market growth annually and continued Biktarvy share gains.</td><td>ìš°ë¦¬ì˜ ë›°ì–´ë‚œ ìƒì—…ì  ì„±ê³¼ì™€ ì˜ˆìƒë³´ë‹¤ ë†’ì€ í‰ê·  ì‹¤í˜„ê°€ê²©ì€ 5% ì„±ì¥ì´ë¼ëŠ” ì—…ë°ì´íŠ¸ëœ ê°€ì´ë˜ìŠ¤ë¥¼ ì´ˆê³¼í–ˆìŠµë‹ˆë‹¤. ë©”ë””ì¼€ì–´ íŒŒíŠ¸D ì¬ì„¤ê³„ì™€ ê´€ë ¨ëœ ì•½ 9ì–µ ë‹¬ëŸ¬ì˜ ì—­í’ì„ ì œì™¸í•˜ë©´, ìš°ë¦¬ì˜ HIV ì‚¬ì—…ì€ ì „ë…„ ëŒ€ë¹„ 10% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 10ì—ì„œ HIV ì¹˜ë£Œì œë¥¼ ë” ìì„¸íˆ ì‚´í´ë³´ê² ìŠµë‹ˆë‹¤. ë¹…íƒ€ë¹„ì˜ 4ë¶„ê¸° ë§¤ì¶œì€ 40ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 5% ì¦ê°€í–ˆìœ¼ë©°, ì—°ê°„ ë§¤ì¶œì€ 143ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 7% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë†’ì€ ìˆ˜ìš”ì— ì˜í•´ ì£¼ë„ë˜ì—ˆìœ¼ë‚˜ í‰ê·  ì‹¤í˜„ê°€ê²© í•˜ë½ìœ¼ë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìˆ˜ìš” ì£¼ë„ ì„±ì¥ì€ ì—°ê°„ 2~3%ì˜ ì¹˜ë£Œì œ ì‹œì¥ ì„±ì¥ê³¼ ë¹…íƒ€ë¹„ì˜ ì§€ì†ì ì¸ ì ìœ ìœ¨ í™•ëŒ€ë¥¼ ë°˜ì˜í•©ë‹ˆë‹¤.</td></tr>
<tr><td>In the U.S., for example, Biktarvy's share is more than 52% with year-over-year gains every quarter since launch. It's clear Biktarvy continues to set the bar for HIV treatment and remains the #1 prescribed regimen for both treatment naive and switch across major markets. We are rapidly advancing towards the launch of BIC/LEN, our investigational once-daily oral combining bictegravir, the most prescribed integrase inhibitor with our breakthrough capsid inhibitor lenacapavir in virologically suppressed people with HIV, including those on complex regimens. BIC/LEN could further expand our lead in the switch market following potential launch in the second half of this year.</td><td>ì˜ˆë¥¼ ë“¤ì–´ ë¯¸êµ­ì—ì„œ ë¹…íƒ€ë¹„ì˜ ì ìœ ìœ¨ì€ 52%ë¥¼ ë„˜ì–´ì„°ìœ¼ë©°, ì¶œì‹œ ì´í›„ ë§¤ ë¶„ê¸° ì „ë…„ ëŒ€ë¹„ ì¦ê°€ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ë¹…íƒ€ë¹„ëŠ” ê³„ì†í•´ì„œ HIV ì¹˜ë£Œì˜ ê¸°ì¤€ì„ ì œì‹œí•˜ê³  ìˆìœ¼ë©°, ì£¼ìš” ì‹œì¥ì—ì„œ ì¹˜ë£Œ ë¯¸ê²½í—˜ í™˜ìì™€ ì „í™˜ í™˜ì ëª¨ë‘ì—ê²Œ 1ìœ„ ì²˜ë°© ìš”ë²•ìœ¼ë¡œ ìë¦¬ë§¤ê¹€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë°”ì´ëŸ¬ìŠ¤í•™ì ìœ¼ë¡œ ì–µì œëœ HIV ê°ì—¼ì¸, ë³µì¡í•œ ìš”ë²•ì„ ì‚¬ìš©í•˜ëŠ” í™˜ìë¥¼ í¬í•¨í•˜ì—¬, ê°€ì¥ ë§ì´ ì²˜ë°©ë˜ëŠ” ì¸í…Œê·¸ë¼ì œ ì–µì œì œì¸ ë¹…í…Œê·¸ë¼ë¹„ë¥´ì™€ íšê¸°ì ì¸ ìº¡ì‹œë“œ ì–µì œì œ ë ˆë‚˜ì¹´íŒŒë¹„ë¥´ë¥¼ ê²°í•©í•œ 1ì¼ 1íšŒ ê²½êµ¬ íˆ¬ì—¬ ì„ìƒì‹œí—˜ìš© ì‹ ì•½ BIC/LENì˜ ì¶œì‹œë¥¼ ë¹ ë¥´ê²Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. BIC/LENì€ ì˜¬í•´ í•˜ë°˜ê¸° ì¶œì‹œ ê°€ëŠ¥ì„±ì— ë”°ë¼ ì „í™˜ ì‹œì¥ì—ì„œ ìš°ë¦¬ì˜ ì„ ë‘ ìœ„ì¹˜ë¥¼ ë”ìš± í™•ëŒ€í•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>This regimen represents the first of up to 7 potential HIV product launches through 2033. Now moving to Slide 11. We've had another exceptional quarter for our HIV prevention business, which grew 53% year-over-year, driven by favorable access, strong commercial execution and continued U.S. market growth of approximately 13% year-over-year. Our fourth quarter sales of Descovy were up an impressive 33% year-over-year. For the full year, Descovy sales were $2.8 billion, up 31% year-over-year, driven by increased demand in HIV prevention and higher average realized price.</td><td>ì´ ìš”ë²•ì€ 2033ë…„ê¹Œì§€ ì¶œì‹œë  ìµœëŒ€ 7ê°œì˜ ì ì¬ì  HIV ì œí’ˆ ì¤‘ ì²« ë²ˆì§¸ë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤. ì´ì œ ìŠ¬ë¼ì´ë“œ 11ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. HIV ì˜ˆë°© ì‚¬ì—…ì—ì„œ ë˜ í•œ ë²ˆ íƒì›”í•œ ë¶„ê¸° ì‹¤ì ì„ ê±°ë‘ì—ˆìœ¼ë©°, ìœ ë¦¬í•œ ì ‘ê·¼ì„±, ê°•ë ¥í•œ ì˜ì—… ì‹¤í–‰ë ¥, ê·¸ë¦¬ê³  ì „ë…„ ëŒ€ë¹„ ì•½ 13%ì˜ ì§€ì†ì ì¸ ë¯¸êµ­ ì‹œì¥ ì„±ì¥ì— í˜ì…ì–´ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 53% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° Descovy ë§¤ì¶œì€ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 33%ë¼ëŠ” ì¸ìƒì ì¸ ì¦ê°€ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ Descovy ë§¤ì¶œì€ 28ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 31% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” HIV ì˜ˆë°© ë¶„ì•¼ì˜ ìˆ˜ìš” ì¦ê°€ì™€ í‰ê·  ì‹¤í˜„ ê°€ê²© ìƒìŠ¹ì— ê¸°ì¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Descovy performance in HIV prevention, which accounts for roughly 80% of its sales continues to exceed expectations with record U.S. market share greater than 45%. Similarly, Yeztugo continues to perform strongly across several key launch indicators. Yeztugo fourth quarter sales were $96 million, and full year Yeztugo sales were $150 million, in line with our guidance we shared in the third quarter. Building upon this early success, we recently launched our Yeztugo branded direct-to-consumer campaign, highlighting Yeztugo's dosing schedule and efficacy and reflecting the broad diversity represented in our purpose trials.</td><td>HIV ì˜ˆë°© ë¶„ì•¼ì—ì„œ Descovyì˜ ì‹¤ì ì€ ë§¤ì¶œì˜ ì•½ 80%ë¥¼ ì°¨ì§€í•˜ê³  ìˆìœ¼ë©°, ë¯¸êµ­ ì‹œì¥ì ìœ ìœ¨ì´ 45%ë¥¼ ë„˜ì–´ ì‚¬ìƒ ìµœê³ ì¹˜ë¥¼ ê¸°ë¡í•˜ëŠ” ë“± ê¸°ëŒ€ì¹˜ë¥¼ ì§€ì†ì ìœ¼ë¡œ ìƒíšŒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì°¬ê°€ì§€ë¡œ YeztugoëŠ” ì—¬ëŸ¬ ì£¼ìš” ì¶œì‹œ ì§€í‘œì—ì„œ ê°•ë ¥í•œ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. Yeztugoì˜ 4ë¶„ê¸° ë§¤ì¶œì€ 9,600ë§Œ ë‹¬ëŸ¬ì˜€ìœ¼ë©°, ì—°ê°„ ë§¤ì¶œì€ 1ì–µ 5,000ë§Œ ë‹¬ëŸ¬ë¡œ 3ë¶„ê¸°ì— ê³µìœ í–ˆë˜ ê°€ì´ë˜ìŠ¤ì™€ ì¼ì¹˜í•©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì´ˆê¸° ì„±ê³µì„ ë°”íƒ•ìœ¼ë¡œ, ìµœê·¼ Yeztugoì˜ íˆ¬ì•½ ì¼ì •ê³¼ íš¨ëŠ¥ì„ ê°•ì¡°í•˜ê³  ì„ìƒì‹œí—˜ì— ì°¸ì—¬í•œ ê´‘ë²”ìœ„í•œ ë‹¤ì–‘ì„±ì„ ë°˜ì˜í•œ ë¸Œëœë“œ ì†Œë¹„ì ì§ì ‘ ëŒ€ìƒ(DTC) ìº í˜ì¸ì„ ì‹œì‘í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect this DTC campaign to broaden awareness of Yeztugo and contribute to a consistent build in Yeztugo sales in the coming quarters. Coverage for Yeztugo continues to grow, and I'm thrilled to share that we have achieved our goal of 90% coverage well ahead of our 1-year target. This includes all major payers. Additionally, approximately 90% of covered individuals can access Yeztugo with $0 co-pay. We continue to work on an account-by-account basis to support pull-through as quickly as possible. While we have more to do, we are making great progress here as we support clinicians and their offices navigate the new logistics associated with a twice yearly injectable regimen.</td><td>ì €í¬ëŠ” ì´ë²ˆ DTC ìº í˜ì¸ì´ ì˜ˆì¦ˆíˆ¬ê³ ì— ëŒ€í•œ ì¸ì§€ë„ë¥¼ í™•ëŒ€í•˜ê³  í–¥í›„ ë¶„ê¸°ì— ì˜ˆì¦ˆíˆ¬ê³  ë§¤ì¶œì˜ ì§€ì†ì ì¸ ì„±ì¥ì— ê¸°ì—¬í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ì˜ˆì¦ˆíˆ¬ê³ ì˜ ë³´í—˜ ì ìš© ë²”ìœ„ëŠ” ê³„ì† í™•ëŒ€ë˜ê³  ìˆìœ¼ë©°, 1ë…„ ëª©í‘œë³´ë‹¤ í›¨ì”¬ ì•ì„œ 90% ë³´í—˜ ì ìš© ëª©í‘œë¥¼ ë‹¬ì„±í–ˆë‹¤ëŠ” ì†Œì‹ì„ ì „í•˜ê²Œ ë˜ì–´ ë§¤ìš° ê¸°ì©ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ëª¨ë“  ì£¼ìš” ë³´í—˜ì‚¬ê°€ í¬í•¨ë©ë‹ˆë‹¤. ë˜í•œ ë³´í—˜ ì ìš© ëŒ€ìƒìì˜ ì•½ 90%ê°€ ë³¸ì¸ë¶€ë‹´ê¸ˆ $0ë¡œ ì˜ˆì¦ˆíˆ¬ê³ ë¥¼ ì´ìš©í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ê°€ëŠ¥í•œ í•œ ì‹ ì†í•˜ê²Œ ì²˜ë°© ì „í™˜ì„ ì§€ì›í•˜ê¸° ìœ„í•´ ê³„ì •ë³„ë¡œ ì§€ì†ì ìœ¼ë¡œ í˜‘ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•„ì§ í•´ì•¼ í•  ì¼ì´ ë” ìˆì§€ë§Œ, 6ê°œì›”ì— í•œ ë²ˆ íˆ¬ì—¬í•˜ëŠ” ì£¼ì‚¬ì œ ìš”ë²•ê³¼ ê´€ë ¨ëœ ìƒˆë¡œìš´ ì—…ë¬´ í”„ë¡œì„¸ìŠ¤ë¥¼ ì„ìƒì˜ì™€ ê·¸ë“¤ì˜ ì§„ë£Œì‹¤ì´ ì›í™œíˆ ì§„í–‰í•  ìˆ˜ ìˆë„ë¡ ì§€ì›í•˜ë©´ì„œ ì´ ë¶€ë¶„ì—ì„œ í° ì§„ì „ì„ ì´ë£¨ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Given our expectations for a steady, durable and long-term built in sales, we expect full year 2026 Yeztugo revenue of approximately $800 million compared to $150 million in 2025. Highlighting that Yeztugo is well on its way to achieving blockbuster status. We continue to offer the most compelling HIV prevention portfolio available including the 6 monthly Yeztugo injectable with its transformative potential on the HIV epidemic, in addition to DESCOVY for PrEP, the current market-leading branded oral. Our goal this year is to continue to drive rapid adoption of HIV prevention, and we expect both brands to demonstrate robust growth in 2026.</td><td>ì¥ê¸°ì ìœ¼ë¡œ ì•ˆì •ì ì´ê³  ì§€ì† ê°€ëŠ¥í•œ ë§¤ì¶œ ì„±ì¥ì´ ë‚´ì¬ë˜ì–´ ìˆë‹¤ëŠ” ì „ë§ì— ë”°ë¼, 2025ë…„ 1ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ ëŒ€ë¹„ 2026ë…„ ì˜ˆì¦ˆíˆ¬ê³ ì˜ ì—°ê°„ ë§¤ì¶œì€ ì•½ 8ì–µ ë‹¬ëŸ¬ì— ë‹¬í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ëŠ” ì˜ˆì¦ˆíˆ¬ê³ ê°€ ë¸”ë¡ë²„ìŠ¤í„° ì§€ìœ„ ë‹¬ì„±ì„ í–¥í•´ ìˆœì¡°ë¡­ê²Œ ë‚˜ì•„ê°€ê³  ìˆìŒì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ë‹¹ì‚¬ëŠ” HIV ì „ì—¼ë³‘ì— ëŒ€í•œ í˜ì‹ ì  ì ì¬ë ¥ì„ ì§€ë‹Œ 6ê°œì›” ì£¼ê¸° ì˜ˆì¦ˆíˆ¬ê³  ì£¼ì‚¬ì œì™€ í•¨ê»˜, í˜„ì¬ ì‹œì¥ì„ ì„ ë„í•˜ëŠ” ë¸Œëœë“œ ê²½êµ¬ì œì¸ ë°ìŠ¤ì½”ë¹„ í¬ í”„ë ™(DESCOVY for PrEP)ì„ í¬í•¨í•˜ì—¬ ê°€ì¥ ê²½ìŸë ¥ ìˆëŠ” HIV ì˜ˆë°© í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ê³„ì† ì œê³µí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ìš°ë¦¬ì˜ ëª©í‘œëŠ” HIV ì˜ˆë°©ì˜ ë¹ ë¥¸ ë„ì…ì„ ì§€ì†ì ìœ¼ë¡œ ì´‰ì§„í•˜ëŠ” ê²ƒì´ë©°, 2026ë…„ì—ëŠ” ë‘ ë¸Œëœë“œ ëª¨ë‘ ê°•ë ¥í•œ ì„±ì¥ì„ ë³´ì¼ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤.</td></tr>
<tr><td>For 2026, we expect total HIV sales, including both treatment and prevention to grow approximately 6% compared to 2025, as shown on Slide 12. Looking at quarterly trends and as a reminder, we expect our normal HIV seasonal inventory drawdown in the first quarter of 2026. As announced in December, there are manageable headwinds associated with the drug pricing agreement with the U.S. government to lower Medicaid pricing for some of our products, including Genvoya and Odefsey. Additionally, our guidance reflects some potential shifts into lower-priced channels associated with proposed changes to the Affordable Care Act.</td><td>2026ë…„ì—ëŠ” ì¹˜ë£Œì œì™€ ì˜ˆë°©ì œë¥¼ í¬í•¨í•œ ì „ì²´ HIV ë§¤ì¶œì´ 2025ë…„ ëŒ€ë¹„ ì•½ 6% ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” ìŠ¬ë¼ì´ë“œ 12ì— ë‚˜ì™€ ìˆìŠµë‹ˆë‹¤. ë¶„ê¸°ë³„ ì¶”ì´ë¥¼ ì‚´í´ë³´ë©´, ì°¸ê³ ë¡œ 2026ë…„ 1ë¶„ê¸°ì—ëŠ” í†µìƒì ì¸ HIV ê³„ì ˆì  ì¬ê³  ê°ì†Œê°€ ì˜ˆìƒë©ë‹ˆë‹¤. 12ì›”ì— ë°œí‘œí•œ ë°”ì™€ ê°™ì´, Genvoyaì™€ Odefseyë¥¼ í¬í•¨í•œ ì¼ë¶€ ì œí’ˆì˜ ë©”ë””ì¼€ì´ë“œ ê°€ê²©ì„ ì¸í•˜í•˜ê¸°ë¡œ í•œ ë¯¸êµ­ ì •ë¶€ì™€ì˜ ì˜ì•½í’ˆ ê°€ê²© í˜‘ì •ê³¼ ê´€ë ¨í•˜ì—¬ ê´€ë¦¬ ê°€ëŠ¥í•œ ì—­í’ì´ ìˆìŠµë‹ˆë‹¤. ë˜í•œ, ë‹¹ì‚¬ì˜ ê°€ì´ë˜ìŠ¤ì—ëŠ” ê±´ê°•ë³´í—˜ê°œí˜ë²•(Affordable Care Act) ê°œì •ì•ˆê³¼ ê´€ë ¨í•˜ì—¬ ì €ê°€ ì±„ë„ë¡œì˜ ì¼ë¶€ ì´ë™ ê°€ëŠ¥ì„±ì´ ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In total, these headwinds are expected to impact HIV growth by about 2% in 2026 compared to 2025. Absent these headwinds, our HIV business is expected to grow 8% in 2026, highlighting the underlying strength of our HIV business. Turning to liver disease on Slide 13. Full year sales of $3.2 billion were up 6% year-over-year, primarily driven by higher demand and partially offset by lower average realized price. In the fourth quarter, liver sales were $844 million, up 17% year-over-year and 3% sequentially, driven by another quarter of continued strength for Livdelzi in primary biliary cholangitis or PBC.</td><td>ì „ì²´ì ìœ¼ë¡œ ì´ëŸ¬í•œ ì—­í’ì€ 2025ë…„ ëŒ€ë¹„ 2026ë…„ HIV ì„±ì¥ë¥ ì— ì•½ 2% ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­í’ì´ ì—†ì—ˆë‹¤ë©´, ë‹¹ì‚¬ì˜ HIV ì‚¬ì—…ì€ 2026ë…„ì— 8% ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” HIV ì‚¬ì—…ì˜ ê·¼ë³¸ì ì¸ ê°•ì ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 13ì˜ ê°„ì§ˆí™˜ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì—°ê°„ ë§¤ì¶œ 32ì–µ ë‹¬ëŸ¬ëŠ” ì „ë…„ ëŒ€ë¹„ 6% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ ìˆ˜ìš” ì¦ê°€ì— ê¸°ì¸í•˜ê³  í‰ê·  ì‹¤í˜„ ê°€ê²© í•˜ë½ìœ¼ë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. 4ë¶„ê¸° ê°„ì§ˆí™˜ ë§¤ì¶œì€ 8ì–µ 4,400ë§Œ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 17%, ì „ë¶„ê¸° ëŒ€ë¹„ 3% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ì›ë°œì„± ë‹´ì¦™ì„± ë‹´ê´€ì—¼(PBC) ì¹˜ë£Œì œì¸ Livdelziì˜ ì§€ì†ì ì¸ ê°•ì„¸ê°€ ì´ì–´ì§„ ë˜ í•œ ë¶„ê¸°ì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Livdelzi grew a remarkable 42% sequentially to $150 million, driven by strong patient demand, further accelerated by the withdrawal of a competitor product in the U.S. With much of this switching activity now behind us, we are pleased to start 2026 as the U.S. market share leader with more than 50% in second-line PBC. Moving to Trodelvy on Slide 14. Full year 2025 sales increased 6% to $1.4 billion, primarily driven by higher demand in metastatic breast cancer treatment which more than offset the expected impact from the bladder cancer withdrawal in the U.S. at the end of 2024.</td><td>LivdelziëŠ” ê°•ë ¥í•œ í™˜ì ìˆ˜ìš”ì— í˜ì…ì–´ ì „ë¶„ê¸° ëŒ€ë¹„ 42% ì¦ê°€í•œ 1ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ë©° ë†€ë¼ìš´ ì„±ì¥ì„ ë³´ì˜€ìŠµë‹ˆë‹¤. ì´ëŠ” ë¯¸êµ­ ë‚´ ê²½ìŸ ì œí’ˆì˜ ì² ìˆ˜ë¡œ ë”ìš± ê°€ì†í™”ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì œí’ˆ ì „í™˜ í™œë™ì´ ëŒ€ë¶€ë¶„ ë§ˆë¬´ë¦¬ëœ ê°€ìš´ë°, 2026ë…„ì„ 2ì°¨ ì¹˜ë£Œ PBC ì‹œì¥ì—ì„œ 50% ì´ìƒì˜ ì ìœ ìœ¨ì„ ë³´ìœ í•œ ë¯¸êµ­ ì‹œì¥ ì„ ë‘ì£¼ìë¡œ ì‹œì‘í•˜ê²Œ ë˜ì–´ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤.<br><br>14í˜ì´ì§€ì˜ Trodelvyë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. 2025ë…„ ì „ì²´ ë§¤ì¶œì€ 6% ì¦ê°€í•œ 14ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ ì „ì´ì„± ìœ ë°©ì•” ì¹˜ë£Œì—ì„œì˜ ìˆ˜ìš” ì¦ê°€ì— ê¸°ì¸í•œ ê²ƒìœ¼ë¡œ, 2024ë…„ ë§ ë¯¸êµ­ì—ì„œì˜ ë°©ê´‘ì•” ì ì‘ì¦ ì² ìˆ˜ë¡œ ì¸í•œ ì˜ˆìƒ ì˜í–¥ì„ ìƒì‡„í•˜ê³ ë„ ë‚¨ëŠ” ìˆ˜ì¹˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>In the fourth quarter, Trodelvy sales were $384 million, up 8% both year-over-year and sequentially, driven by higher demand. Building on Trodelvy's strong 2025 performance, we shared back-to-back positive Phase III ASCENT-03 and ASCENT-04 readouts. These results contribute to the strong body of evidence for Trodelvy across lines of therapy in metastatic triple-negative breast cancer and continue to drive demand growth. In both these studies, the investigational Trodelvy regimen demonstrated a highly statistically significant and clinically meaningful progression-free survival benefit over the standard of care.</td><td>4ë¶„ê¸°ì— íŠ¸ë¡œë¸ë¹„(Trodelvy) ë§¤ì¶œì€ 3ì–µ 8,400ë§Œ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•˜ì—¬ ì „ë…„ ë™ê¸° ëŒ€ë¹„ ë° ì „ë¶„ê¸° ëŒ€ë¹„ ëª¨ë‘ 8% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ìˆ˜ìš” ì¦ê°€ì— ê¸°ì¸í•©ë‹ˆë‹¤. íŠ¸ë¡œë¸ë¹„ì˜ ê°•ë ¥í•œ 2025ë…„ ì‹¤ì ì„ ë°”íƒ•ìœ¼ë¡œ, ìš°ë¦¬ëŠ” 3ìƒ ì„ìƒì‹œí—˜ì¸ ASCENT-03ê³¼ ASCENT-04ì˜ ê¸ì •ì ì¸ ê²°ê³¼ë¥¼ ì—°ì´ì–´ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ê³¼ë“¤ì€ ì „ì´ì„± ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•”ì˜ ì—¬ëŸ¬ ì¹˜ë£Œ ë‹¨ê³„ì— ê±¸ì¹œ íŠ¸ë¡œë¸ë¹„ì˜ ê°•ë ¥í•œ ì„ìƒ ê·¼ê±°ë¥¼ ë’·ë°›ì¹¨í•˜ë©°, ì§€ì†ì ì¸ ìˆ˜ìš” ì„±ì¥ì„ ê²¬ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë‘ ì„ìƒì‹œí—˜ ëª¨ë‘ì—ì„œ íŠ¸ë¡œë¸ë¹„ ì‹œí—˜ ìš”ë²•ì€ í‘œì¤€ ì¹˜ë£Œë²• ëŒ€ë¹„ í†µê³„ì ìœ¼ë¡œ ë§¤ìš° ìœ ì˜ë¯¸í•˜ê³  ì„ìƒì ìœ¼ë¡œ ì˜ë¯¸ ìˆëŠ” ë¬´ì§„í–‰ ìƒì¡´ê¸°ê°„(progression-free survival) ê°œì„  íš¨ê³¼ë¥¼ ì…ì¦í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>These potentially practice-changing data have now been published in the New England Journal of Medicine and have been recognized by the NCCN in their updated breast cancer guidelines. Trodelvy is now the only antibody drug conjugate to be recommended by the NCCN for first-line PD-L1 positive and PD-L1 negative as well as second-line metastatic triple-negative breast cancer. As the leading regimen in second line, Trodelvy is already well established with oncologists and these updates build momentum for Trodelvy ahead of potential first-line launches expected later this year.</td><td>ì´ëŸ¬í•œ ì§„ë£Œ ê´€í–‰ì„ ë³€í™”ì‹œí‚¬ ìˆ˜ ìˆëŠ” ë°ì´í„°ëŠ” í˜„ì¬ ë‰´ì‰ê¸€ëœë“œ ì˜í•™ì €ë„(New England Journal of Medicine)ì— ê²Œì¬ë˜ì—ˆìœ¼ë©°, NCCNì˜ ì—…ë°ì´íŠ¸ëœ ìœ ë°©ì•” ê°€ì´ë“œë¼ì¸ì—ì„œ ì¸ì •ë°›ì•˜ìŠµë‹ˆë‹¤. íŠ¸ë¡œë¸ë¹„ëŠ” í˜„ì¬ NCCNì—ì„œ 1ì°¨ ì¹˜ë£Œ PD-L1 ì–‘ì„± ë° PD-L1 ìŒì„±, ê·¸ë¦¬ê³  2ì°¨ ì¹˜ë£Œ ì „ì´ì„± ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•”ì— ê¶Œê³ ë˜ëŠ” ìœ ì¼í•œ í•­ì²´-ì•½ë¬¼ ì ‘í•©ì²´ì…ë‹ˆë‹¤. 2ì°¨ ì¹˜ë£Œì—ì„œ ì„ ë„ì ì¸ ì¹˜ë£Œë²•ìœ¼ë¡œì„œ íŠ¸ë¡œë¸ë¹„ëŠ” ì´ë¯¸ ì¢…ì–‘í•™ ì „ë¬¸ì˜ë“¤ ì‚¬ì´ì—ì„œ í™•ê³ íˆ ìë¦¬ì¡ì•˜ìœ¼ë©°, ì´ëŸ¬í•œ ì—…ë°ì´íŠ¸ë“¤ì€ ì˜¬í•´ í›„ë°˜ ì˜ˆìƒë˜ëŠ” 1ì°¨ ì¹˜ë£Œ ì¶œì‹œë¥¼ ì•ë‘ê³  íŠ¸ë¡œë¸ë¹„ì˜ ëª¨ë©˜í…€ì„ êµ¬ì¶•í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Moving to cell therapy on Slide 15 and on behalf of Cindy and the Kite team, full year cell therapy sales were $1.8 billion, down 7% year-over-year, reflecting ongoing in and out-of-class competition. For the fourth quarter, cell therapy sales were $458 million, up 6% sequentially due to higher-than-expected patient treatments in advance of holidays in addition to onetime pricing adjustments. Year-over-year, fourth quarter cell therapy sales were down 6%, consistent with the trends we have discussed throughout 2025. For 2026, we continue to expect these competitive headwinds including in several countries outside the U.S., where we expect new entrants this year.</td><td>ìŠ¬ë¼ì´ë“œ 15ì˜ ì„¸í¬ì¹˜ë£Œì œë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì‹ ë””ì™€ Kite íŒ€ì„ ëŒ€í‘œí•˜ì—¬ ë§ì”€ë“œë¦¬ë©´, ì—°ê°„ ì„¸í¬ì¹˜ë£Œì œ ë§¤ì¶œì€ 18ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ëŒ€ë¹„ 7% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ë™ì¼ ê³„ì—´ ë‚´ì™¸ì˜ ì§€ì†ì ì¸ ê²½ìŸì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. 4ë¶„ê¸° ì„¸í¬ì¹˜ë£Œì œ ë§¤ì¶œì€ 4ì–µ 5,800ë§Œ ë‹¬ëŸ¬ë¡œ ì „ë¶„ê¸° ëŒ€ë¹„ 6% ì¦ê°€í–ˆëŠ”ë°, ì´ëŠ” ì—°íœ´ ì „ ì˜ˆìƒë³´ë‹¤ ë§ì€ í™˜ì ì¹˜ë£Œì™€ ì¼íšŒì„± ê°€ê²© ì¡°ì •ì— ê¸°ì¸í•©ë‹ˆë‹¤. ì „ë…„ ë™ê¸° ëŒ€ë¹„ë¡œëŠ” 4ë¶„ê¸° ì„¸í¬ì¹˜ë£Œì œ ë§¤ì¶œì´ 6% ê°ì†Œí–ˆìœ¼ë©°, ì´ëŠ” 2025ë…„ ë‚´ë‚´ ë…¼ì˜í•´ì˜¨ ì¶”ì„¸ì™€ ì¼ì¹˜í•©ë‹ˆë‹¤. 2026ë…„ì—ëŠ” ë¯¸êµ­ ì™¸ ì—¬ëŸ¬ êµ­ê°€ì—ì„œ ì‹ ê·œ ì§„ì…ìë“¤ì´ ì˜ˆìƒë˜ëŠ” ë“± ì´ëŸ¬í•œ ê²½ìŸ ì••ë ¥ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Additionally, cell therapy volumes are being impacted by a growing number of clinical trials, which is exciting for our industry and for the patients who could benefit from innovative new therapies from Kite and others. That said, this represents another near-term headwind. Overall, we expect Kite revenue to decline approximately 10% in 2026 compared to 2025. Looking to the second half of the year, the team is preparing for the potential launch of anito-cel in fourth line and later relapsed or refractory multiple myeloma.</td><td>ë˜í•œ, ì„¸í¬ì¹˜ë£Œì œ ë¬¼ëŸ‰ì€ ì¦ê°€í•˜ëŠ” ì„ìƒì‹œí—˜ ìˆ˜ë¡œ ì¸í•´ ì˜í–¥ì„ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ ì—…ê³„ì™€ Kite ë° ë‹¤ë¥¸ ê¸°ì—…ë“¤ì˜ í˜ì‹ ì ì¸ ì‹ ê·œ ì¹˜ë£Œì œë¡œë¶€í„° í˜œíƒì„ ë°›ì„ ìˆ˜ ìˆëŠ” í™˜ìë“¤ì—ê²ŒëŠ” ê³ ë¬´ì ì¸ ì¼ì…ë‹ˆë‹¤. ê·¸ëŸ¬ë‚˜ ì´ëŠ” ë˜ ë‹¤ë¥¸ ë‹¨ê¸° ì—­í’ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” Kite ë§¤ì¶œì´ 2025ë…„ ëŒ€ë¹„ 2026ë…„ì— ì•½ 10% ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. í•˜ë°˜ê¸°ë¥¼ ì „ë§í•˜ë©´, íŒ€ì€ 4ì°¨ ì¹˜ë£Œ ì´ìƒì˜ ì¬ë°œì„± ë˜ëŠ” ë¶ˆì‘ì„± ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…ì—ì„œ anito-celì˜ ì ì¬ì  ì¶œì‹œë¥¼ ì¤€ë¹„í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We believe anito-cel potential best-in-disease profile combined with Kite's exceptional manufacturing capabilities and industry-leading turnaround times puts us in a favorable position ahead of a potential commercial launch. Wrapping up our fourth quarter and 2025 on Slide 16, I'd like to highlight the exceptional strength of our existing commercial portfolio as well as our robust launch pipeline with the potential for 4 launches later this year.</td><td>4ë¶„ê¸°ì™€ 2025ë…„ ì „ë§ì„ ë§ˆë¬´ë¦¬í•˜ëŠ” ìŠ¬ë¼ì´ë“œ 16ì—ì„œ, ì €ëŠ” ì˜¬í•´ í›„ë°˜ 4ê°œì˜ ì œí’ˆ ì¶œì‹œ ê°€ëŠ¥ì„±ê³¼ í•¨ê»˜ ê¸°ì¡´ ìƒì—… í¬íŠ¸í´ë¦¬ì˜¤ì˜ íƒì›”í•œ ê°•ì ê³¼ ê²¬ê³ í•œ ì¶œì‹œ íŒŒì´í”„ë¼ì¸ì„ ê°•ì¡°í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤.<br><br>ìš°ë¦¬ëŠ” ì•„ë‹ˆí† ì…€(anito-cel)ì˜ ì ì¬ì  ë™ì¢… ìµœê³  í”„ë¡œíŒŒì¼ê³¼ Kiteì˜ ë›°ì–´ë‚œ ì œì¡° ì—­ëŸ‰ ë° ì—…ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ì²˜ë¦¬ ì‹œê°„ì´ ê²°í•©ë˜ì–´, ì ì¬ì ì¸ ìƒì—… ì¶œì‹œë¥¼ ì•ë‘ê³  ìœ ë¦¬í•œ ìœ„ì¹˜ì— ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We are committed to remaining focused on our ongoing launches of Livdelzi and Yeztugo in addition to ensuring that we are prepared to have an immediate impact with the potential launches of anito-cel in multiple myeloma, Trodelvy in first-line metastatic triple-negative breast cancer, BIC/LEN in HIV treatment and Bulevirtide in chronic hepatitis D. The addition of these potentially transformative therapies to our portfolio is incredibly energizing for our teams. We look forward to extending the reach of Gilead's therapies to many more patients who can benefit from them in 2026. And with that, I'll hand the call over to Dietmar.</td><td>ì €í¬ëŠ” Livdelziì™€ Yeztugoì˜ ì§€ì†ì ì¸ ì¶œì‹œì— ì§‘ì¤‘í•˜ëŠ” ë™ì‹œì—, ë‹¤ë°œì„± ê³¨ìˆ˜ì¢… ì¹˜ë£Œì œ anito-cel, 1ì°¨ ì¹˜ë£Œ ì „ì´ì„± ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•” ì¹˜ë£Œì œ Trodelvy, HIV ì¹˜ë£Œì œ BIC/LEN, ê·¸ë¦¬ê³  ë§Œì„± Dí˜• ê°„ì—¼ ì¹˜ë£Œì œ Bulevirtideì˜ ì ì¬ì  ì¶œì‹œì— ëŒ€ë¹„í•˜ì—¬ ì¦‰ê°ì ì¸ ì˜í–¥ë ¥ì„ ë°œíœ˜í•  ìˆ˜ ìˆë„ë¡ ì¤€ë¹„í•˜ëŠ” ë° ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì ì¬ì ìœ¼ë¡œ í˜ì‹ ì ì¸ ì¹˜ë£Œì œë“¤ì´ ì €í¬ í¬íŠ¸í´ë¦¬ì˜¤ì— ì¶”ê°€ë˜ëŠ” ê²ƒì€ íŒ€ì—ê²Œ ì—„ì²­ë‚œ í™œë ¥ì„ ë¶ˆì–´ë„£ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ì—ëŠ” ê¸¸ë¦¬ì–´ë“œì˜ ì¹˜ë£Œì œë“¤ì´ í˜œíƒì„ ë°›ì„ ìˆ˜ ìˆëŠ” ë” ë§ì€ í™˜ìë“¤ì—ê²Œ ë„ë‹¬í•  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•©ë‹ˆë‹¤. ê·¸ëŸ¼ ì´ì œ Dietmarì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Dietmar Berger<br>Chief Medical Officer<br><br>Thank you, Johanna, and good afternoon, everyone. I'd like to start by reflecting on 2025 and thanking the research and development teams and partners for an exceptional year of clinical execution. As shown in our 2025 milestones, on Slide 18, we received regulatory approvals for lenacapavir, our first-in-class capsid inhibitor for HIV prevention in the U.S., EU and 12 other countries. Additionally, we provided updates on 7 Phase III or pivotal Phase II trials, including positive updates for bictegravir plus lenacapavir, Trodelvy and anito-cel.</td><td>ë””íŠ¸ë§ˆë¥´ ë² ë¥´ê±°<br>ìµœê³ ì˜í•™ì±…ì„ì<br><br>ìš”í•œë‚˜, ê°ì‚¬í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. ë¨¼ì € 2025ë…„ì„ ë˜ëŒì•„ë³´ë©° íƒì›”í•œ ì„ìƒ ì‹¤í–‰ì„ ë³´ì—¬ì¤€ ì—°êµ¬ê°œë°œíŒ€ê³¼ íŒŒíŠ¸ë„ˆë“¤ì—ê²Œ ê°ì‚¬ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 18ì˜ 2025ë…„ ë§ˆì¼ìŠ¤í†¤ì—ì„œ ë³´ì‹œëŠ” ë°”ì™€ ê°™ì´, ìš°ë¦¬ëŠ” HIV ì˜ˆë°©ì„ ìœ„í•œ ìµœì´ˆì˜ ìº¡ì‹œë“œ ì–µì œì œì¸ ë ˆë‚˜ì¹´íŒŒë¹„ë¥´ì— ëŒ€í•´ ë¯¸êµ­, EU ë° ê¸°íƒ€ 12ê°œêµ­ì—ì„œ ê·œì œ ìŠ¹ì¸ì„ ë°›ì•˜ìŠµë‹ˆë‹¤. ë˜í•œ ë¹…í…Œê·¸ë¼ë¹„ë¥´+ë ˆë‚˜ì¹´íŒŒë¹„ë¥´, íŠ¸ë¡œë¸ë¹„, ì•„ë‹ˆí† -ì…€ì„ í¬í•¨í•œ 7ê±´ì˜ 3ìƒ ë˜ëŠ” ì¤‘ì¶”ì  2ìƒ ì„ìƒì‹œí—˜ì— ëŒ€í•œ ì—…ë°ì´íŠ¸ë¥¼ ì œê³µí–ˆìœ¼ë©°, ê¸ì •ì ì¸ ê²°ê³¼ë“¤ì„ ë°œí‘œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Looking ahead to 2026 and beyond, we are well positioned to progress our clinical programs across our 3 core therapeutic areas. Starting with HIV on Slide 19. We continue to advance a comprehensive pipeline with lenacapavir as the backbone. Our HIV pipeline could support up to 7 additional daily, weekly, monthly, twice yearly or yearly HIV product launches by the end of 2033. In the fourth quarter, we announced positive top line results from ARTISTRY-1 and 2 evaluating once-daily bictegravir, the most prescribed integrase inhibitor with lenacapavir, our breakthrough capsid inhibitor.</td><td>2026ë…„ê³¼ ê·¸ ì´í›„ë¥¼ ì „ë§í•˜ë©´, ìš°ë¦¬ëŠ” 3ê°œ í•µì‹¬ ì¹˜ë£Œ ì˜ì—­ì— ê±¸ì³ ì„ìƒ í”„ë¡œê·¸ë¨ì„ ì§„í–‰í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. 19í˜ì´ì§€ì˜ HIVë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë ˆë‚˜ì¹´íŒŒë¹„ë¥´(lenacapavir)ë¥¼ ì¤‘ì¶”ë¡œ í•˜ëŠ” í¬ê´„ì ì¸ íŒŒì´í”„ë¼ì¸ì„ ê³„ì† ë°œì „ì‹œí‚¤ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ HIV íŒŒì´í”„ë¼ì¸ì€ 2033ë…„ ë§ê¹Œì§€ ì¼ì¼, ì£¼ê°„, ì›”ê°„, 6ê°œì›” ë˜ëŠ” ì—°ê°„ íˆ¬ì—¬ ë°©ì‹ì˜ ìµœëŒ€ 7ê°œ ì¶”ê°€ HIV ì œí’ˆ ì¶œì‹œë¥¼ ì§€ì›í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. 4ë¶„ê¸°ì— ìš°ë¦¬ëŠ” ê°€ì¥ ë§ì´ ì²˜ë°©ë˜ëŠ” ì¸í…Œê·¸ë¼ì œ ì–µì œì œì¸ ë¹…í…Œê·¸ë¼ë¹„ë¥´(bictegravir)ì™€ ìš°ë¦¬ì˜ í˜ì‹ ì ì¸ ìº¡ì‹œë“œ ì–µì œì œì¸ ë ˆë‚˜ì¹´íŒŒë¹„ë¥´ë¥¼ í‰ê°€í•˜ëŠ” ARTISTRY-1ê³¼ 2ì˜ ê¸ì •ì ì¸ ì£¼ìš” ê²°ê³¼ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect to share detailed results from our positive Phase III trials at the CROI meeting in February with a potential FDA decision by the end of the year. Looking at our long-acting programs. We plan to share Phase III update from our ISLEND-1 and ISLEND-2 trials, evaluating islatravir plus in the first half of 2026. And for our twice yearly treatment program, we plan to initiate our Phase III trial evaluating lenacapavir plus broadly neutralizing antibodies in the second half of the year. Further, we have now completed our evaluation of the Phase I data for our long-acting INSTI candidates GS-3242 and GS-1219 as well as GS-1614 and islatravir prodrug.</td><td>ì €í¬ëŠ” 2ì›” CROI íšŒì˜ì—ì„œ ê¸ì •ì ì¸ 3ìƒ ì„ìƒì‹œí—˜ì˜ ìƒì„¸í•œ ê²°ê³¼ë¥¼ ê³µìœ í•  ì˜ˆì •ì´ë©°, ì—°ë§ê¹Œì§€ FDA ìŠ¹ì¸ ê²°ì •ì´ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¥ê¸° ì§€ì†í˜• í”„ë¡œê·¸ë¨ì„ ì‚´í´ë³´ë©´, 2026ë…„ ìƒë°˜ê¸°ì— islatravir plusë¥¼ í‰ê°€í•˜ëŠ” ISLEND-1 ë° ISLEND-2 ì„ìƒì‹œí—˜ì˜ 3ìƒ ì—…ë°ì´íŠ¸ë¥¼ ê³µìœ í•  ê³„íšì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì—° 2íšŒ íˆ¬ì—¬ ì¹˜ë£Œ í”„ë¡œê·¸ë¨ì˜ ê²½ìš°, ì˜¬í•´ í•˜ë°˜ê¸°ì— lenacapavirì™€ ê´‘ë²”ìœ„ ì¤‘í™”í•­ì²´ë¥¼ í‰ê°€í•˜ëŠ” 3ìƒ ì„ìƒì‹œí—˜ì„ ì‹œì‘í•  ê³„íšì…ë‹ˆë‹¤. ë˜í•œ, í˜„ì¬ ì¥ê¸° ì§€ì†í˜• INSTI í›„ë³´ë¬¼ì§ˆì¸ GS-3242ì™€ GS-1219, ê·¸ë¦¬ê³  GS-1614ì™€ islatravir ì „êµ¬ì•½ë¬¼ì— ëŒ€í•œ 1ìƒ ë°ì´í„° í‰ê°€ë¥¼ ì™„ë£Œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Consistent with the time line shared during our HIV analyst event in December 2024, we have identified DS-3242 as the most promising program with lenacapavir and prioritized its development as a potential twice yearly HIV treatment. As a result and as a reminder, we have discontinued the development of a twice yearly regimen with GS-1219 and a quarterly regimen with GS-1614. Turning to liver disease on Slide 20. We remain committed to further evaluating Livdelzi to potentially improve the standard of care for more patients with PBC.</td><td>2024ë…„ 12ì›” HIV ì• ë„ë¦¬ìŠ¤íŠ¸ ì´ë²¤íŠ¸ì—ì„œ ê³µìœ í•œ ì¼ì •ì— ë”°ë¼, ì €í¬ëŠ” ë ˆë‚˜ì¹´íŒŒë¹„ë¥´ì™€ í•¨ê»˜ DS-3242ë¥¼ ê°€ì¥ ìœ ë§í•œ í”„ë¡œê·¸ë¨ìœ¼ë¡œ ì„ ì •í–ˆìœ¼ë©°, ì ì¬ì ì¸ ì—° 2íšŒ HIV ì¹˜ë£Œì œë¡œì„œì˜ ê°œë°œì„ ìš°ì„ ìˆœìœ„ì— ë‘ì—ˆìŠµë‹ˆë‹¤. ê·¸ ê²°ê³¼, ë‹¤ì‹œ í•œë²ˆ ë§ì”€ë“œë¦¬ìë©´, GS-1219ë¥¼ ì´ìš©í•œ ì—° 2íšŒ ìš”ë²•ê³¼ GS-1614ë¥¼ ì´ìš©í•œ ë¶„ê¸°ë³„ ìš”ë²•ì˜ ê°œë°œì„ ì¤‘ë‹¨í–ˆìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 20ì˜ ê°„ì§ˆí™˜ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì €í¬ëŠ” ë” ë§ì€ ì›ë°œì„± ë‹´ì¦™ì„± ë‹´ê´€ì—¼(PBC) í™˜ìë“¤ì˜ í‘œì¤€ ì¹˜ë£Œë¥¼ ì ì¬ì ìœ¼ë¡œ ê°œì„ í•˜ê¸° ìœ„í•´ Livdelzië¥¼ ì§€ì†ì ìœ¼ë¡œ í‰ê°€í•˜ëŠ” ë° ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>At the liver meeting in November, we presented late-breaking real-world data showing that Livdelzi is an effective and well-tolerated alternative for PBC patients switching from obeticholic acid. Later this year, we expect to provide an update from our Phase III IDEAL study, evaluating Livdelzi in PBC patients with ALP levels between 1 and 1.67x the upper limit of normal, patients typically excluded from Phase III studies. If positive, these data could support the expansion of Livdelzi to incomplete responders to UDCA and potentially enable even more second-line PBC patients to achieve better biochemical and symptomatic control of their PBC. Moving to oncology on Slide 21.</td><td>11ì›” ê°„í•™íšŒì—ì„œ ìš°ë¦¬ëŠ” ì˜¤ë² í‹°ì½œì‚°ì—ì„œ ì „í™˜í•œ PBC í™˜ìë“¤ì—ê²Œ Livdelziê°€ íš¨ê³¼ì ì´ê³  ë‚´ì•½ì„±ì´ ìš°ìˆ˜í•œ ëŒ€ì•ˆì„ì„ ë³´ì—¬ì£¼ëŠ” ì‹¤ì œ ì„ìƒ ë°ì´í„°ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì˜¬í•´ í›„ë°˜ì—ëŠ” ALP ìˆ˜ì¹˜ê°€ ì •ìƒ ìƒí•œì¹˜ì˜ 1ë°°ì—ì„œ 1.67ë°° ì‚¬ì´ì¸ PBC í™˜ìë“¤, ì¦‰ ì¼ë°˜ì ìœ¼ë¡œ 3ìƒ ì„ìƒì‹œí—˜ì—ì„œ ì œì™¸ë˜ëŠ” í™˜ìë“¤ì„ ëŒ€ìƒìœ¼ë¡œ Livdelzië¥¼ í‰ê°€í•˜ëŠ” 3ìƒ IDEAL ì—°êµ¬ì˜ ì—…ë°ì´íŠ¸ë¥¼ ì œê³µí•  ì˜ˆì •ì…ë‹ˆë‹¤. ë§Œì•½ ê¸ì •ì ì¸ ê²°ê³¼ê°€ ë‚˜ì˜¨ë‹¤ë©´, ì´ ë°ì´í„°ëŠ” UDCAì— ë¶ˆì™„ì „ ë°˜ì‘ì„ ë³´ì´ëŠ” í™˜ìë“¤ë¡œ Livdelziì˜ ì ì‘ì¦ì„ í™•ëŒ€í•˜ëŠ” ê²ƒì„ ë’·ë°›ì¹¨í•  ìˆ˜ ìˆìœ¼ë©°, ì ì¬ì ìœ¼ë¡œ ë” ë§ì€ 2ì°¨ ì¹˜ë£Œ PBC í™˜ìë“¤ì´ ë” ë‚˜ì€ ìƒí™”í•™ì  ë° ì¦ìƒì  PBC ì¡°ì ˆì„ ë‹¬ì„±í•  ìˆ˜ ìˆê²Œ í•  ê²ƒì…ë‹ˆë‹¤. 21ë²ˆ ìŠ¬ë¼ì´ë“œì˜ ì¢…ì–‘í•™ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Trodelvy has demonstrated clinically meaningful survival benefit in 2 Phase III trials establishing it as a leading regimen in its approved indications. Most recently, Trodelvy has demonstrated highly statistically significant and clinically meaningful progression-free survival benefit across first-line metastatic triple-negative breast cancer patients. Full data from the Phase III ASCENT-03 and ASCENT-04 trials were published in the New England Journal of Medicine in October 2025 and January 2026.</td><td>TrodelvyëŠ” 2ê±´ì˜ 3ìƒ ì„ìƒì‹œí—˜ì—ì„œ ì„ìƒì ìœ¼ë¡œ ì˜ë¯¸ ìˆëŠ” ìƒì¡´ ê¸°ê°„ ê°œì„  íš¨ê³¼ë¥¼ ì…ì¦í•˜ì—¬ ìŠ¹ì¸ëœ ì ì‘ì¦ì—ì„œ ì„ ë„ì ì¸ ì¹˜ë£Œë²•ìœ¼ë¡œ ìë¦¬ë§¤ê¹€í–ˆìŠµë‹ˆë‹¤. ê°€ì¥ ìµœê·¼ì—ëŠ” Trodelvyê°€ 1ì°¨ ì¹˜ë£Œ ì „ì´ì„± ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•” í™˜ìë“¤ì„ ëŒ€ìƒìœ¼ë¡œ í†µê³„ì ìœ¼ë¡œ ë§¤ìš° ìœ ì˜ë¯¸í•˜ê³  ì„ìƒì ìœ¼ë¡œ ì˜ë¯¸ ìˆëŠ” ë¬´ì§„í–‰ ìƒì¡´ê¸°ê°„ ê°œì„  íš¨ê³¼ë¥¼ ì…ì¦í–ˆìŠµë‹ˆë‹¤. 3ìƒ ASCENT-03 ë° ASCENT-04 ì„ìƒì‹œí—˜ì˜ ì „ì²´ ë°ì´í„°ëŠ” 2025ë…„ 10ì›”ê³¼ 2026ë…„ 1ì›” ë‰´ì‰ê¸€ëœë“œ ì˜í•™ì €ë„(New England Journal of Medicine)ì— ê²Œì¬ë˜ì—ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect FDA decisions for Trodelvy in first-line metastatic TNBC patients who are not candidates for PD-1 inhibitors and for Trodelvy plus pembrolizumab in first-line PD-L1 positive metastatic TNBC in the second half of 2026. Ahead of the FDA decisions, the NCCN updated their breast cancer guidelines to reflect the practice-changing nature of these results, reinforcing our confidence in Trodelvy's clinical profile. We also have 4 Phase III studies that continue to evaluate Trodelvy's potential in additional tumor types.</td><td>ì €í¬ëŠ” PD-1 ì–µì œì œ í›„ë³´ê°€ ì•„ë‹Œ 1ì°¨ ì „ì´ì„± TNBC í™˜ì ëŒ€ìƒ Trodelvyì™€ PD-L1 ì–‘ì„± 1ì°¨ ì „ì´ì„± TNBC ëŒ€ìƒ Trodelvyì™€ pembrolizumab ë³‘ìš©ìš”ë²•ì— ëŒ€í•œ FDA ìŠ¹ì¸ ê²°ì •ì´ 2026ë…„ í•˜ë°˜ê¸°ì— ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. FDA ìŠ¹ì¸ ê²°ì •ì— ì•ì„œ, NCCNì€ ì´ëŸ¬í•œ ê²°ê³¼ì˜ ì§„ë£Œ ê´€í–‰ ë³€í™” íŠ¹ì„±ì„ ë°˜ì˜í•˜ì—¬ ìœ ë°©ì•” ê°€ì´ë“œë¼ì¸ì„ ì—…ë°ì´íŠ¸í–ˆìœ¼ë©°, ì´ëŠ” Trodelvyì˜ ì„ìƒ í”„ë¡œíŒŒì¼ì— ëŒ€í•œ ì €í¬ì˜ í™•ì‹ ì„ ë”ìš± ê°•í™”ì‹œì¼œ ì¤ë‹ˆë‹¤. ë˜í•œ ì €í¬ëŠ” ì¶”ê°€ ì¢…ì–‘ ìœ í˜•ì—ì„œ Trodelvyì˜ ì ì¬ë ¥ì„ í‰ê°€í•˜ëŠ” 4ê°œì˜ 3ìƒ ì„ìƒì‹œí—˜ì„ ê³„ì† ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Notably, we expect updates from two of the Phase III trials this year, including ASCENT-GYN-01 evaluating Trodelvy in second-line metastatic endometrial cancer in the second half of this year, as well as EVOKE-03, exploring Trodelvy plus pembro in first-line metastatic PD-L1 high non-small cell lung cancer. Moving to cell therapy on Slide 22, and on behalf of Cindy and the Kite team, I will touch upon some of our updates on our needle cell program. Notably, we have filed anito-cel based on our update from the Phase II iMMagine-1 trial in fourth line or later relapsed or refractory multiple myeloma at ASH in December.</td><td>íŠ¹íˆ ì˜¬í•´ ë‘ ê±´ì˜ 3ìƒ ì„ìƒì‹œí—˜ ê²°ê³¼ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì²«ì§¸ëŠ” 2ì°¨ ì¹˜ë£Œ ì „ì´ì„± ìê¶ë‚´ë§‰ì•”ì—ì„œ Trodelvyë¥¼ í‰ê°€í•˜ëŠ” ASCENT-GYN-01 ì‹œí—˜ìœ¼ë¡œ ì˜¬í•´ í•˜ë°˜ê¸°ì— ê²°ê³¼ê°€ ë‚˜ì˜¬ ì˜ˆì •ì´ë©°, ë‘˜ì§¸ëŠ” 1ì°¨ ì¹˜ë£Œ ì „ì´ì„± PD-L1 ê³ ë°œí˜„ ë¹„ì†Œì„¸í¬íì•”ì—ì„œ Trodelvyì™€ í¨ë¸Œë¡¤ë¦¬ì£¼ë§™ ë³‘ìš©ìš”ë²•ì„ íƒìƒ‰í•˜ëŠ” EVOKE-03 ì‹œí—˜ì…ë‹ˆë‹¤. 22í˜ì´ì§€ ì„¸í¬ì¹˜ë£Œì œë¡œ ë„˜ì–´ê°€ì„œ, Cindyì™€ Kite íŒ€ì„ ëŒ€ì‹ í•˜ì—¬ ì €í¬ ë‹ˆë“¤ ì„¸í¬ í”„ë¡œê·¸ë¨ì˜ ì¼ë¶€ ì—…ë°ì´íŠ¸ ì‚¬í•­ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. íŠ¹íˆ ì§€ë‚œ 12ì›” ASHì—ì„œ ë°œí‘œí•œ 4ì°¨ ì¹˜ë£Œ ì´ìƒì˜ ì¬ë°œì„± ë˜ëŠ” ë¶ˆì‘ì„± ë‹¤ë°œì„±ê³¨ìˆ˜ì¢… ëŒ€ìƒ 2ìƒ iMMagine-1 ì„ìƒì‹œí—˜ ì—…ë°ì´íŠ¸ë¥¼ ê¸°ë°˜ìœ¼ë¡œ ì•„ë‹ˆí† ì…€(anito-cel)ì„ ì‹ ì²­í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Anito-cel demonstrated clinically meaningful efficacy with 96% overall response, including 74% complete response and 95% measurable residual disease negativity. Additionally, anito-cel demonstrated a predictable and manageable safety profile with no delayed or non-ICANS neurotoxicities and no immune effector cell-associated enterocolitis. Based on these exciting data, we are energized to potentially bring anito-cel to patients in the second half of this year. Longer term, we see additional opportunity for anito-cel with our Phase III iMMagine-3 study in second, third and fourth line relapsed or refractory multiple myeloma, enrolling in record time.</td><td>ì•„ë‹ˆí† -ì…€(Anito-cel)ì€ 96%ì˜ ì „ì²´ ë°˜ì‘ë¥ (overall response), 74%ì˜ ì™„ì „ ê´€í•´ìœ¨(complete response), ê·¸ë¦¬ê³  95%ì˜ ë¯¸ì„¸ì”ì¡´ì§ˆí™˜ ìŒì„±ë¥ (measurable residual disease negativity)ì„ í¬í•¨í•˜ì—¬ ì„ìƒì ìœ¼ë¡œ ì˜ë¯¸ ìˆëŠ” íš¨ëŠ¥ì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤. ë˜í•œ ì•„ë‹ˆí† -ì…€ì€ ì§€ì—°ì„± ë˜ëŠ” ë¹„-ICANS ì‹ ê²½ë…ì„±ì´ ì—†ê³  ë©´ì—­ íš¨ê³¼ ì„¸í¬ ê´€ë ¨ ì¥ì—¼(immune effector cell-associated enterocolitis)ì´ ì—†ëŠ” ì˜ˆì¸¡ ê°€ëŠ¥í•˜ê³  ê´€ë¦¬ ê°€ëŠ¥í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ì„ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê³ ë¬´ì ì¸ ë°ì´í„°ë¥¼ ë°”íƒ•ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ì˜¬í•´ í•˜ë°˜ê¸°ì— ì•„ë‹ˆí† -ì…€ì„ í™˜ìë“¤ì—ê²Œ ì œê³µí•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ë©° í™œë ¥ì„ ì–»ê³  ìˆìŠµë‹ˆë‹¤. ì¥ê¸°ì ìœ¼ë¡œëŠ”, ê¸°ë¡ì ì¸ ì†ë„ë¡œ ë“±ë¡ì„ ì§„í–‰ ì¤‘ì¸ 2ì°¨, 3ì°¨, 4ì°¨ ì¬ë°œì„± ë˜ëŠ” ë¶ˆì‘ì„± ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…(relapsed or refractory multiple myeloma)ì„ ëŒ€ìƒìœ¼ë¡œ í•œ 3ìƒ iMMagine-3 ì—°êµ¬ë¥¼ í†µí•´ ì•„ë‹ˆí† -ì…€ì˜ ì¶”ê°€ì ì¸ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We are also planning a pivotal program in newly diagnosed multiple myeloma. With our broader and rapidly advancing clinical development program, we expect anito-cel to potentially reach more patients earlier in the treatment paradigm. Wrapping up on Slide 23. Our key milestones for 2026 include 5 Phase III readouts as well as 5 FDA decisions for Bulevirtide for chronic hepatitis delta, BIC/LEN for virologically suppressed people with HIV, Trodelvy in first-line PD-L1 positive and negative metastatic triple-negative breast cancer and anito-cel in fourth line and later relapsed or refractory multiple myeloma.</td><td>ë˜í•œ ìƒˆë¡œ ì§„ë‹¨ëœ ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…ì— ëŒ€í•œ í”¼ë²— í”„ë¡œê·¸ë¨ë„ ê³„íší•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”ìš± ê´‘ë²”ìœ„í•˜ê³  ë¹ ë¥´ê²Œ ì§„í–‰ë˜ëŠ” ì„ìƒ ê°œë°œ í”„ë¡œê·¸ë¨ì„ í†µí•´ anito-celì´ ì¹˜ë£Œ íŒ¨ëŸ¬ë‹¤ì„ì˜ ë” ì´ë¥¸ ë‹¨ê³„ì—ì„œ ë” ë§ì€ í™˜ìë“¤ì—ê²Œ ë„ë‹¬í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 23ìœ¼ë¡œ ë§ˆë¬´ë¦¬í•˜ê² ìŠµë‹ˆë‹¤. 2026ë…„ ì£¼ìš” ë§ˆì¼ìŠ¤í†¤ìœ¼ë¡œëŠ” 5ê±´ì˜ 3ìƒ ì„ìƒ ê²°ê³¼ ë°œí‘œì™€ 5ê±´ì˜ FDA ìŠ¹ì¸ ê²°ì •ì´ ì˜ˆì •ë˜ì–´ ìˆìŠµë‹ˆë‹¤. êµ¬ì²´ì ìœ¼ë¡œëŠ” ë§Œì„± Dí˜• ê°„ì—¼ ì¹˜ë£Œì œ Bulevirtide, HIV ë°”ì´ëŸ¬ìŠ¤ ì–µì œ í™˜ì ëŒ€ìƒ BIC/LEN, PD-L1 ì–‘ì„± ë° ìŒì„± ì „ì´ì„± ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•” 1ì°¨ ì¹˜ë£Œì œ Trodelvy, ê·¸ë¦¬ê³  4ì°¨ ì´ìƒ ì¬ë°œì„± ë˜ëŠ” ë¶ˆì‘ì„± ë‹¤ë°œì„± ê³¨ìˆ˜ì¢… ì¹˜ë£Œì œ anito-celì— ëŒ€í•œ ê²°ì •ë“¤ì…ë‹ˆë‹¤.</td></tr>
<tr><td>While these pipeline milestones reflect some of our later-stage catalysts, I would like to remind you we have 53 ongoing clinical programs and will continue our progress across our portfolio, including KITE-753, our next-generation CD19, CD20, bicistronic CAR-T, enrolling for its pivotal trial for third-line large B-cell lymphoma, GS-1427, a once daily oral alpha-4-beta-7 inhibitor for inflammatory bowel disease, and edecesertib, our IRAK-4 inhibitor for cutaneous lupus erythematosus. And with that, I will turn over the call to Andy. Andrew Dickinson<br>Chief Financial Officer<br><br>Thank you, Dietmar, and good afternoon, everyone.</td><td>ì´ëŸ¬í•œ íŒŒì´í”„ë¼ì¸ ë§ˆì¼ìŠ¤í†¤ë“¤ì´ ì¼ë¶€ í›„ê¸° ë‹¨ê³„ ì´‰ë§¤ì œë“¤ì„ ë°˜ì˜í•˜ê³  ìˆì§€ë§Œ, ì €í¬ê°€ 53ê°œì˜ ì§„í–‰ ì¤‘ì¸ ì„ìƒ í”„ë¡œê·¸ë¨ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©° í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì— ê±¸ì³ ì§€ì†ì ìœ¼ë¡œ ì§„ì „ì„ ì´ë£¨ê³  ìˆë‹¤ëŠ” ì ì„ ìƒê¸°ì‹œì¼œ ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” 3ì°¨ ì¹˜ë£Œ ëŒ€í˜• Bì„¸í¬ ë¦¼í”„ì¢…ì— ëŒ€í•œ í”¼ë³´íƒˆ ì„ìƒì‹œí—˜ì— ë“±ë¡ ì¤‘ì¸ ì°¨ì„¸ëŒ€ CD19, CD20 ë°”ì´ì‹œìŠ¤íŠ¸ë¡œë‹‰ CAR-Tì¸ KITE-753, ì—¼ì¦ì„± ì¥ì§ˆí™˜ ì¹˜ë£Œì œì¸ 1ì¼ 1íšŒ ê²½êµ¬ ì•ŒíŒŒ-4-ë² íƒ€-7 ì–µì œì œ GS-1427, ê·¸ë¦¬ê³  í”¼ë¶€ í™ë°˜ì„± ë£¨í‘¸ìŠ¤ ì¹˜ë£Œì œì¸ IRAK-4 ì–µì œì œ ì—ë°ì„¸ì„œíŒì´ í¬í•¨ë©ë‹ˆë‹¤. ì´ì œ Andyì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Andrew Dickinson<br>ìµœê³ ì¬ë¬´ì±…ì„ì<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Dietmar. ê·¸ë¦¬ê³  ì—¬ëŸ¬ë¶„ ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ.</td></tr>
<tr><td>Starting on Slide 25, full year 2025 total product sales of $28.9 billion were up 1% from 2024 and above our $28.4 billion to $28.7 billion guidance range driven by demand-led HIV sales growth that more than offset the $1.1 billion headwind related to Part D redesign and $900 million lower Veklury revenue. Excluding the Part D redesign impact, our total product sales grew nearly 5%. Base business revenue, which reflects total product sales, excluding Veklury, was $28 billion up nearly $1.2 billion or 4% from 2024, exceeding our $27.4 billion to $27.7 billion guidance range. Excluding the impact of the Part D redesign, our base business grew 8%.</td><td>ìŠ¬ë¼ì´ë“œ 25ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. 2025ë…„ ì—°ê°„ ì´ ì œí’ˆ ë§¤ì¶œì€ 289ì–µ ë‹¬ëŸ¬ë¡œ 2024ë…„ ëŒ€ë¹„ 1% ì¦ê°€í–ˆìœ¼ë©°, ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì¸ 284ì–µ~287ì–µ ë‹¬ëŸ¬ë¥¼ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ìˆ˜ìš” ì£¼ë„ì˜ HIV ë§¤ì¶œ ì„±ì¥ì´ Part D ì¬ì„¤ê³„ ê´€ë ¨ 11ì–µ ë‹¬ëŸ¬ì˜ ì—­í’ê³¼ Veklury ë§¤ì¶œ 9ì–µ ë‹¬ëŸ¬ ê°ì†Œë¥¼ ìƒì‡„í•˜ê³ ë„ ë‚¨ì•˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. Part D ì¬ì„¤ê³„ ì˜í–¥ì„ ì œì™¸í•˜ë©´, ì´ ì œí’ˆ ë§¤ì¶œì€ ê±°ì˜ 5% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. <br><br>Vekluryë¥¼ ì œì™¸í•œ ì´ ì œí’ˆ ë§¤ì¶œì„ ë°˜ì˜í•˜ëŠ” ê¸°ë³¸ ì‚¬ì—… ë§¤ì¶œì€ 280ì–µ ë‹¬ëŸ¬ë¡œ 2024ë…„ ëŒ€ë¹„ ì•½ 12ì–µ ë‹¬ëŸ¬, ì¦‰ 4% ì¦ê°€í•˜ì—¬ ê°€ì´ë˜ìŠ¤ ë²”ìœ„ì¸ 274ì–µ~277ì–µ ë‹¬ëŸ¬ë¥¼ ì´ˆê³¼ ë‹¬ì„±í–ˆìŠµë‹ˆë‹¤. Part D ì¬ì„¤ê³„ ì˜í–¥ì„ ì œì™¸í•˜ë©´, ê¸°ë³¸ ì‚¬ì—…ì€ 8% ì„±ì¥í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Our strong revenue results reflected HIV growth of 6% or $1.1 billion to $20.8 billion, driven by strong growth for Biktarvy and Descovy, which grew 7% and 31% respectively, from 2024 as well as the launch of Yeztugo. And our liver business grew 6% to $3.2 billion, reflecting growing demand primarily driven by Livdelzi. Full year 2025 Veklury revenue was $911 million, a decline of $900 million or 49% from 2024 and mostly in line with our expectations given lower COVID-19-related hospitalization trends. Moving to our full year non-GAAP results on Slide 26. Product gross margin was 86.4%, in line with our guidance of 86%.</td><td>ìš°ë¦¬ì˜ ê²¬ì¡°í•œ ë§¤ì¶œ ì‹¤ì ì€ HIV ë¶€ë¬¸ì´ 6% ì„±ì¥í•˜ì—¬ 11ì–µ ë‹¬ëŸ¬ ì¦ê°€í•œ 208ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•œ ê²ƒì„ ë°˜ì˜í•©ë‹ˆë‹¤. ì´ëŠ” Biktarvyì™€ Descovyì˜ ê°•ë ¥í•œ ì„±ì¥ì— í˜ì…ì€ ê²ƒìœ¼ë¡œ, ê°ê° 2024ë…„ ëŒ€ë¹„ 7%ì™€ 31% ì„±ì¥í–ˆìœ¼ë©°, Yeztugoì˜ ì¶œì‹œë„ ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê°„ì§ˆí™˜ ì‚¬ì—…ë¶€ëŠ” 6% ì„±ì¥í•˜ì—¬ 32ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆëŠ”ë°, ì´ëŠ” ì£¼ë¡œ Livdelziê°€ ê²¬ì¸í•œ ìˆ˜ìš” ì¦ê°€ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. 2025ë…„ ì—°ê°„ Veklury ë§¤ì¶œì€ 9ì–µ 1,100ë§Œ ë‹¬ëŸ¬ë¡œ, 2024ë…„ ëŒ€ë¹„ 9ì–µ ë‹¬ëŸ¬ ê°ì†Œí•˜ì—¬ 49% í•˜ë½í–ˆìœ¼ë©°, COVID-19 ê´€ë ¨ ì…ì› ì¶”ì„¸ ê°ì†Œë¥¼ ê°ì•ˆí•  ë•Œ ëŒ€ì²´ë¡œ ìš°ë¦¬ì˜ ì˜ˆìƒê³¼ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤. ìŠ¬ë¼ì´ë“œ 26ì˜ ì—°ê°„ non-GAAP ì‹¤ì ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì œí’ˆ ë§¤ì¶œì´ì´ìµë¥ ì€ 86.4%ë¡œ, ìš°ë¦¬ì˜ ê°€ì´ë˜ìŠ¤ì¸ 86%ì™€ ì¼ì¹˜í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>R&D expenses of $5.7 billion were down 1% compared to 2024 and in line with our guidance of R&D flat on a dollar basis for 2025. Acquired IPR&D expenses were approximately $1 billion, in line with our expected annual investment in earlier-stage opportunities that are part of our normal course of business development. And SG&A expenses of $5.6 billion were down 5% compared to 2024 within our guidance range, reflecting lower general and administrative expenses, partially offset by sales and marketing investments to support Yeztugo's launch. Overall, our operating margin for full year 2025 was 45%.</td><td>R&D ë¹„ìš©ì€ 57ì–µ ë‹¬ëŸ¬ë¡œ 2024ë…„ ëŒ€ë¹„ 1% ê°ì†Œí–ˆìœ¼ë©°, 2025ë…„ R&Dë¥¼ ë‹¬ëŸ¬ ê¸°ì¤€ìœ¼ë¡œ ë³´í•© ìˆ˜ì¤€ìœ¼ë¡œ ìœ ì§€í•˜ê² ë‹¤ëŠ” ë‹¹ì‚¬ì˜ ê°€ì´ë˜ìŠ¤ì™€ ì¼ì¹˜í•©ë‹ˆë‹¤. ì·¨ë“í•œ IPR&D ë¹„ìš©ì€ ì•½ 10ì–µ ë‹¬ëŸ¬ë¡œ, ì •ìƒì ì¸ ì‚¬ì—… ê°œë°œ ê³¼ì •ì˜ ì¼í™˜ìœ¼ë¡œ ì´ˆê¸° ë‹¨ê³„ ê¸°íšŒì— ëŒ€í•œ ì—°ê°„ íˆ¬ì ì˜ˆìƒì¹˜ì™€ ì¼ì¹˜í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  íŒë§¤ê´€ë¦¬ë¹„ëŠ” 56ì–µ ë‹¬ëŸ¬ë¡œ 2024ë…„ ëŒ€ë¹„ 5% ê°ì†Œí–ˆìœ¼ë©° ê°€ì´ë˜ìŠ¤ ë²”ìœ„ ë‚´ì— ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¼ë°˜ê´€ë¦¬ë¹„ ê°ì†Œë¥¼ ë°˜ì˜í•œ ê²ƒì´ë©°, Yeztugo ì¶œì‹œë¥¼ ì§€ì›í•˜ê¸° ìœ„í•œ íŒë§¤ ë° ë§ˆì¼€íŒ… íˆ¬ìë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ 2025ë…„ ì „ì²´ ì—°ë„ ì˜ì—…ì´ìµë¥ ì€ 45%ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Excluding acquired IPR&D and the $400 million nonrecurring other revenue related to the IP asset sale in the third quarter, our operating margin was roughly 48% for the full year. This underscores our ability to continue expense discipline while increasing investment in new and ongoing launches. The non-GAAP effective tax rate was 18.3%, roughly in line with our guidance of approximately 19% and down from 25.9% in 2024, primarily driven by the prior year nondeductible acquired IPR&D charge for the acquisition of CymaBay.</td><td>ì¸ìˆ˜í•œ IPR&Dì™€ 3ë¶„ê¸° IP ìì‚° ë§¤ê°ê³¼ ê´€ë ¨ëœ 4ì–µ ë‹¬ëŸ¬ì˜ ì¼íšŒì„± ê¸°íƒ€ ìˆ˜ìµì„ ì œì™¸í•˜ë©´, ì—°ê°„ ì˜ì—…ì´ìµë¥ ì€ ì•½ 48%ì˜€ìŠµë‹ˆë‹¤. ì´ëŠ” ì‹ ê·œ ë° ì§„í–‰ ì¤‘ì¸ ì œí’ˆ ì¶œì‹œì— ëŒ€í•œ íˆ¬ìë¥¼ ëŠ˜ë¦¬ë©´ì„œë„ ë¹„ìš© ê·œìœ¨ì„ ì§€ì†ì ìœ¼ë¡œ ìœ ì§€í•  ìˆ˜ ìˆëŠ” ìš°ë¦¬ì˜ ì—­ëŸ‰ì„ ë³´ì—¬ì¤ë‹ˆë‹¤. Non-GAAP ì‹¤íš¨ì„¸ìœ¨ì€ 18.3%ë¡œ, ì•½ 19%ë¼ëŠ” ê°€ì´ë˜ìŠ¤ì™€ ëŒ€ì²´ë¡œ ì¼ì¹˜í•˜ë©°, 2024ë…„ì˜ 25.9%ì—ì„œ í•˜ë½í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ ì „ë…„ë„ CymaBay ì¸ìˆ˜ì™€ ê´€ë ¨í•˜ì—¬ ì„¸ê¸ˆ ê³µì œê°€ ë¶ˆê°€ëŠ¥í–ˆë˜ IPR&D ë¹„ìš©ì— ê¸°ì¸í•©ë‹ˆë‹¤.</td></tr>
<tr><td>And finally, non-GAAP diluted EPS was $8.15, in line with our 2025 guidance of $8.05 to $8.25 and driven by lower acquired IPR&D expenses, higher revenues and lower SG&A expenses. Excluding the approximately $3.14 per share impact related to the CymaBay transaction, non-GAAP diluted EPS increased by $0.40 compared to 2024. To quickly recap the fourth quarter on Slide 27. Total product sales were $7.9 billion, up 5% year-over-year, with base business growth partially offset by the expected decline in Veklury sales. Excluding Veklury, total product sales were $7.7 billion, up 7% from the same period in 2024, primarily driven by higher sales for our HIV and liver disease products.</td><td>ë§ˆì§€ë§‰ìœ¼ë¡œ, non-GAAP í¬ì„ ì£¼ë‹¹ìˆœì´ìµì€ 8.15ë‹¬ëŸ¬ë¡œ, 2025ë…„ ê°€ì´ë˜ìŠ¤ì¸ 8.05ë‹¬ëŸ¬ì—ì„œ 8.25ë‹¬ëŸ¬ ë²”ìœ„ì— ë¶€í•©í–ˆìœ¼ë©°, ì´ëŠ” ì¸ìˆ˜ ê´€ë ¨ IPR&D ë¹„ìš© ê°ì†Œ, ë§¤ì¶œ ì¦ê°€ ë° íŒë§¤ê´€ë¦¬ë¹„ ê°ì†Œì— ê¸°ì¸í–ˆìŠµë‹ˆë‹¤. CymaBay ì¸ìˆ˜ ê±°ë˜ì™€ ê´€ë ¨ëœ ì£¼ë‹¹ ì•½ 3.14ë‹¬ëŸ¬ì˜ ì˜í–¥ì„ ì œì™¸í•˜ë©´, non-GAAP í¬ì„ ì£¼ë‹¹ìˆœì´ìµì€ 2024ë…„ ëŒ€ë¹„ 0.40ë‹¬ëŸ¬ ì¦ê°€í–ˆìŠµë‹ˆë‹¤.<br><br>27í˜ì´ì§€ì˜ 4ë¶„ê¸° ì‹¤ì ì„ ê°„ëµíˆ ìš”ì•½í•˜ê² ìŠµë‹ˆë‹¤. ì´ ì œí’ˆ ë§¤ì¶œì€ 79ì–µ ë‹¬ëŸ¬ë¡œ ì „ë…„ ë™ê¸° ëŒ€ë¹„ 5% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ê¸°ë³¸ ì‚¬ì—…ì˜ ì„±ì¥ì´ ì˜ˆìƒëœ Veklury ë§¤ì¶œ ê°ì†Œë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ëœ ê²°ê³¼ì…ë‹ˆë‹¤. Vekluryë¥¼ ì œì™¸í•œ ì´ ì œí’ˆ ë§¤ì¶œì€ 77ì–µ ë‹¬ëŸ¬ë¡œ 2024ë…„ ë™ê¸° ëŒ€ë¹„ 7% ì¦ê°€í–ˆìœ¼ë©°, ì´ëŠ” ì£¼ë¡œ HIV ë° ê°„ì§ˆí™˜ ì¹˜ë£Œì œì˜ ë§¤ì¶œ ì¦ê°€ì— ê¸°ì¸í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Moving to the fourth quarter P&L on Slide 28. R&D expenses were $1.6 billion, down 3% relative to the same period in 2024 and SG&A expenses were $1.7 billion, down 9% year-over-year primarily due to lower G&A expenses. Overall, our non-GAAP diluted earnings per share was $1.86 in the fourth quarter of 2025 compared to $1.90 in the same period in 2024, primarily due to higher acquired IPR&D expenses, partially offset by higher product sales and lower SG&A expenses. Looking at our full year guidance on Slide 29. We expect 2026 total product sales between $29.6 billion and $30 billion.</td><td>28í˜ì´ì§€ì˜ 4ë¶„ê¸° ì†ìµê³„ì‚°ì„œë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. R&D ë¹„ìš©ì€ 16ì–µ ë‹¬ëŸ¬ë¡œ 2024ë…„ ë™ê¸° ëŒ€ë¹„ 3% ê°ì†Œí–ˆìœ¼ë©°, SG&A ë¹„ìš©ì€ 17ì–µ ë‹¬ëŸ¬ë¡œ ì£¼ë¡œ ì¼ë°˜ê´€ë¦¬ë¹„ ê°ì†Œë¡œ ì¸í•´ ì „ë…„ ëŒ€ë¹„ 9% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ 2025ë…„ 4ë¶„ê¸° non-GAAP í¬ì„ ì£¼ë‹¹ìˆœì´ìµì€ 1.86ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” 2024ë…„ ë™ê¸°ì˜ 1.90ë‹¬ëŸ¬ì™€ ë¹„êµë©ë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ ì·¨ë“ IPR&D ë¹„ìš© ì¦ê°€ì— ê¸°ì¸í•˜ë©°, ì œí’ˆ ë§¤ì¶œ ì¦ê°€ì™€ SG&A ë¹„ìš© ê°ì†Œë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë˜ì—ˆìŠµë‹ˆë‹¤. 29í˜ì´ì§€ì˜ ì—°ê°„ ê°€ì´ë˜ìŠ¤ë¥¼ ë³´ì‹œë©´, 2026ë…„ ì´ ì œí’ˆ ë§¤ì¶œì€ 296ì–µ ë‹¬ëŸ¬ì—ì„œ 300ì–µ ë‹¬ëŸ¬ ì‚¬ì´ë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect total Veklury sales of approximately $600 million, highlighting a $300 million headwind that we expect to more than offset in our base business. We, therefore, expect base business sales between $29 million and $29.4 billion growth of 4% to 5% compared to 2025. Moving to the non-GAAP P&L for the full year 2026. We expect product gross margin of approximately 87%, R&D expenses to increase a low single-digit percentage from 2025, acquired IPR&D investments of approximately $300 million, reflecting known commitments associated with prior collaborations and partnerships.</td><td>ì €í¬ëŠ” Veklury ì´ ë§¤ì¶œì´ ì•½ 6ì–µ ë‹¬ëŸ¬ì— ë‹¬í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” 3ì–µ ë‹¬ëŸ¬ì˜ ì—­í’ì„ ì˜ë¯¸í•˜ì§€ë§Œ ê¸°ë³¸ ì‚¬ì—…ì—ì„œ ì´ë¥¼ ìƒì‡„í•˜ê³ ë„ ë‚¨ì„ ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ê¸°ë³¸ ì‚¬ì—… ë§¤ì¶œì€ 290ì–µ~294ì–µ ë‹¬ëŸ¬ ì‚¬ì´ë¡œ 2025ë…„ ëŒ€ë¹„ 4~5% ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. <br><br>2026ë…„ ì „ì²´ ì—°ë„ ë¹„-GAAP ì†ìµê³„ì‚°ì„œë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì œí’ˆ ë§¤ì¶œì´ì´ìµë¥ ì€ ì•½ 87%, R&D ë¹„ìš©ì€ 2025ë…„ ëŒ€ë¹„ ë‚®ì€ í•œ ìë¦¿ìˆ˜ ì¦ê°€ìœ¨ì„ ì˜ˆìƒí•˜ë©°, ì·¨ë“í•œ ì§„í–‰ ì¤‘ì¸ ì—°êµ¬ê°œë°œ(IPR&D) íˆ¬ìëŠ” ì•½ 3ì–µ ë‹¬ëŸ¬ë¡œ, ì´ëŠ” ì´ì „ í˜‘ë ¥ ë° íŒŒíŠ¸ë„ˆì‹­ê³¼ ê´€ë ¨ëœ ê¸°ì¡´ ì•½ì •ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Consistent with our approach in 2025, we will highlight incremental acquired IPR&D expenses as we announce new transactions throughout the year. And SG&A expenses to increase by a mid-single-digit percentage relative to 2025, reflecting higher investments in sales and marketing to support our commercial launches, offset in part by lower G&A expenses. We expect full year 2026 non-GAAP operating income of between $13.8 billion and $14.3 billion, a tax rate of approximately 20% and non-GAAP diluted EPS in the range of $8.45 and $8.85 per share.</td><td>2025ë…„ì˜ ì ‘ê·¼ ë°©ì‹ê³¼ ì¼ê´€ë˜ê²Œ, ì—°ì¤‘ ìƒˆë¡œìš´ ê±°ë˜ë¥¼ ë°œí‘œí•  ë•Œë§ˆë‹¤ ì¦ë¶„ ì¸ìˆ˜ IPR&D ë¹„ìš©ì„ ë³„ë„ë¡œ ê°•ì¡°í•  ì˜ˆì •ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  íŒë§¤ê´€ë¦¬ë¹„ëŠ” 2025ë…„ ëŒ€ë¹„ ì¤‘ê°„ í•œ ìë¦¿ìˆ˜ ë¹„ìœ¨ë¡œ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ”ë°, ì´ëŠ” ìƒì—…ì  ì¶œì‹œë¥¼ ì§€ì›í•˜ê¸° ìœ„í•œ ì˜ì—… ë° ë§ˆì¼€íŒ… íˆ¬ì ì¦ê°€ë¥¼ ë°˜ì˜í•˜ë©°, ì¼ë°˜ê´€ë¦¬ë¹„ ê°ì†Œë¡œ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„ë  ê²ƒì…ë‹ˆë‹¤. 2026ë…„ ì—°ê°„ non-GAAP ì˜ì—…ì´ìµì€ 138ì–µ ë‹¬ëŸ¬ì—ì„œ 143ì–µ ë‹¬ëŸ¬ ì‚¬ì´, ì„¸ìœ¨ì€ ì•½ 20%, ê·¸ë¦¬ê³  non-GAAP í¬ì„ ì£¼ë‹¹ìˆœì´ìµì€ ì£¼ë‹¹ 8.45ë‹¬ëŸ¬ì—ì„œ 8.85ë‹¬ëŸ¬ ë²”ìœ„ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>As Johanna mentioned, and as shown on Slide 30, a we expect an approximate 2% headwind to growth in 2026, primarily associated with the impact of the drug pricing agreement announced in December 2025 and the expected impact of updates to the Affordable Care Act. I'll note that absent these updates, our full year growth would be in the range of 6% to 7%. Additionally, we expect HIV to grow approximately 6% in 2026. And within HIV, we expect 2026 Yeztugo revenue of approximately $800 million. In cell therapy, we expect full year 2026 revenues to decline approximately 10% compared to 2025, reflecting continued competitive headwinds related to our Kite portfolio.</td><td>ìš”í•œë‚˜ê°€ ì–¸ê¸‰í–ˆë“¯ì´, ê·¸ë¦¬ê³  ìŠ¬ë¼ì´ë“œ 30ì— ë‚˜ì™€ ìˆëŠ” ê²ƒì²˜ëŸ¼, ìš°ë¦¬ëŠ” 2026ë…„ì— ì•½ 2%ì˜ ì„±ì¥ ì—­í’ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ 2025ë…„ 12ì›”ì— ë°œí‘œëœ ì•½ê°€ í˜‘ìƒì˜ ì˜í–¥ê³¼ ì˜ë£Œë³´í—˜ê°œí˜ë²•(Affordable Care Act) ê°œì •ì˜ ì˜ˆìƒ ì˜í–¥ê³¼ ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê°œì •ì´ ì—†ì—ˆë‹¤ë©´, ìš°ë¦¬ì˜ ì—°ê°„ ì„±ì¥ë¥ ì€ 6%ì—ì„œ 7% ë²”ìœ„ì— ìˆì—ˆì„ ê²ƒì´ë¼ëŠ” ì ì„ ë§ì”€ë“œë¦½ë‹ˆë‹¤. ì¶”ê°€ë¡œ, HIV ë¶€ë¬¸ì€ 2026ë…„ì— ì•½ 6% ì„±ì¥í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. HIV ë‚´ì—ì„œ, ìš°ë¦¬ëŠ” 2026ë…„ ì˜ˆì¦ˆíˆ¬ê³ (Yeztugo) ë§¤ì¶œì´ ì•½ 8ì–µ ë‹¬ëŸ¬ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì„¸í¬ì¹˜ë£Œì œ ë¶€ë¬¸ì—ì„œëŠ”, 2025ë…„ ëŒ€ë¹„ 2026ë…„ ì—°ê°„ ë§¤ì¶œì´ ì•½ 10% ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ëŠ”ë°, ì´ëŠ” ì¹´ì´íŠ¸(Kite) í¬íŠ¸í´ë¦¬ì˜¤ì™€ ê´€ë ¨ëœ ì§€ì†ì ì¸ ê²½ìŸ ì—­í’ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>On Slide 31, we returned $5.9 billion to shareholders in 2025, and we remain committed to returning on average, at least 50% of our free cash flow to shareholders. In 2025, this included $1.9 billion of share repurchases, primarily intended to offset equity dilution at a minimum in addition to opportunistic repurchases. Combined with our dividend, we returned approximately 63% of our free cash flow to shareholders in 2025. In terms of business development, we are confident that we have built a robust and diverse portfolio that can support Gilead's growth.</td><td>ìŠ¬ë¼ì´ë“œ 31ì„ ë³´ì‹œë©´, 2025ë…„ì— ì£¼ì£¼ë“¤ì—ê²Œ 59ì–µ ë‹¬ëŸ¬ë¥¼ í™˜ì›í–ˆìœ¼ë©°, í‰ê· ì ìœ¼ë¡œ ì‰ì—¬í˜„ê¸ˆíë¦„ì˜ ìµœì†Œ 50%ë¥¼ ì£¼ì£¼ë“¤ì—ê²Œ í™˜ì›í•˜ê² ë‹¤ëŠ” ì•½ì†ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2025ë…„ì—ëŠ” 19ì–µ ë‹¬ëŸ¬ì˜ ìì‚¬ì£¼ ë§¤ì…ì´ í¬í•¨ë˜ì—ˆëŠ”ë°, ì´ëŠ” ì£¼ë¡œ ìµœì†Œí•œ ì£¼ì‹ í¬ì„ì„ ìƒì‡„í•˜ê¸° ìœ„í•œ ê²ƒê³¼ ë”ë¶ˆì–´ ê¸°íšŒì  ë§¤ì…ì„ ìœ„í•œ ê²ƒì´ì—ˆìŠµë‹ˆë‹¤. ë°°ë‹¹ê¸ˆê³¼ í•©ì‚°í•˜ì—¬, 2025ë…„ ì‰ì—¬í˜„ê¸ˆíë¦„ì˜ ì•½ 63%ë¥¼ ì£¼ì£¼ë“¤ì—ê²Œ í™˜ì›í–ˆìŠµë‹ˆë‹¤. ì‚¬ì—… ê°œë°œ ì¸¡ë©´ì—ì„œ, ìš°ë¦¬ëŠ” ê¸¸ë¦¬ì–´ë“œì˜ ì„±ì¥ì„ ë’·ë°›ì¹¨í•  ìˆ˜ ìˆëŠ” ê²¬ê³ í•˜ê³  ë‹¤ì–‘í•œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ êµ¬ì¶•í–ˆë‹¤ê³  í™•ì‹ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>At the same time, we are carefully strengthening our early-stage pipeline to position Gilead well for the long term, typically investing about $1 billion annually in smaller licensing deals, partnerships and acquisitions. Additionally, we are proactive and disciplined in our approach to later stage acquisitions that support our strategic goals and add new growth opportunities. Overall, we are pleased with Gilead's consistent strong performance highlighted by our clinical and commercial execution and supported by our disciplined operating model. We continue to be well positioned for near-term and long-term growth, and we remain focused on delivering on our strategic commitments.</td><td>ë™ì‹œì—, ìš°ë¦¬ëŠ” ê¸¸ë¦¬ì–´ë“œì˜ ì¥ê¸°ì  í¬ì§€ì…”ë‹ì„ ìœ„í•´ ì´ˆê¸° ë‹¨ê³„ íŒŒì´í”„ë¼ì¸ì„ ì‹ ì¤‘í•˜ê²Œ ê°•í™”í•˜ê³  ìˆìœ¼ë©°, ì¼ë°˜ì ìœ¼ë¡œ ì†Œê·œëª¨ ë¼ì´ì„ ì‹± ê³„ì•½, íŒŒíŠ¸ë„ˆì‹­ ë° ì¸ìˆ˜ì— ì—°ê°„ ì•½ 10ì–µ ë‹¬ëŸ¬ë¥¼ íˆ¬ìí•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ, ìš°ë¦¬ì˜ ì „ëµì  ëª©í‘œë¥¼ ë’·ë°›ì¹¨í•˜ê³  ìƒˆë¡œìš´ ì„±ì¥ ê¸°íšŒë¥¼ ì¶”ê°€í•˜ëŠ” í›„ê¸° ë‹¨ê³„ ì¸ìˆ˜ì— ëŒ€í•´ì„œë„ ì„ ì œì ì´ê³  ê·œìœ¨ ìˆëŠ” ì ‘ê·¼ ë°©ì‹ì„ ì·¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ì„ìƒ ë° ìƒì—…ì  ì‹¤í–‰ë ¥ìœ¼ë¡œ ê°•ì¡°ë˜ê³  ê·œìœ¨ ìˆëŠ” ìš´ì˜ ëª¨ë¸ë¡œ ë’·ë°›ì¹¨ë˜ëŠ” ê¸¸ë¦¬ì–´ë“œì˜ ì§€ì†ì ì¸ ê°•ë ¥í•œ ì‹¤ì ì— ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë‹¨ê¸° ë° ì¥ê¸° ì„±ì¥ì„ ìœ„í•œ ì¢‹ì€ í¬ì§€ì…˜ì„ ê³„ì† ìœ ì§€í•˜ê³  ìˆìœ¼ë©°, ì „ëµì  ì•½ì† ì´í–‰ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With that, I'll invite Rebecca to begin the Q&A.</td><td>ê·¸ëŸ¼ ì´ì œ Rebeccaì—ê²Œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ì‹œì‘í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Gilead Sciences Q4 2025 ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>## ì£¼ìš” ì¬ë¬´ ì„±ê³¼<br>- **2025ë…„ ì—°ê°„ ë§¤ì¶œ**: 289ì–µ ë‹¬ëŸ¬ (ì „ë…„ ëŒ€ë¹„ +1%, Part D ì˜í–¥ ì œì™¸ ì‹œ +5%)<br>- **ê¸°ë³¸ ì‚¬ì—… ë§¤ì¶œ**: 280ì–µ ë‹¬ëŸ¬ (+4%, Part D ì˜í–¥ ì œì™¸ ì‹œ +8%), ê°€ì´ë˜ìŠ¤ ìƒíšŒ<br>- **HIV ì‚¬ì—…**: 208ì–µ ë‹¬ëŸ¬ (+6%, Part D ì˜í–¥ 9ì–µ ë‹¬ëŸ¬ ì œì™¸ ì‹œ +10%)<br>  - Biktarvy: 143ì–µ ë‹¬ëŸ¬ (+7%), ë¯¸êµ­ ì‹œì¥ì ìœ ìœ¨ 52% ì´ìƒ<br>  - HIV ì˜ˆë°© í¬íŠ¸í´ë¦¬ì˜¤: +47% ì„±ì¥<br>  - Yeztugo (2íšŒ/ë…„ ì£¼ì‚¬ì œ): 1.5ì–µ ë‹¬ëŸ¬, 90% ë³´í—˜ ì»¤ë²„ë¦¬ì§€ ì¡°ê¸° ë‹¬ì„±<br>- **ê°„ì§ˆí™˜ ì‚¬ì—…**: 32ì–µ ë‹¬ëŸ¬ (+6%), Livdelziê°€ ë¯¸êµ­ 2ì°¨ ì¹˜ë£Œ ì‹œì¥ì ìœ ìœ¨ 50% ì´ˆê³¼<br>- **ë¹„GAAP EPS**: 8.15ë‹¬ëŸ¬ (ê°€ì´ë˜ìŠ¤ ë¶€í•©)<br><br>## 2026ë…„ ê°€ì´ë˜ìŠ¤ ë° ì „ë§<br>- **ì´ ë§¤ì¶œ ì „ë§**: 296~300ì–µ ë‹¬ëŸ¬ (ê¸°ë³¸ ì‚¬ì—… +4~5%)<br>- **HIV ì„±ì¥ë¥ **: ì•½ +6% (ì•½ê°€ í˜‘ìƒ ë° ACA ë³€ê²½ìœ¼ë¡œ 2% ì—­í’, ì´ ì œì™¸ ì‹œ +8%)<br>- **Yeztugo ë§¤ì¶œ ëª©í‘œ**: ì•½ 8ì–µ ë‹¬ëŸ¬ (2025ë…„ 1.5ì–µ ë‹¬ëŸ¬ ëŒ€ë¹„ ëŒ€í­ ì¦ê°€)<br>- **ì„¸í¬ì¹˜ë£Œ(Kite)**: ì•½ -10% ì˜ˆìƒ (ê²½ìŸ</p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] Our first question comes from Chris Schott at JPM.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>[ìš´ì˜ì ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ JPMì˜ Chris Schottë‹˜ê»˜ì„œ ì£¼ì…¨ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Christopher Schott: JPMorgan Chase & Co, Research Division Just wanted to kick off with a question on Yeztugo. Can you just elaborate a little bit more on the assumptions driving the $800 million guidance? And maybe as part of that, as we start to think about patients now needing to be redosed on the drug, what type of refill rates are you anticipating as we think about kind of going through 2026 and beyond?</td><td>**Christopher Schott:** <response><br><br>Yeztugoì— ëŒ€í•´ ë¨¼ì € ì§ˆë¬¸ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. 8ì–µ ë‹¬ëŸ¬ ê°€ì´ë˜ìŠ¤ë¥¼ ì´ë„ëŠ” ê°€ì •ë“¤ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ê·¸ì™€ ê´€ë ¨í•´ì„œ, ì´ì œ í™˜ìë“¤ì´ ì¬íˆ¬ì—¬ë¥¼ ë°›ì•„ì•¼ í•˜ëŠ” ì‹œì ì´ ë˜ë©´ì„œ, 2026ë…„ê³¼ ê·¸ ì´í›„ë¥¼ ìƒê°í•  ë•Œ ì–´ëŠ ì •ë„ì˜ ì¬ì²˜ë°©ë¥ (refill rate)ì„ ì˜ˆìƒí•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Chairman & CEO: Thanks, Chris, Dan O'Day. Welcome to the call. I'd invite Johanna to cover that point. Thank you.</td><td>**Chairman & CEO:** ê°ì‚¬í•©ë‹ˆë‹¤, Chris. Dan O'Dayì…ë‹ˆë‹¤. í†µí™”ì— ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. í•´ë‹¹ ì§ˆë¬¸ì€ Johannaê°€ ë‹µë³€í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Johanna Mercier: Chief Commercial & Corporate Affairs Officer Thanks, Dan, and thanks, Chris, for the question. So yes, so -- one, let me start with how excited we are with Yeztugo. I think as we closed out 2025 and really building momentum coming into 2026. All of our key launch indicators are basically tracking or exceeding our expectation. And that includes, of course, access, which is where it starts with about 90% payer coverage. So all major payers are now covering Yeztugo. About 90% of those with $0 co-pay. So that's really important for people that want to have access to this medicine. I would just remind everyone that as we pull through this great access, it takes a little bit of time, right, because you do it by account by account, and you're basically navigating logistics for HCPs and their clinics -- around an injectable versus a very oral market to begin with. So that scheduling coordination administration. So that just takes a little bit of time. And the teams are working diligently to make sure that happens as quickly as possible. We also launched, you might have seen a very recent DTC campaign. Our whole campaign is 1-2 PrEP campaigns, which is really meant to increase awareness for HIV prevention and, of course, brand recognition for Yeztugo as it really differentiates itself both from an efficacy as well as its dosing and really intended to appeal to a much broader audience than past HIV prevention campaigns and hopefully folks are seeing that. It is a very consumer-friendly campaign, and we expect that to kind of pull through as well and make sure that people are talking to their physicians about the potential opportunities of Yeztugo. So all of our indicators, intakes, access, HCP awareness, conversion rates are all tracking in the right direction. So we're excited about that. And looking ahead, we really expect to drive very durable, sustained long-term growth of Yeztugo. So that's not just 2026 continued growth and momentum quarter-on-quarter will -- we'll build on that but also well beyond 2026 as we expand the HIV and normalize HIV prevention for everyone. To your point around persistency, we don't have an assumption at this point in time because it's still really quite early. As you think about a late launch in June of last year, with very little access as we launched and building access into Q3, there's really only a small number of individuals that are eligible for that second dose or second injection. But we're really quite encouraged by early data. We're tracking it closely and continue to focus on ensuring that individuals return for their second injection and then well beyond that. We have a lot of activities planned that are ongoing and have started -- ever since we started the launch of Yeztugo, around making sure HCPs are thinking about that auto refill script, making sure that our specialty pharmacy partners are reaching out proactively to all of their individuals that are on PrEP and making sure they're reminding them as well as the work that we do here at Gilead both with digital reminders as well as proactive outreach with our access program. So more to come on that, but we're excited about what Yeztugo has to offer for individuals looking or wanting to need and need HIV PrEP. So more to come.</td><td>**Johanna Mercier:** ê°ì‚¬í•©ë‹ˆë‹¤, Dan. ê·¸ë¦¬ê³  Chris, ì§ˆë¬¸ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ë¨¼ì € Yeztugoì— ëŒ€í•´ ì €í¬ê°€ ì–¼ë§ˆë‚˜ ê¸°ëŒ€í•˜ê³  ìˆëŠ”ì§€ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. 2025ë…„ì„ ë§ˆë¬´ë¦¬í•˜ê³  2026ë…„ìœ¼ë¡œ ì ‘ì–´ë“¤ë©´ì„œ ì •ë§ íƒ„ë ¥ì„ ë°›ê³  ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤. ì£¼ìš” ì¶œì‹œ ì§€í‘œë“¤ì´ ê¸°ë³¸ì ìœ¼ë¡œ ì €í¬ ì˜ˆìƒì„ ì¶©ì¡±í•˜ê±°ë‚˜ ì´ˆê³¼í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ë¬¼ë¡  ì ‘ê·¼ì„±ë„ í¬í•¨ë˜ëŠ”ë°, ì•½ 90%ì˜ ë³´í—˜ì ì»¤ë²„ë¦¬ì§€(payer coverage)ë¡œ ì‹œì‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¦‰, ëª¨ë“  ì£¼ìš” ë³´í—˜ì‚¬ë“¤ì´ í˜„ì¬ Yeztugoë¥¼ ë³´ì¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ ì¤‘ ì•½ 90%ê°€ ë³¸ì¸ë¶€ë‹´ê¸ˆ 0ë‹¬ëŸ¬ë¡œ ì œê³µë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì´ ì¹˜ë£Œì œì— ì ‘ê·¼í•˜ê³ ì í•˜ëŠ” í™˜ìë“¤ì—ê²Œ ì •ë§ ì¤‘ìš”í•œ ë¶€ë¶„ì…ë‹ˆë‹¤. ëª¨ë“  ë¶„ë“¤ê»˜ ë§ì”€ë“œë¦¬ê³  ì‹¶ì€ ê²ƒì€, ì´ëŸ¬í•œ í›Œë¥­í•œ ì ‘ê·¼ì„±ì„ ì‹¤ì œë¡œ êµ¬í˜„í•˜ëŠ” ë°ëŠ” ì•½ê°„ì˜ ì‹œê°„ì´ ì†Œìš”ëœë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ê³„ì •ë³„ë¡œ í•˜ë‚˜í•˜ë‚˜ ì§„í–‰í•´ì•¼ í•˜ê³ , ê¸°ë³¸ì ìœ¼ë¡œ ê²½êµ¬ìš© ì‹œì¥ì—ì„œ ì£¼ì‚¬ì œë¡œì˜ ì „í™˜ì´ê¸° ë•Œë¬¸ì— ì˜ë£Œì§„ê³¼ í´ë¦¬ë‹‰ì˜ ë¬¼ë¥˜ë¥¼ ì¡°ìœ¨í•´ì•¼ í•©ë‹ˆë‹¤. ì¼ì • ì¡°ì •ê³¼ íˆ¬ì—¬ ê´€ë¦¬ ë“±ì´ í•„ìš”í•˜ì£ . ê·¸ë˜ì„œ ë‹¤ì†Œ ì‹œê°„ì´ ê±¸ë¦½ë‹ˆë‹¤. ìš°ë¦¬ íŒ€ì€ ì´ ê³¼ì •ì´ ìµœëŒ€í•œ ì‹ ì†í•˜ê²Œ ì´ë£¨ì–´ì§ˆ ìˆ˜ ìˆë„ë¡ ì—´ì‹¬íˆ ë…¸ë ¥í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ìµœê·¼ì— DTC(ì†Œë¹„ì ì§ì ‘ ê´‘ê³ ) ìº í˜ì¸ì„ ì‹œì‘í–ˆëŠ”ë° ë³´ì…¨ì„ ê²ë‹ˆë‹¤. ì €í¬ì˜ ì „ì²´ ìº í˜ì¸ì€ 1-2 PrEP ìº í˜ì¸ìœ¼ë¡œ, HIV ì˜ˆë°©ì— ëŒ€í•œ ì¸ì‹ì„ ë†’ì´ê³  ë¬¼ë¡  Yeztugoì— ëŒ€í•œ ë¸Œëœë“œ ì¸ì§€ë„ë¥¼ ë†’ì´ê¸° ìœ„í•œ ê²ƒì…ë‹ˆë‹¤. YeztugoëŠ” íš¨ëŠ¥ê³¼ íˆ¬ì—¬ ë°©ì‹ ì¸¡ë©´ì—ì„œ ì°¨ë³„í™”ë˜ì–´ ìˆìœ¼ë©°, ê³¼ê±° HIV ì˜ˆë°© ìº í˜ì¸ë³´ë‹¤ í›¨ì”¬ ë” í­ë„“ì€ ëŒ€ì¤‘ì—ê²Œ ì–´í•„í•˜ë„ë¡ ê¸°íšë˜ì—ˆìŠµë‹ˆë‹¤. ë§ì€ ë¶„ë“¤ì´ ì´ë¥¼ ë³´ê³  ê³„ì‹œê¸¸ ë°”ëë‹ˆë‹¤. ë§¤ìš° ì†Œë¹„ì ì¹œí™”ì ì¸ ìº í˜ì¸ì´ë©°, ì´ë¥¼ í†µí•´ ì‚¬ëŒë“¤ì´ ì˜ì‚¬ì™€ Yeztugoì˜ ì ì¬ì  ê¸°íšŒì— ëŒ€í•´ ìƒë‹´í•˜ë„ë¡ ìœ ë„í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ëª¨ë“  ì§€í‘œë“¤, ì¦‰ ì‹ ê·œ ì²˜ë°©, ì ‘ê·¼ì„±, ì˜ë£Œì§„ ì¸ì§€ë„, ì „í™˜ìœ¨ ëª¨ë‘ ì˜¬ë°”ë¥¸ ë°©í–¥ìœ¼ë¡œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì ì— ëŒ€í•´ ë§¤ìš° ê³ ë¬´ì ìœ¼ë¡œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œ Yeztugoì˜ ë§¤ìš° ì§€ì† ê°€ëŠ¥í•˜ê³  ê²¬ê³ í•œ ì¥ê¸° ì„±ì¥ì„ ì´ëŒì–´ë‚¼ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•©ë‹ˆë‹¤. ë”°ë¼ì„œ 2026ë…„ë¿ë§Œ ì•„ë‹ˆë¼ ê·¸ ì´í›„ì—ë„ ë¶„ê¸°ë³„ë¡œ ì§€ì†ì ì¸ ì„±ì¥ê³¼ ëª¨ë©˜í…€ì„ êµ¬ì¶•í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. HIV ì˜ˆë°©ì„ í™•ëŒ€í•˜ê³  ëª¨ë“  ì‚¬ëŒì—ê²Œ ì •ìƒí™”ì‹œì¼œ ë‚˜ê°€ë©´ì„œ ë§ì´ì£ . ì§€ì†ì„±ì— ëŒ€í•œ ì§ˆë¬¸ê³¼ ê´€ë ¨í•´ì„œëŠ”, í˜„ ì‹œì ì—ì„œ êµ¬ì²´ì ì¸ ê°€ì •ì„ ì„¸ìš°ê¸°ëŠ” ì•„ì§ ì´ë¦…ë‹ˆë‹¤. ì‘ë…„ 6ì›” ëŠ¦ì€ ì¶œì‹œì˜€ê³ , ì¶œì‹œ ë‹¹ì‹œ ì ‘ê·¼ì„±ì´ ë§¤ìš° ì œí•œì ì´ì—ˆìœ¼ë©° 3ë¶„ê¸°ì— ë“¤ì–´ì„œì•¼ ì ‘ê·¼ì„±ì´ ê°œì„ ë˜ê¸° ì‹œì‘í–ˆë‹¤ëŠ” ì ì„ ê³ ë ¤í•˜ë©´, ì‹¤ì œë¡œ ë‘ ë²ˆì§¸ íˆ¬ì—¬ë‚˜ ë‘ ë²ˆì§¸ ì£¼ì‚¬ë¥¼ ë°›ì„ ìê²©ì´ ë˜ëŠ” í™˜ì ìˆ˜ê°€ ì•„ì§ ë§¤ìš° ì ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ˆê¸° ë°ì´í„°ëŠ” ìƒë‹¹íˆ ê³ ë¬´ì ì…ë‹ˆë‹¤. ë©´ë°€íˆ ì¶”ì í•˜ê³  ìˆìœ¼ë©°, í™˜ìë“¤ì´ ë‘ ë²ˆì§¸ ì£¼ì‚¬ë¥¼ ë§ìœ¼ëŸ¬ ë‹¤ì‹œ ë°©ë¬¸í•˜ê³  ê·¸ ì´í›„ì—ë„ ê³„ì† ì´ì–´ì§ˆ ìˆ˜ ìˆë„ë¡ í•˜ëŠ” ë° ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. Yeztugo ì¶œì‹œ ì´í›„ ì§€ê¸ˆê¹Œì§€ ì§„í–‰í•´ì˜¨ ë‹¤ì–‘í•œ í™œë™ë“¤ì´ ìˆìŠµë‹ˆë‹¤. ì˜ë£Œì§„ë“¤ì´ ìë™ ì¬ì²˜ë°©ì— ëŒ€í•´ ì¸ì§€í•  ìˆ˜ ìˆë„ë¡ í•˜ê³ , ì „ë¬¸ì•½êµ­ íŒŒíŠ¸ë„ˆë“¤ì´ PrEPì„ ë³µìš©í•˜ëŠ” ëª¨ë“  í™˜ìë“¤ì—ê²Œ ì„ ì œì ìœ¼ë¡œ ì—°ë½í•˜ì—¬ ë³µì•½ì„ ìƒê¸°ì‹œí‚¤ë„ë¡ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ê¸¸ë¦¬ì–´ë“œ ìì²´ì ìœ¼ë¡œë„ ë””ì§€í„¸ ë¦¬ë§ˆì¸ë”ì™€ ì ‘ê·¼ì„± í”„ë¡œê·¸ë¨ì„ í†µí•œ ì„ ì œì  ì•„ì›ƒë¦¬ì¹˜ í™œë™ì„ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ì•ìœ¼ë¡œ ë” ë§ì€ ì†Œì‹ì„ ì „í•´ë“œë¦¬ê² ì§€ë§Œ, HIV PrEPì´ í•„ìš”í•œ ë¶„ë“¤ì„ ìœ„í•´ Yeztugoê°€ ì œê³µí•  ìˆ˜ ìˆëŠ” ê°€ì¹˜ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¶”í›„ ë” ìì„¸í•œ ë‚´ìš©ì„ ê³µìœ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Louise Chen at Scotiabank.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ìŠ¤ì½”ìƒ¤ë±…í¬ì˜ ë£¨ì´ì¦ˆ ì²¸ìœ¼ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Louise Chen: Scotiabank Global Banking and Markets, Research Division I wanted to ask you what type of share gains you expect for anito-cel in the fourth-line setting if you're approved, especially in light of competition from entrenched players?</td><td>**Louise Chen:** <response><br><br>4ì°¨ ì¹˜ë£Œì œë¡œ ìŠ¹ì¸ì„ ë°›ê²Œ ë˜ë©´, íŠ¹íˆ ê¸°ì¡´ ê²½ìŸì‚¬ë“¤ì„ ê³ ë ¤í•  ë•Œ ì•„ë‹ˆí† ì…€(anito-cel)ì´ ì–´ëŠ ì •ë„ì˜ ì‹œì¥ ì ìœ ìœ¨ì„ í™•ë³´í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Chairman & CEO: Thanks, Louise. Dan here. I'll turn it over to Cindy, who is with us here.</td><td>**Chairman & CEO:** ê°ì‚¬í•©ë‹ˆë‹¤, Louise. Danì…ë‹ˆë‹¤. ì—¬ê¸° í•¨ê»˜ ê³„ì‹  Cindyì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Cindy Perettie: Executive Vice President of Kite Thanks, Louise. Just as a reminder, our expectation is that we would be launching the second half of this year. And once we have approval, there's a period of time where we turn on our qualified authorized treatment centers so that they're able to treat. So there's that component right after approval. The market for fourth line multiple myeloma is a $3.5 billion market. We expect because the launch is the second half of the year, and we need to turn on our authorized treatment centers, modest contributions in 2026. However, in 2027, we will have a full year of sales. We expect over time to become the market leader, given our excellent efficacy profile and differentiated safety profile, in particular with the delayed neurotoxicities and enterocolitis. I think the last piece I would add is that we are bringing forward our world-class manufacturing. And so we are ready for launch. We will have the ability to serve the market at launch with 99% reliability and 16-day turnaround time, which again is very differentiated from the existing products on the market today.</td><td>**Cindy Perettie:** ê°ì‚¬í•©ë‹ˆë‹¤, Louise. ë¨¼ì € ë§ì”€ë“œë¦¬ë©´, ì €í¬ëŠ” ì˜¬í•´ í•˜ë°˜ê¸°ì— ì¶œì‹œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ìŠ¹ì¸ì„ ë°›ê³  ë‚˜ë©´ ì¸ì¦ëœ ì¹˜ë£Œì„¼í„°ë“¤ì´ ì‹¤ì œë¡œ ì¹˜ë£Œë¥¼ ì‹œì‘í•  ìˆ˜ ìˆë„ë¡ ì¤€ë¹„í•˜ëŠ” ê¸°ê°„ì´ í•„ìš”í•©ë‹ˆë‹¤. ìŠ¹ì¸ ì§í›„ì— ì´ëŸ¬í•œ ê³¼ì •ì´ ì§„í–‰ë©ë‹ˆë‹¤.<br><br>4ì°¨ ì¹˜ë£Œ ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…(fourth line multiple myeloma) ì‹œì¥ì€ 35ì–µ ë‹¬ëŸ¬ ê·œëª¨ì…ë‹ˆë‹¤. ì¶œì‹œê°€ í•˜ë°˜ê¸°ì— ì´ë£¨ì–´ì§€ê³  ì¸ì¦ ì¹˜ë£Œì„¼í„°ë“¤ì„ ê°€ë™í•´ì•¼ í•˜ê¸° ë•Œë¬¸ì—, 2026ë…„ì—ëŠ” ë§¤ì¶œ ê¸°ì—¬ë„ê°€ ì œí•œì ì¼ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ 2027ë…„ì—ëŠ” ì—°ê°„ ì „ì²´ ë§¤ì¶œì´ ë°œìƒí•  ê²ƒì…ë‹ˆë‹¤.<br><br>ì €í¬ëŠ” ìš°ìˆ˜í•œ íš¨ëŠ¥ í”„ë¡œíŒŒì¼ê³¼ ì°¨ë³„í™”ëœ ì•ˆì „ì„± í”„ë¡œíŒŒì¼, íŠ¹íˆ ì§€ì—°ì„± ì‹ ê²½ë…ì„±ê³¼ ì¥ì—¼ ì¸¡ë©´ì—ì„œì˜ ì¥ì ì„ ë°”íƒ•ìœ¼ë¡œ ì¥ê¸°ì ìœ¼ë¡œ ì‹œì¥ ì„ ë‘ì£¼ìê°€ ë  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. <response><br><br>ë§ˆì§€ë§‰ìœ¼ë¡œ ë§ë¶™ì´ìë©´, ì €í¬ëŠ” ì„¸ê³„ ìµœê³  ìˆ˜ì¤€ì˜ ì œì¡° ì—­ëŸ‰ì„ ì•ë‹¹ê²¨ ì¤€ë¹„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¶œì‹œ ì¤€ë¹„ëŠ” ì™„ë£Œë˜ì—ˆìŠµë‹ˆë‹¤. ì¶œì‹œì™€ ë™ì‹œì— 99%ì˜ ì‹ ë¢°ì„±ê³¼ 16ì¼ì˜ ì²˜ë¦¬ ê¸°ê°„ìœ¼ë¡œ ì‹œì¥ì— ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•  ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì„ ê°–ì¶”ê²Œ ë©ë‹ˆë‹¤. ì´ëŠ” í˜„ì¬ ì‹œì¥ì— ë‚˜ì™€ ìˆëŠ” ê¸°ì¡´ ì œí’ˆë“¤ê³¼ ë¹„êµí–ˆì„ ë•Œ ë§¤ìš° ì°¨ë³„í™”ëœ ê²½ìŸë ¥ì…ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Operator: Our next question comes from Tazeen Ahmad at Bank of America.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ì˜ Tazeen Ahmadë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Tazeen Ahmad: BofA Securities, Research Division Okay. Great. On Yeztugo, how should we be thinking about the growth outlook? Are you expecting to begin to see cannibalization of the DESCOVY PrEP sales as early as this year? And then connected to that, how should we be thinking about the evolution of net price for Yeztugo throughout the launch? Should we expect to see a decay over time like we've seen with other HIV therapies?</td><td>**Tazeen Ahmad:** <response><br><br>ì¢‹ìŠµë‹ˆë‹¤. Yeztugo ê´€ë ¨í•´ì„œ ì„±ì¥ ì „ë§ì„ ì–´ë–»ê²Œ ë´ì•¼ í• ê¹Œìš”? ì˜¬í•´ë¶€í„° DESCOVY PrEP ë§¤ì¶œì´ ì ì‹ë˜ëŠ” í˜„ìƒì„ ë³´ê¸° ì‹œì‘í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì‹œë‚˜ìš”? ê·¸ë¦¬ê³  ì´ì™€ ê´€ë ¨í•´ì„œ, ì¶œì‹œ ê¸°ê°„ ë™ì•ˆ Yeztugoì˜ ìˆœê°€ê²©(net price) ë³€í™”ë¥¼ ì–´ë–»ê²Œ ë´ì•¼ í• ê¹Œìš”? ë‹¤ë¥¸ HIV ì¹˜ë£Œì œë“¤ì—ì„œ ë´¤ë˜ ê²ƒì²˜ëŸ¼ ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ê°€ê²© í•˜ë½ì„ ì˜ˆìƒí•´ì•¼ í• ê¹Œìš”?<br><br></response></td></tr>
<tr><td>Johanna Mercier: Chief Commercial & Corporate Affairs Officer Sure. It's Johanna again. Thanks, Tazeen, for the question. So we do expect, as we come into 2026, we have strong growth momentum already. So Q1 will be -- will start with modest growth and then kind of build on that quarter after quarter in light of all the different pieces including access, including the DTC awareness campaign, including a lot of the work that we're doing in the field to drive to awareness. So all of that will build on that growth momentum. And in addition to that, we're also doing market expansion strategies as well with very targeted communities. And so we do believe that Yeztugo is going to be the strong performant. And over time, we believe that Yeztugo will be the market leader in HIV prevention just because of the incredible profile that it offers for folks. Having said that, in 2026, we believe that Descovy continues to grow through in 2026. As you saw in 2025, we had the highest performance share for Descovy we've ever seen. This is driven by many factors, namely commercial execution, really strong market, of course, but also unrestricted access. So all the pieces are coming together. And all the boats are rising, and it has a lot to do with the awareness in HIV PrEP. Because of the PURPOSE 1 and PURPOSE 2 trials for Yeztugo, really building up the market. So we believe Descovy will continue to grow through 2026. And over time, of course, that will erode as Yeztugo takes the leading share in HIV prevention. I think the final point you were asking about was gross to net. We obviously don't discuss gross to net for our products, but I would say that Yeztugo's value proposition is quite differentiated. And we feel strongly that, that is being recognized, and that's in line with the 90% access in less than 6 months that we've been able to achieve. So really pleased so far with what we've been seeing and making sure that value continues to get recognized for HIV PrEP users.</td><td>**Johanna Mercier:** ë„¤, ë‹¤ì‹œ ì¡°ì•ˆë‚˜ì…ë‹ˆë‹¤. íƒ€ì§„, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. 2026ë…„ìœ¼ë¡œ ë“¤ì–´ê°€ë©´ì„œ ì´ë¯¸ ê°•ë ¥í•œ ì„±ì¥ ëª¨ë©˜í…€ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. 1ë¶„ê¸°ëŠ” ì™„ë§Œí•œ ì„±ì¥ìœ¼ë¡œ ì‹œì‘í•´ì„œ ë¶„ê¸°ë§ˆë‹¤ ì ì°¨ ì„±ì¥ì„¸ë¥¼ ìŒ“ì•„ê°ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì ‘ê·¼ì„± ê°œì„ , DTC ì¸ì§€ë„ ìº í˜ì¸, ê·¸ë¦¬ê³  í˜„ì¥ì—ì„œ ì¸ì§€ë„ ì œê³ ë¥¼ ìœ„í•´ ì§„í–‰ ì¤‘ì¸ ë‹¤ì–‘í•œ í™œë™ë“¤ì´ ëª¨ë‘ í¬í•¨ë©ë‹ˆë‹¤. ì´ ëª¨ë“  ìš”ì†Œë“¤ì´ ì„±ì¥ ëª¨ë©˜í…€ì„ ë”ìš± ê°•í™”í•  ê²ƒì…ë‹ˆë‹¤. ì—¬ê¸°ì— ë”í•´ íŠ¹ì • ì»¤ë®¤ë‹ˆí‹°ë¥¼ íƒ€ê²Ÿìœ¼ë¡œ í•œ ì‹œì¥ í™•ëŒ€ ì „ëµë„ í•¨ê»˜ ì¶”ì§„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì˜ˆì¦ˆíˆ¬ê³ ê°€ ê°•ë ¥í•œ ì„±ê³¼ë¥¼ ë‚¼ ê²ƒìœ¼ë¡œ í™•ì‹ í•©ë‹ˆë‹¤. ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ ì˜ˆì¦ˆíˆ¬ê³ (Yeztugo)ê°€ ì œê³µí•˜ëŠ” ë†€ë¼ìš´ í”„ë¡œíŒŒì¼ ë•ë¶„ì— HIV ì˜ˆë°© ì‹œì¥ì˜ ë¦¬ë”ê°€ ë  ê²ƒìœ¼ë¡œ ë¯¿ìŠµë‹ˆë‹¤. ê·¸ë ‡ê¸´ í•˜ì§€ë§Œ, 2026ë…„ì—ë„ ë°ìŠ¤ì½”ë¹„(Descovy)ëŠ” ê³„ì† ì„±ì¥í•  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. 2025ë…„ì— ë³´ì…¨ë“¯ì´, ë°ìŠ¤ì½”ë¹„ëŠ” ì—­ëŒ€ ìµœê³ ì˜ ì‹œì¥ ì ìœ ìœ¨ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì—¬ëŸ¬ ìš”ì¸ì— ì˜í•´ ì£¼ë„ë˜ì—ˆëŠ”ë°, ìƒì—…ì  ì‹¤í–‰ë ¥, ë§¤ìš° ê°•ë ¥í•œ ì‹œì¥ í™˜ê²½, ê·¸ë¦¬ê³  ë¬´ì œí•œ ì ‘ê·¼ì„± ë“±ì´ ê·¸ê²ƒì…ë‹ˆë‹¤. ëª¨ë“  ìš”ì†Œë“¤ì´ í•¨ê»˜ ë§ì•„ë–¨ì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ëª¨ë“  ë°°ê°€ í•¨ê»˜ ë– ì˜¤ë¥´ê³  ìˆëŠ”ë°, ì´ëŠ” HIV PrEPì— ëŒ€í•œ ì¸ì‹ ì œê³ ì™€ ë§ì€ ê´€ë ¨ì´ ìˆìŠµë‹ˆë‹¤. ì˜ˆì¦ˆíˆ¬ê³ ì˜ PURPOSE 1ê³¼ PURPOSE 2 ì„ìƒì‹œí—˜ì´ ì‹¤ì œë¡œ ì‹œì¥ì„ í‚¤ìš°ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ë°ìŠ¤ì½”ë¹„ëŠ” 2026ë…„ê¹Œì§€ ê³„ì† ì„±ì¥í•  ê²ƒìœ¼ë¡œ ë¯¿ìŠµë‹ˆë‹¤. ë¬¼ë¡  ì‹œê°„ì´ ì§€ë‚˜ë©´ì„œ Yeztugoê°€ HIV ì˜ˆë°© ë¶„ì•¼ì—ì„œ ì„ ë„ì ì¸ ì ìœ ìœ¨ì„ ì°¨ì§€í•˜ê²Œ ë˜ë©´ ì´ëŸ¬í•œ ë¶€ë¶„ì€ ì ì°¨ ê°ì†Œí•  ê²ƒì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ì§ˆë¬¸í•˜ì‹  ë¶€ë¶„ì€ ì´ë§¤ì¶œ ëŒ€ë¹„ ìˆœë§¤ì¶œ(gross to net)ì— ê´€í•œ ê²ƒì´ì—ˆëŠ”ë°ìš”. ì €í¬ëŠ” ì œí’ˆë³„ ì´ë§¤ì¶œ ëŒ€ë¹„ ìˆœë§¤ì¶œì— ëŒ€í•´ì„œëŠ” êµ¬ì²´ì ìœ¼ë¡œ ë…¼ì˜í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤ë§Œ, Yeztugoì˜ ê°€ì¹˜ ì œì•ˆì€ ìƒë‹¹íˆ ì°¨ë³„í™”ë˜ì–´ ìˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ê°€ì¹˜ê°€ ì¸ì •ë°›ê³  ìˆë‹¤ëŠ” ì ì„ í™•ì‹ í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” 6ê°œì›” ì´ë‚´ì— 90%ì˜ ì ‘ê·¼ì„±ì„ ë‹¬ì„±í•œ ê²ƒê³¼ë„ ì¼ë§¥ìƒí†µí•©ë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ ë³´ì—¬ì¤€ ì„±ê³¼ì— ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìœ¼ë©°, HIV PrEP ì‚¬ìš©ìë“¤ì„ ìœ„í•´ ì´ëŸ¬í•œ ê°€ì¹˜ê°€ ê³„ì†í•´ì„œ ì¸ì •ë°›ì„ ìˆ˜ ìˆë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Michael Yee at UBS.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ UBSì˜ Michael Yeeë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Michael Yee: UBS Investment Bank, Research Division Maybe a question for Dietmar or the team. Your long-acting Q6 month treatment drug, which I guess could be a super bictegravir long-acting 3242. I think you said entered Phase II, can you tell us a little bit about the profile of that drug and what you're seeing in Phase I to get you excited? Is that going to be a CROI, I guess, coming up in a week or 2? And how do you compare that to, I think, Shionogi's product, which -- or their investment into ViiV. And I'm sure you're aware that they're also excited about their Q6M as well. So maybe compare and contrast and what gets you excited about your product.</td><td>**Michael Yee:** 6ê°œì›” ì§€ì†í˜• ì¹˜ë£Œì œ, ì¦‰ ìŠˆí¼ ë¹…í…Œê·¸ë¼ë¹„ë¥´ ì¥ê¸°ì§€ì†í˜• 3242ì— ëŒ€í•´ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. 2ìƒì— ì§„ì…í–ˆë‹¤ê³  ë§ì”€í•˜ì‹  ê²ƒìœ¼ë¡œ ì•„ëŠ”ë°, ì´ ì•½ë¬¼ì˜ í”„ë¡œíŒŒì¼ê³¼ 1ìƒì—ì„œ í™•ì¸í•˜ì‹  ê³ ë¬´ì ì¸ ê²°ê³¼ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? 1~2ì£¼ í›„ì— ì—´ë¦¬ëŠ” CROIì—ì„œ ë°œí‘œ ì˜ˆì •ì¸ê°€ìš”? ê·¸ë¦¬ê³  ì‹œì˜¤ë…¸ê¸°ê°€ ViiVì— íˆ¬ìí•œ ì œí’ˆê³¼ ë¹„êµí•˜ë©´ ì–´ë–¤ê°€ìš”? ì‹œì˜¤ë…¸ê¸°ë„ ìì‚¬ì˜ 6ê°œì›” ì§€ì†í˜• ì œí’ˆì— ëŒ€í•´ ìƒë‹¹íˆ ê¸°ëŒ€í•˜ê³  ìˆëŠ” ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·€ì‚¬ ì œí’ˆì˜ ì°¨ë³„ì ê³¼ ê¸°ëŒ€ë˜ëŠ” ë¶€ë¶„ì— ëŒ€í•´ ë¹„êµ ì„¤ëª… ë¶€íƒë“œë¦½ë‹ˆë‹¤.</td></tr>
<tr><td>Chief Medical Officer: Yes. Thank you, Michael, for the question. I mean first of all, I really want to say that I'm excited about the breadth of the program that we have, right, not only the Q6 month, also the upcoming, for example, weekly treatment that we have with islatravir and lenacapavir. And really the options between the daily, weekly, monthly and then every 6 months, treatments that we're developing specifically for the once every 6 months. I also want to point out that we have two programs in development. One is for lenacapavir plus broadly neutralizing antibodies. Obviously, that is an infusion and comes with everything that you need to do from an infusion perspective. However, there's a real unmet need and the study -- the interest in the study is really high. So we feel that will be an important addition. And that will come even a little earlier than the 3242 based combination. Now 3242 is obviously a long-acting INSTI, we firmly believe that an integrase inhibitor is important in this combination and I think that also sets us apart from some of the other options that are out there. And you know all the benefits of the INSTI, starting with, for example, the tolerability, but then also really the resistance profile and the forgiveness. And then we feel that, that translates also into the once every 6-month treatment. And then obviously, the combination with lenacapavir, so you have the INSTI again, plus the capsid inhibitor, which we feel is a really important combination. So yes, you will see more data, more information about 3242 during the year, and we're really looking forward to detail that. I don't want to go too much into the comparison to the competitors. But please keep in mind that they cannot face once every 6-month treatment on one product only. They also need a combination. So we need to look at the overall development program that they have and that they have put together to then really bring their products forward as compared to the two options that I've laid out that we have in development.</td><td>**Chief Medical Officer:** ë„¤, Michael, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ìš°ì„  ì €í¬ê°€ ë³´ìœ í•œ í”„ë¡œê·¸ë¨ì˜ í­ë„“ì€ ë²”ìœ„ì— ëŒ€í•´ ì •ë§ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤. 6ê°œì›” ì œí˜•ë¿ë§Œ ì•„ë‹ˆë¼, ì˜ˆë¥¼ ë“¤ì–´ ì´ìŠ¬ë¼íŠ¸ë¼ë¹„ë¥´(islatravir)ì™€ ë ˆë‚˜ì¹´íŒŒë¹„ë¥´(lenacapavir)ë¥¼ í™œìš©í•œ ì£¼ 1íšŒ ì¹˜ë£Œì œë„ ê³§ ì¶œì‹œë  ì˜ˆì •ì…ë‹ˆë‹¤. ì¼ì¼, ì£¼ê°„, ì›”ê°„, ê·¸ë¦¬ê³  6ê°œì›”ë§ˆë‹¤ íˆ¬ì—¬í•˜ëŠ” ì¹˜ë£Œ ì˜µì…˜ë“¤ì„ ê°œë°œí•˜ê³  ìˆëŠ”ë°, íŠ¹íˆ 6ê°œì›” ì œí˜•ì˜ ê²½ìš° í˜„ì¬ ë‘ ê°€ì§€ í”„ë¡œê·¸ë¨ì„ ê°œë°œ ì¤‘ì…ë‹ˆë‹¤.<br><br>í•˜ë‚˜ëŠ” ë ˆë‚˜ì¹´íŒŒë¹„ë¥´ì™€ ê´‘ë²”ìœ„ ì¤‘í™”í•­ì²´(broadly neutralizing antibodies)ë¥¼ ê²°í•©í•œ í”„ë¡œê·¸ë¨ì…ë‹ˆë‹¤. ë¬¼ë¡  ì´ê²ƒì€ ì£¼ì…(infusion) ë°©ì‹ì´ê¸° ë•Œë¬¸ì— ì£¼ì… ê´€ì ì—ì„œ í•„ìš”í•œ ëª¨ë“  ì ˆì°¨ê°€ ìˆ˜ë°˜ë©ë‹ˆë‹¤. í•˜ì§€ë§Œ ì¶©ì¡±ë˜ì§€ ì•Šì€ ì‹¤ì§ˆì ì¸ ì˜ë£Œ ìˆ˜ìš”ê°€ ìˆê³ , ì´ ì—°êµ¬ì— ëŒ€í•œ ê´€ì‹¬ë„ ë§¤ìš° ë†’ìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì¤‘ìš”í•œ ì¶”ê°€ ì˜µì…˜ì´ ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŠ” 3242 ê¸°ë°˜ ë³‘ìš©ìš”ë²•ë³´ë‹¤ë„ ì¡°ê¸ˆ ë” ì¼ì° ë‚˜ì˜¬ ê²ƒì…ë‹ˆë‹¤. 3242ëŠ” ëª…ë°±íˆ ì¥ê¸° ì§€ì†í˜• ì¸í…Œê·¸ë¼ì œ ì–µì œì œ(INSTI)ì´ë©°, ì €í¬ëŠ” ì´ ë³‘ìš©ìš”ë²•ì—ì„œ ì¸í…Œê·¸ë¼ì œ ì–µì œì œê°€ ì¤‘ìš”í•˜ë‹¤ê³  í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì ì´ ì‹œì¥ì˜ ë‹¤ë¥¸ ì˜µì…˜ë“¤ê³¼ ì°¨ë³„í™”ë˜ëŠ” ë¶€ë¶„ì´ê¸°ë„ í•©ë‹ˆë‹¤. ì¸í…Œê·¸ë¼ì œ ì–µì œì œì˜ ëª¨ë“  ì¥ì ì„ ì˜ ì•„ì‹¤ í…ë°ìš”, ì˜ˆë¥¼ ë“¤ì–´ ë‚´ì•½ì„±ë¶€í„° ì‹œì‘í•´ì„œ ë‚´ì„± í”„ë¡œíŒŒì¼ê³¼ ìš©ì„œì„±(forgiveness)ê¹Œì§€ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ íŠ¹ì„±ë“¤ì´ 6ê°œì›”ë§ˆë‹¤ í•œ ë²ˆ íˆ¬ì—¬í•˜ëŠ” ì¹˜ë£Œë²•ì—ë„ ê·¸ëŒ€ë¡œ ì ìš©ëœë‹¤ê³  ë´…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‹¹ì—°íˆ ë ˆë‚˜ì¹´íŒŒë¹„ë¥´(lenacapavir)ì™€ì˜ ë³‘ìš©ì´ ìˆëŠ”ë°, ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ ì¸í…Œê·¸ë¼ì œ ì–µì œì œì— ìº¡ì‹œë“œ ì–µì œì œ(capsid inhibitor)ë¥¼ ë”í•œ ê²ƒìœ¼ë¡œ, ì´ê²ƒì´ ì •ë§ ì¤‘ìš”í•œ ì¡°í•©ì´ë¼ê³  ìƒê°í•©ë‹ˆë‹¤. ë„¤, ì˜¬í•´ ì¤‘ì— 3242ì— ëŒ€í•œ ë” ë§ì€ ë°ì´í„°ì™€ ì •ë³´ë¥¼ ë³´ì‹œê²Œ ë  ê²ƒì´ê³ , ì €í¬ëŠ” ê·¸ ì„¸ë¶€ ë‚´ìš©ì„ ê³µìœ í•˜ê¸°ë¥¼ ì •ë§ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê²½ìŸì‚¬ì™€ì˜ ë¹„êµì— ëŒ€í•´ì„œëŠ” ë„ˆë¬´ ê¹Šì´ ë“¤ì–´ê°€ê³  ì‹¶ì§€ ì•ŠìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ëª…ì‹¬í•˜ì…”ì•¼ í•  ì ì€, ê²½ìŸì‚¬ë“¤ì€ ë‹¨ì¼ ì œí’ˆë§Œìœ¼ë¡œëŠ” 6ê°œì›”ë§ˆë‹¤ í•œ ë²ˆ íˆ¬ì—¬í•˜ëŠ” ì¹˜ë£Œë¥¼ ë‹¬ì„±í•  ìˆ˜ ì—†ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë“¤ë„ ë³‘ìš©ìš”ë²•ì´ í•„ìš”í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ê°€ ê°œë°œ ì¤‘ì¸ ë‘ ê°€ì§€ ì˜µì…˜ê³¼ ë¹„êµí•˜ë ¤ë©´, ê²½ìŸì‚¬ë“¤ì´ ì‹¤ì œë¡œ ì œí’ˆì„ ë°œì „ì‹œí‚¤ê¸° ìœ„í•´ êµ¬ì„±í•˜ê³  ì¤€ë¹„í•œ ì „ì²´ ê°œë°œ í”„ë¡œê·¸ë¨ì„ ì‚´í´ë´ì•¼ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Brian Abrahams at RBC Capital Markets.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ RBC ìºí”¼íƒˆ ë§ˆì¼“ì˜ ë¸Œë¼ì´ì–¸ ì—ì´ë¸ŒëŸ¬í–„ìŠ¤ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Brian Abrahams: RBC Capital Markets, Research Division Congrats on the quarter. Give us a little bit more detail on your once-yearly injectable lenacapavir for PrEP on the slides today. And I was wondering if you could maybe -- just talk about what you need to show out of PURPOSE 365 in order to support approval? And how are you planning to position that in the market if successful?</td><td>**Brian Abrahams:** <response><br><br>ì´ë²ˆ ë¶„ê¸° ì‹¤ì ì„ ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ì˜¤ëŠ˜ ìŠ¬ë¼ì´ë“œì—ì„œ PrEPìš© ì—° 1íšŒ ì£¼ì‚¬ì œì¸ ë ˆë‚˜ì¹´íŒŒë¹„ë¥´ì— ëŒ€í•´ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  ìŠ¹ì¸ì„ ë’·ë°›ì¹¨í•˜ê¸° ìœ„í•´ PURPOSE 365 ì„ìƒì‹œí—˜ì—ì„œ ì–´ë–¤ ê²°ê³¼ë¥¼ ë³´ì—¬ì¤˜ì•¼ í•˜ëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì„±ê³µí•  ê²½ìš° ì‹œì¥ì—ì„œ ì–´ë–»ê²Œ í¬ì§€ì…”ë‹í•  ê³„íšì´ì‹ ì§€ë„ ê¶ê¸ˆí•©ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Chairman & CEO: Thanks, Brian. Back to Dietmar.</td><td>**Chairman & CEO:** ê°ì‚¬í•©ë‹ˆë‹¤, Brian. ë‹¤ì‹œ Dietmarì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chief Medical Officer: Yes. I'll start with the profile. And really, what is so great about lenacapavir is that it's such a versatile product, right? And we do understand the pharmacokinetics and the target coverage and some of the scientific underpinnings of lenacapavir for prevention really well. So the study PURPOSE 365 is a PK-based study. It's a smaller study. Obviously, it has been recruiting very well and continues to recruit very well. But it's a smaller study where we basically need to demonstrate target coverage and the right pharmacokinetics and peak levels, trough levels, et cetera. So that we can demonstrate effective prevention. That's how the study has been designed. Obviously, we're looking forward to see the data by looking at PK, looking at safety. It will be an intramuscular injection, which is also an important differentiation that we're looking forward to demonstrate. But we feel it can really bringing a very important benefit with a longer-term interval to patients. I'll hand over to Johanna for the market.</td><td>**Chief Medical Officer:** ë„¤, í”„ë¡œíŒŒì¼ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë ˆë‚˜ì¹´íŒŒë¹„ë¥´ì˜ ì •ë§ í›Œë¥­í•œ ì ì€ ë§¤ìš° ë‹¤ì¬ë‹¤ëŠ¥í•œ ì œí’ˆì´ë¼ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì €í¬ëŠ” ì˜ˆë°© ëª©ì ì˜ ë ˆë‚˜ì¹´íŒŒë¹„ë¥´ì— ëŒ€í•œ ì•½ë™í•™(pharmacokinetics)ê³¼ í‘œì  ì»¤ë²„ë¦¬ì§€, ê·¸ë¦¬ê³  ê³¼í•™ì  ê¸°ë°˜ì„ ë§¤ìš° ì˜ ì´í•´í•˜ê³  ìˆìŠµë‹ˆë‹¤. PURPOSE 365 ì—°êµ¬ëŠ” ì•½ë™í•™ ê¸°ë°˜ ì—°êµ¬ì…ë‹ˆë‹¤. ë¹„êµì  ì†Œê·œëª¨ ì—°êµ¬ì´ì§€ë§Œ, ì‹¤ì œë¡œ í™˜ì ëª¨ì§‘ì´ ë§¤ìš° ì˜ ì§„í–‰ë˜ì–´ ì™”ê³  ê³„ì†í•´ì„œ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì†Œê·œëª¨ ì—°êµ¬ì´ê¸° ë•Œë¬¸ì— ê¸°ë³¸ì ìœ¼ë¡œ í‘œì  ì»¤ë²„ë¦¬ì§€ì™€ ì ì ˆí•œ ì•½ë™í•™, ìµœê³  ë†ë„, ìµœì € ë†ë„ ë“±ì„ ì…ì¦í•´ì•¼ í•©ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ íš¨ê³¼ì ì¸ ì˜ˆë°©ì„ ì…ì¦í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ì—°êµ¬ê°€ ì„¤ê³„ëœ ë°©ì‹ì…ë‹ˆë‹¤. ë‹¹ì—°íˆ ì €í¬ëŠ” ì•½ë™í•™ê³¼ ì•ˆì „ì„±ì„ ì‚´í´ë³´ë©´ì„œ ë°ì´í„°ë¥¼ í™•ì¸í•˜ê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¼ìœ¡ ì£¼ì‚¬ë¡œ íˆ¬ì—¬ë  ì˜ˆì •ì´ë©°, ì´ê²ƒë„ ì €í¬ê°€ ì…ì¦í•˜ê³ ì í•˜ëŠ” ì¤‘ìš”í•œ ì°¨ë³„í™” ìš”ì†Œì…ë‹ˆë‹¤. ë” ê¸´ íˆ¬ì—¬ ê°„ê²©ìœ¼ë¡œ í™˜ìë“¤ì—ê²Œ ë§¤ìš° ì¤‘ìš”í•œ í˜œíƒì„ ì œê³µí•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì‹œì¥ ê´€ë ¨ ë‚´ìš©ì€ ìš”í•œë‚˜ì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Johanna Mercier: Chief Commercial & Corporate Affairs Officer Yes. Thanks, Brian. The -- I would just add to what Dietmar was saying is the fact that it's 12 months. We've been very clear with the market research that we've seen that frequency or less frequency in the HIV PrEP setting specifically is the most important. And that's why Yeztugo being such an important innovation to this marketplace every 6 months, let alone the potential of going to every 12 months. Really would potentially attract a larger population if you were thinking that you just had to go to the physician's office once a year for that injection. So I think there's an opportunity to broaden the addressable population as well as there are some folks as well that might have unstable housing or situations that once a year would also be ideal for them. So it's a real market expansion opportunity for us as we see this with that potential with 365.</td><td>**Johanna Mercier:** ë„¤, ê°ì‚¬í•©ë‹ˆë‹¤, Brian. Dietmarê°€ ë§ì”€ë“œë¦° ë‚´ìš©ì— ë§ë¶™ì´ìë©´, 12ê°œì›”ì´ë¼ëŠ” ì ì´ í•µì‹¬ì…ë‹ˆë‹¤. ì €í¬ê°€ ì‹¤ì‹œí•œ ì‹œì¥ ì¡°ì‚¬ë¥¼ í†µí•´ ëª…í™•í•˜ê²Œ í™•ì¸í•œ ë°”ë¡œëŠ”, HIV PrEP í™˜ê²½ì—ì„œ íˆ¬ì—¬ ë¹ˆë„, íŠ¹íˆ ë‚®ì€ íˆ¬ì—¬ ë¹ˆë„ê°€ ê°€ì¥ ì¤‘ìš”í•œ ìš”ì†Œì…ë‹ˆë‹¤. ê·¸ë˜ì„œ Yeztugoê°€ 6ê°œì›”ë§ˆë‹¤ íˆ¬ì—¬í•  ìˆ˜ ìˆë‹¤ëŠ” ê²ƒë§Œìœ¼ë¡œë„ ì´ ì‹œì¥ì— ë§¤ìš° ì¤‘ìš”í•œ í˜ì‹ ì´ë©°, ë” ë‚˜ì•„ê°€ 12ê°œì›”ë§ˆë‹¤ íˆ¬ì—¬í•  ìˆ˜ ìˆëŠ” ê°€ëŠ¥ì„±ê¹Œì§€ ê³ ë ¤í•œë‹¤ë©´, ì •ë§ í° ì˜ë¯¸ê°€ ìˆìŠµë‹ˆë‹¤. 1ë…„ì— ë‹¨ í•œ ë²ˆë§Œ ë³‘ì›ì— ê°€ì„œ ì£¼ì‚¬ë¥¼ ë§ìœ¼ë©´ ëœë‹¤ê³  ìƒê°í•´ë³´ì„¸ìš”. ê·¸ë ‡ê²Œ ë˜ë©´ í›¨ì”¬ ë” ë§ì€ ì‚¬ëŒë“¤ì´ ì´ ì¹˜ë£Œë²•ì„ ì„ íƒí•  ê°€ëŠ¥ì„±ì´ ë†’ì•„ì§‘ë‹ˆë‹¤. 365ì˜ ì ì¬ë ¥ì„ ê³ ë ¤í•  ë•Œ, ì´ëŠ” ìš°ë¦¬ì—ê²Œ ì‹¤ì§ˆì ì¸ ì‹œì¥ í™•ëŒ€ ê¸°íšŒë¼ê³  ë´…ë‹ˆë‹¤. ëŒ€ìƒ ì¸êµ¬ë¥¼ ë„“í ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ìˆê³ , ë˜í•œ ë¶ˆì•ˆì •í•œ ì£¼ê±° í™˜ê²½ì´ë‚˜ ìƒí™©ì— ì²˜í•œ ë¶„ë“¤ì—ê²Œë„ ì—° 1íšŒ íˆ¬ì•½ì´ ì´ìƒì ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chairman & CEO: And Brian, I would just remind what we've already stated, which is could be available as early as 2028. The trial is recruiting well. Thank you.</td><td>**Chairman & CEO:** ê·¸ë¦¬ê³  ë¸Œë¼ì´ì–¸, ì´ë¯¸ ë§ì”€ë“œë¦° ë‚´ìš©ì„ ë‹¤ì‹œ í•œë²ˆ ìƒê¸°ì‹œì¼œ ë“œë¦¬ìë©´, ë¹ ë¥´ë©´ 2028ë…„ì— ì¶œì‹œ ê°€ëŠ¥í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì„ìƒì‹œí—˜ ëª¨ì§‘ì€ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Umer Raffat at Evercore.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ ì—ë²„ì½”ì–´ì˜ ìš°ë¨¸ ë¼íŒŒíŠ¸ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Umer Raffat: Evercore ISI Institutional Equities, Research Division I was quite intrigued by your mention of the Trodelvy Phase III in endometrial, perhaps in second half of this year, which makes me wonder it's probably an interim analysis you're effectively guiding to. Can you speak to your confidence overall heading into this interim? And is it fair to say that the size of the indication is generally similar to triple-negative breast?</td><td>**Umer Raffat:** Evercore ISI ê¸°ê´€íˆ¬ìì ì£¼ì‹ë¶€ë¬¸, ë¦¬ì„œì¹˜ ë¶€ì„œì…ë‹ˆë‹¤. ì˜¬í•´ í•˜ë°˜ê¸°ì— ì˜ˆì •ëœ ìê¶ë‚´ë§‰ì•” ëŒ€ìƒ Trodelvy 3ìƒ ì‹œí—˜ ì–¸ê¸‰ì´ ìƒë‹¹íˆ í¥ë¯¸ë¡œì› ìŠµë‹ˆë‹¤. ì•„ë§ˆë„ ì¤‘ê°„ë¶„ì„(interim analysis) ê²°ê³¼ë¥¼ ë§ì”€í•˜ì‹œëŠ” ê²ƒ ê°™ì€ë°ìš”. ì´ë²ˆ ì¤‘ê°„ë¶„ì„ì„ ì•ë‘ê³  ì „ë°˜ì ì¸ í™•ì‹  ìˆ˜ì¤€ì´ ì–´ëŠ ì •ë„ì¸ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  ì´ ì ì‘ì¦ì˜ ì‹œì¥ ê·œëª¨ê°€ ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•”(triple-negative breast cancer)ê³¼ ëŒ€ì²´ë¡œ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì´ë¼ê³  ë´ë„ ë ê¹Œìš”?</td></tr>
<tr><td>Chief Medical Officer: So let me just talk about the study and then later on Johanna can chime in. Thanks for the question, Umer. Obviously, we are primarily intrigued about endometrial because of the earlier study, right, because of the Phase II TROPiCS-03 study, the basket trial that we did where we saw a median OS of 15 months in that population. That data was published at ESMO 2024. We feel with data like that, this would be a really important addition to the treatment options for second-line endometrial cancer patients. We're not providing details regarding the exact evaluation that we're going to do. But we're really looking forward to seeing the data later this year. I want to say second-line endometrial cancer is, of course, more of an incremental opportunity, but I'll hand over to Johanna, if she wants to comment on that further.</td><td>**Chief Medical Officer:** ë¨¼ì € ì œê°€ ì—°êµ¬ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê³ , ì´í›„ì— Johannaê°€ ë³´ì¶©í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. Umer, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì €í¬ê°€ ìê¶ë‚´ë§‰ì•”ì— ì£¼ëª©í•˜ëŠ” ì´ìœ ëŠ” ëª…í™•í•©ë‹ˆë‹¤. ì´ì „ ì—°êµ¬ ê²°ê³¼ ë•Œë¬¸ì…ë‹ˆë‹¤. Phase II TROPiCS-03 ì—°êµ¬, ì¦‰ ë°”ìŠ¤ì¼“ ì„ìƒì‹œí—˜ì—ì„œ í•´ë‹¹ í™˜ìêµ°ì˜ ì¤‘ì•™ ì „ì²´ìƒì¡´ê¸°ê°„(median OS)ì´ 15ê°œì›”ë¡œ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì´ ë°ì´í„°ëŠ” ESMO 2024ì—ì„œ ë°œí‘œë˜ì—ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ê³¼ë¥¼ ë°”íƒ•ìœ¼ë¡œ, ì´ ì¹˜ë£Œì œê°€ 2ì°¨ ì¹˜ë£Œ ìê¶ë‚´ë§‰ì•” í™˜ìë“¤ì—ê²Œ ë§¤ìš° ì¤‘ìš”í•œ ì¹˜ë£Œ ì˜µì…˜ì´ ë  ê²ƒìœ¼ë¡œ íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ê°€ ì§„í–‰í•  êµ¬ì²´ì ì¸ í‰ê°€ ë°©ë²•ì— ëŒ€í•œ ì„¸ë¶€ì‚¬í•­ì€ í˜„ì¬ ê³µê°œí•˜ì§€ ì•Šê³  ìˆìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì˜¬í•´ í›„ë°˜ì— ë‚˜ì˜¬ ë°ì´í„°ë¥¼ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. 2ì°¨ ì¹˜ë£Œ ìê¶ë‚´ë§‰ì•”ì€ ë¬¼ë¡  ì ì§„ì ì¸ ê¸°íšŒë¼ê³  ë³¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤ë§Œ, ì´ ë¶€ë¶„ì— ëŒ€í•´ì„œëŠ” Johannaì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ì¶”ê°€ë¡œ ë§ì”€ë“œë¦´ ë‚´ìš©ì´ ìˆìœ¼ì‹¤ ê²ë‹ˆë‹¤.</td></tr>
<tr><td>Johanna Mercier: Chief Commercial & Corporate Affairs Officer Yes, sure. So I think you're right, Umer, it's basically in line with second-line metastatic TNBC, so more or less about 5,000 or so addressable population in the U.S. So small opportunity, but very important unmet medical need as well for us. So this is where the focus and just the breadth of data for Trodelvy just extends. In addition to that guide that Dietmar was talking about, we also have a potential with EVOKE-03, earlier this year, in our PD-L1 high non-small cell lung cancer setting as well, which would be a much larger market expansion for Trodelvy as well as that was to play out. So we're excited about what's to come for Trodelvy.</td><td>**Johanna Mercier:** ë„¤, ë§ì”€í•˜ì‹  ëŒ€ë¡œ ê¸°ë³¸ì ìœ¼ë¡œ 2ì°¨ ì¹˜ë£Œ ì „ì´ì„± TNBCì™€ ìœ ì‚¬í•œ ê·œëª¨ë¡œ, ë¯¸êµ­ ë‚´ ì¹˜ë£Œ ëŒ€ìƒ í™˜ìê°€ ì•½ 5,000ëª… ì •ë„ì…ë‹ˆë‹¤. ì‹œì¥ ê·œëª¨ëŠ” ì‘ì§€ë§Œ, ì¶©ì¡±ë˜ì§€ ì•Šì€ ì˜ë£Œ ìˆ˜ìš”ê°€ ë§¤ìš° í° ì˜ì—­ì´ê¸° ë•Œë¬¸ì— ì €í¬ì—ê²ŒëŠ” ì¤‘ìš”í•©ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ Trodelvyì˜ ë°ì´í„° í­ê³¼ ì ìš© ë²”ìœ„ê°€ ë”ìš± í™•ì¥ë˜ëŠ” ê²ƒì´ì£ . Dietmarê°€ ì–¸ê¸‰í•œ ê°€ì´ë“œë¼ì¸ ì™¸ì—ë„, ì˜¬í•´ ì´ˆ EVOKE-03 ì„ìƒì„ í†µí•´ PD-L1 ê³ ë°œí˜„ ë¹„ì†Œì„¸í¬íì•”(non-small cell lung cancer) ì˜ì—­ì—ì„œë„ ê°€ëŠ¥ì„±ì„ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì ì‘ì¦ì´ ìŠ¹ì¸ëœë‹¤ë©´ Trodelvyì˜ ì‹œì¥ í™•ëŒ€ ê·œëª¨ëŠ” í›¨ì”¬ ë” ì»¤ì§ˆ ê²ƒì…ë‹ˆë‹¤. Trodelvyì˜ ì•ìœ¼ë¡œì˜ í–‰ë³´ê°€ ê¸°ëŒ€ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next, we have Geoff Meacham at Citibank.</td><td>**Operator:** ë‹¤ìŒì€ ì‹œí‹°ì€í–‰ì˜ ì œí”„ ë¯¸ì²¨ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Geoffrey Meacham: Citigroup Inc., Research Division Great. I had a bigger picture, one for Andy or Dan. You guys have done a ton of Phase III cards at turnover this year and also some launches. You haven't done a larger scale deal in a while. So I guess I wanted to get a sense from you guys as to what voids you think you need to fill? Is it further diversification of safe therapeutic areas? Is it a new product cycle looking to the maybe mid-2030s? Or is there no real BD urgency from you guys at this point?</td><td>**Geoffrey Meacham:** ì˜¬í•´ ë§ì€ 3ìƒ ì¹´ë“œë“¤ì„ ì „í™˜í•˜ì…¨ê³  ì—¬ëŸ¬ ì œí’ˆë„ ì¶œì‹œí•˜ì…¨ìŠµë‹ˆë‹¤. ê·¸ëŸ°ë° ëŒ€ê·œëª¨ ë”œì€ í•œë™ì•ˆ ì—†ì—ˆëŠ”ë°ìš”. ê·¸ë˜ì„œ ì—¬ëŸ¬ë¶„ì´ ìƒê°í•˜ì‹œê¸°ì— ì–´ë–¤ ë¶€ë¶„ì„ ì±„ì›Œì•¼ í•œë‹¤ê³  ë³´ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì•ˆì „í•œ ì¹˜ë£Œ ì˜ì—­ì˜ ì¶”ê°€ ë‹¤ê°í™”ì¸ê°€ìš”? ì•„ë‹ˆë©´ 2030ë…„ëŒ€ ì¤‘ë°˜ì„ ë°”ë¼ë³´ëŠ” ìƒˆë¡œìš´ ì œí’ˆ ì‚¬ì´í´ì¸ê°€ìš”? ì•„ë‹ˆë©´ í˜„ì‹œì ì—ì„œ BD(ì‚¬ì—…ê°œë°œ) ì¸¡ë©´ì˜ ê¸´ê¸‰ì„±ì€ ì—†ë‹¤ê³  ë³´ì‹œëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Chairman & CEO: Thanks a lot, Geoff, I'll start and certainly invite Andy to add. I think we've all been reflecting here at Gilead, about the progress we've made over the past 5 or 6 years. And I think, some of the greatest evidence of that is the fact that we have up to 10 launches now either ongoing or to be introduced over -- between now and 2027. That includes 4 additional launches this year that have already been articulated and 5 Phase III readouts. And importantly, back to your question, Geoff, that's across really all therapeutic areas, which is exactly the design. So we're building this very robust internal portfolio that's been built through original research, early-stage partnerships and collaborations and M&A. So what I would say is that as we approach additional partnerships and M&A, there's 2 pieces to that, of course. The first one is that we have to stay active in what we call kind of earlier stage transactions sometimes referred to as normal course. And we spend roughly around $1 billion every year on that. Again, we can be agnostic to the 3 therapeutic areas and go for the most interesting science, and that's what we have been doing to build this portfolio that is now coming through to us. And as we approach later-stage acquisitions, we do it in the context of the fact that we have the most robust clinical and launch pipeline in our company's history with no major LOEs until 2026. So we're uniquely positioned. We're very ready. We're very proactive and disciplined. We may not have the urgency of other companies in the sector. So we're going to be disciplined around that. But I would say that we very much want to continue to add to our pipeline with appropriate M&A over the course of the coming years as well. And if I haven't said everything, Andy, would you like to add anything to that?</td><td>**Chairman & CEO:** ê°ì‚¬í•©ë‹ˆë‹¤, Geoff. ì œê°€ ë¨¼ì € ë§ì”€ë“œë¦¬ê³  Andyê°€ ë³´ì¶©í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ê¸¸ë¦¬ì–´ë“œì—ì„œ ì§€ë‚œ 5~6ë…„ê°„ ì´ë£¬ ì„±ê³¼ì— ëŒ€í•´ ë§ì€ ê³ ë¯¼ì„ í•´ì™”ìŠµë‹ˆë‹¤. ê·¸ ì¤‘ ê°€ì¥ í° ì„±ê³¼ëŠ” í˜„ì¬ ì§„í–‰ ì¤‘ì´ê±°ë‚˜ 2027ë…„ê¹Œì§€ ì¶œì‹œ ì˜ˆì •ì¸ ì‹ ì œí’ˆì´ ìµœëŒ€ 10ê°œì— ë‹¬í•œë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì˜¬í•´ ì´ë¯¸ ë°œí‘œëœ 4ê°œì˜ ì¶”ê°€ ì¶œì‹œì™€ 5ê°œì˜ 3ìƒ ì„ìƒ ê²°ê³¼ê°€ í¬í•¨ë©ë‹ˆë‹¤. <br><br>Geoff, ì§ˆë¬¸í•˜ì‹  ë¶€ë¶„ê³¼ ê´€ë ¨í•´ì„œ ì¤‘ìš”í•œ ì ì€ ì´ê²ƒì´ ëª¨ë“  ì¹˜ë£Œ ì˜ì—­ì— ê±¸ì³ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì´ ë°”ë¡œ ìš°ë¦¬ê°€ ì˜ë„í•œ ì„¤ê³„ì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìì²´ ì—°êµ¬, ì´ˆê¸° ë‹¨ê³„ íŒŒíŠ¸ë„ˆì‹­ê³¼ í˜‘ë ¥, ê·¸ë¦¬ê³  ì¸ìˆ˜í•©ë³‘ì„ í†µí•´ ë§¤ìš° íƒ„íƒ„í•œ ë‚´ë¶€ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ êµ¬ì¶•í•´ì™”ìŠµë‹ˆë‹¤. ì¶”ê°€ì ì¸ íŒŒíŠ¸ë„ˆì‹­ê³¼ M&Aì— ì ‘ê·¼í•˜ëŠ” ë°©ì‹ì—ëŠ” ë‘ ê°€ì§€ ì¸¡ë©´ì´ ìˆìŠµë‹ˆë‹¤. ì²«ì§¸ëŠ” ì´ˆê¸° ë‹¨ê³„ ê±°ë˜, ì´ë¥¸ë°” ì¼ìƒì ì¸ ê±°ë˜ì—ì„œ í™œë°œí•˜ê²Œ ì›€ì§ì—¬ì•¼ í•œë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì—¬ê¸°ì— ë§¤ë…„ ì•½ 10ì–µ ë‹¬ëŸ¬ ì •ë„ë¥¼ íˆ¬ì…í•˜ê³  ìˆìŠµë‹ˆë‹¤. 3ê°œ ì¹˜ë£Œ ì˜ì—­ì— êµ¬ì• ë°›ì§€ ì•Šê³  ê°€ì¥ í¥ë¯¸ë¡œìš´ ê³¼í•™ê¸°ìˆ ì„ ì¶”êµ¬í•  ìˆ˜ ìˆìœ¼ë©°, ì´ê²ƒì´ ë°”ë¡œ í˜„ì¬ ìš°ë¦¬ì—ê²Œ ì„±ê³¼ë¥¼ ê°€ì ¸ë‹¤ì£¼ê³  ìˆëŠ” í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ êµ¬ì¶•í•´ì˜¨ ë°©ì‹ì…ë‹ˆë‹¤. í›„ê¸° ë‹¨ê³„ ì¸ìˆ˜ë¥¼ ê²€í† í•  ë•ŒëŠ” 2026ë…„ê¹Œì§€ ì£¼ìš” íŠ¹í—ˆë§Œë£Œ(LOE)ê°€ ì—†ëŠ” ë‹¹ì‚¬ ì—­ì‚¬ìƒ ê°€ì¥ íƒ„íƒ„í•œ ì„ìƒ ë° ì¶œì‹œ íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆë‹¤ëŠ” ë§¥ë½ì—ì„œ ì ‘ê·¼í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë…ë³´ì ì¸ ìœ„ì¹˜ì— ìˆìœ¼ë©°, ë§¤ìš° ì¤€ë¹„ë˜ì–´ ìˆê³ , ì ê·¹ì ì´ë©´ì„œë„ ê·œìœ¨ ìˆê²Œ ì›€ì§ì´ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì—…ê³„ ë‚´ ë‹¤ë¥¸ ê¸°ì—…ë“¤ì²˜ëŸ¼ ê¸´ë°•í•œ ìƒí™©ì€ ì•„ë‹™ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ ë¶€ë¶„ì—ì„œëŠ” ê·œìœ¨ ìˆê²Œ ì ‘ê·¼í•  ê²ƒì…ë‹ˆë‹¤. ë‹¤ë§Œ í–¥í›„ ëª‡ ë…„ê°„ ì ì ˆí•œ M&Aë¥¼ í†µí•´ íŒŒì´í”„ë¼ì¸ì„ ì§€ì†ì ìœ¼ë¡œ í™•ëŒ€í•´ ë‚˜ê°€ê³ ì í•˜ëŠ” ì˜ì§€ëŠ” í™•ê³ í•©ë‹ˆë‹¤. Andy, ì œê°€ ë¹ ëœ¨ë¦° ë¶€ë¶„ì´ ìˆë‹¤ë©´ ì¶”ê°€ë¡œ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Chief Financial Officer: I think you covered it well. I mean if you look at the growth that's ahead of us and the cycle that we're entering with all of the launches that are underway or the additional launches that are coming, a reasonable portion of that is driven by our corporate development activities historically. And we continue to want to supplement, both, as Dan said, the early-stage late preclinical, early clinical pipeline through more of the ordinary course deals and we would like to add synergistic, derisked, late-stage assets that will further -- I define it as turbocharge our top line growth and drive even more outsized bottom line growth. And we will be disciplined in that. But we've been very active in this space. We'll continue to be active, and I'm confident that we'll add exciting new products over time when we find the right ones.</td><td>**Chief Financial Officer:** ì˜ ì •ë¦¬í•´ ì£¼ì…¨ìŠµë‹ˆë‹¤. ìš°ë¦¬ ì•ì— ë†“ì¸ ì„±ì¥ê³¼ í˜„ì¬ ì§„í–‰ ì¤‘ì´ê±°ë‚˜ ì•ìœ¼ë¡œ ì˜ˆì •ëœ ì¶œì‹œë“¤ë¡œ ì¸í•´ ì§„ì…í•˜ê²Œ ë  ì‚¬ì´í´ì„ ë³´ë©´, ìƒë‹¹ ë¶€ë¶„ì´ ì—­ì‚¬ì ìœ¼ë¡œ ìš°ë¦¬ì˜ ê¸°ì—…ê°œë°œ í™œë™ì— ì˜í•´ ì£¼ë„ë˜ì–´ ì™”ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ê³„ì†í•´ì„œ ë³´ì™„í•´ ë‚˜ê°€ê³ ì í•©ë‹ˆë‹¤. Danì´ ë§í–ˆë“¯ì´, ì¼ë°˜ì ì¸ ê±°ë˜ë¥¼ í†µí•´ ì „ì„ìƒ í›„ê¸°, ì„ìƒ ì´ˆê¸° ë‹¨ê³„ì˜ íŒŒì´í”„ë¼ì¸ì„ ë³´ê°•í•˜ëŠ” ë™ì‹œì—, ì‹œë„ˆì§€ë¥¼ ë‚¼ ìˆ˜ ìˆê³  ë¦¬ìŠ¤í¬ê°€ ì œê±°ëœ í›„ê¸° ë‹¨ê³„ ìì‚°ë“¤ì„ ì¶”ê°€í•˜ê³  ì‹¶ìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ë§¤ì¶œ ì„±ì¥ì„ ë”ìš± ê°€ì†í™”í•˜ê³  í›¨ì”¬ ë” í° í­ì˜ ìˆ˜ìµ ì„±ì¥ì„ ê²¬ì¸í•  ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì´ ê³¼ì •ì—ì„œ ìš°ë¦¬ëŠ” ê·œìœ¨ì„ ì§€í‚¬ ê²ƒì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ëŠ” ì´ ë¶„ì•¼ì—ì„œ ë§¤ìš° ì ê·¹ì ìœ¼ë¡œ í™œë™í•´ ì™”ìŠµë‹ˆë‹¤. ì•ìœ¼ë¡œë„ ì ê·¹ì ìœ¼ë¡œ í™œë™í•  ê²ƒì´ë©°, ì í•©í•œ ì œí’ˆì„ ë°œê²¬í•˜ë©´ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ í¥ë¯¸ë¡œìš´ ì‹ ì œí’ˆë“¤ì„ ì¶”ê°€í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ í™•ì‹ í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Daina Graybosch at Leerink Partners.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>ë‹¤ìŒ ì§ˆë¬¸ì€ ë¦¬ì–´ë§í¬ íŒŒíŠ¸ë„ˆìŠ¤ì˜ ë‹¤ì´ë‚˜ ê·¸ë ˆì´ë³´ì‰¬ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Daina Graybosch: Leerink Partners LLC, Research Division Yes. One on anito-cel for me. I wonder, and maybe I'm being presumptuous, but what gives you confidence in a second half launch? Does that assume priority review for FDA for anito-cel? And then for your 2027 filing from iMMagine-3, is that going to be on the MRD endpoint or on a survival endpoint?</td><td>**Daina Graybosch:** ë„¤, ì•„ë‹ˆí† ì…€ì— ëŒ€í•´ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì œê°€ ì„±ê¸‰í•œ íŒë‹¨ì¼ ìˆ˜ë„ ìˆì§€ë§Œ, í•˜ë°˜ê¸° ì¶œì‹œì— ëŒ€í•œ í™•ì‹ ì€ ì–´ë””ì„œ ë‚˜ì˜¤ëŠ” ê±´ê°€ìš”? FDAì˜ ìš°ì„  ì‹¬ì‚¬ë¥¼ ê°€ì •í•˜ì‹  ê±´ê°€ìš”? ê·¸ë¦¬ê³  iMMagine-3 ì—°êµ¬ë¥¼ í†µí•œ 2027ë…„ ìŠ¹ì¸ ì‹ ì²­ì€ MRD í‰ê°€ë³€ìˆ˜ë¥¼ ê¸°ë°˜ìœ¼ë¡œ í•˜ëŠ” ê±´ê°€ìš”, ì•„ë‹ˆë©´ ìƒì¡´ìœ¨ í‰ê°€ë³€ìˆ˜ë¥¼ ê¸°ë°˜ìœ¼ë¡œ í•˜ëŠ” ê±´ê°€ìš”?</td></tr>
<tr><td>Cindy Perettie: Executive Vice President of Kite Thanks, Daina. It's Cindy. So for the confidence in anito-cel second half launch, we can't say today, if we have priority review or not. Obviously, that would come with the BLA acceptance, and we'll be sure to let you know as soon as we can on that. But we have confidence in our conversations with the agency around the filing and look forward to being able to share more soon. The second component you asked about around iMMagine-3, we have a dual endpoint, which is both MRD and PFS on the iMMagine-3 study. And that's in line with the guidance that you heard from the FDA not too long ago.</td><td>**Cindy Perettie:** ê°ì‚¬í•©ë‹ˆë‹¤, Daina. Cindyì…ë‹ˆë‹¤. ì•„ë‹ˆí† ì…€(anito-cel)ì˜ í•˜ë°˜ê¸° ì¶œì‹œì— ëŒ€í•œ í™•ì‹ ê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ë©´, í˜„ì¬ë¡œì„œëŠ” ìš°ì„ ì‹¬ì‚¬(priority review) ì—¬ë¶€ë¥¼ ë§ì”€ë“œë¦´ ìˆ˜ ì—†ìŠµë‹ˆë‹¤. ë‹¹ì—°íˆ ì´ëŠ” BLA ìŠ¹ì¸ê³¼ í•¨ê»˜ ê²°ì •ë  ê²ƒì´ë©°, ê°€ëŠ¥í•œ í•œ ë¹¨ë¦¬ ì•Œë ¤ë“œë¦¬ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ë‹¤ë§Œ ì‹ ì²­ ê³¼ì •ì—ì„œ FDAì™€ ë‚˜ëˆˆ ëŒ€í™”ë¥¼ ë°”íƒ•ìœ¼ë¡œ í™•ì‹ ì„ ê°€ì§€ê³  ìˆìœ¼ë©°, ê³§ ë” ë§ì€ ë‚´ìš©ì„ ê³µìœ í•  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë‘ ë²ˆì§¸ë¡œ ì§ˆë¬¸í•˜ì‹  iMMagine-3 ê´€ë ¨í•´ì„œëŠ”, ì´ ì—°êµ¬ì—ì„œ MRDì™€ PFS ë‘ ê°€ì§€ë¥¼ ëª¨ë‘ ì£¼ìš” í‰ê°€ë³€ìˆ˜(dual endpoint)ë¡œ ì„¤ì •í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ì–¼ë§ˆ ì „ FDAë¡œë¶€í„° ë°›ì€ ê°€ì´ë˜ìŠ¤ì™€ ì¼ì¹˜í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our next question comes from Tyler Van Buren, Tyler at TD Cowen.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ TD Cowenì˜ Tyler Van Burenì—ê²Œì„œ ì™”ìŠµë‹ˆë‹¤.<br><br>ì €í¬ì˜ ë‹¤ìŒ ì§ˆë¬¸ì€ TD Cowenì˜ Tylerë¡œë¶€í„° ì™”ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Tyler Van Buren: TD Cowen, Research Division Great. For Trodelvy, are you guys starting to see off-label use in the frontline in advance of formal approval given the very positive readouts and the NCCN recommendation in particular? And what do you expect the opportunity in the front line to be versus the current indication?</td><td>**Tyler Van Buren:** <response><br><br>ì¢‹ìŠµë‹ˆë‹¤. Trodelvy ê´€ë ¨í•´ì„œ ì§ˆë¬¸ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§¤ìš° ê¸ì •ì ì¸ ì„ìƒ ê²°ê³¼ì™€ íŠ¹íˆ NCCN ê¶Œê³ ì‚¬í•­ì„ ê³ ë ¤í•  ë•Œ, ì •ì‹ ìŠ¹ì¸ ì „ì— 1ì°¨ ì¹˜ë£Œì—ì„œ ì ì‘ì¦ ì™¸ ì‚¬ìš©ì´ ë‚˜íƒ€ë‚˜ê³  ìˆë‚˜ìš”? ê·¸ë¦¬ê³  í˜„ì¬ ì ì‘ì¦ ëŒ€ë¹„ 1ì°¨ ì¹˜ë£Œ ì‹œì¥ì—ì„œì˜ ê¸°íšŒë¥¼ ì–´ë–»ê²Œ ì „ë§í•˜ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Johanna Mercier: Chief Commercial & Corporate Affairs Officer Sure, Tyler, I'll take that one. It's Johanna. So post ASCENT-04 presentation at ASCO last June, that's when we started actually seeing a little bit more spontaneous use of Trodelvy, both in the first-line setting, but also strengthening our position -- our leadership position in the second-line setting as well. So that's been kind of building. Obviously, that spontaneous use. There's no promotion against first line. There's only education from our medical team, field teams around the data publications in the New England Journal of Medicine and you highlighted as well, the NCCN guidelines. We are -- Trodelvy is now the only ADC that is recommended both in first-line PD-L1-positive and PD-L1-negative metastatic TNBC as well as second-line setting. So we're excited about that and the impact it can have on patients because this disease is such an aggressive form of breast cancer. To your market opportunity, it's about double or so. If you think about second line setting into the first-line setting. There's about 10,000-or-so women in the first-line setting that are looking for care and really an opportunity for Trodelvy to have an impact here both in PD-L1 negative and PD-L1 positive with pembro. The other opportunity, of course, if you think about it is in DOT, your duration of treatment basically doubles, right? Second-line setting, because of the aggressiveness of this disease is 4 to 5 months. And so therefore, as you think about first line, it's about double, it's 9 to 10 months, which gives a little bit more hope to these women. So definitely an important advancement in triple-negative breast cancer with Trodelvy, as the lead.</td><td>**Johanna Mercier:** ë„¤, ì œê°€ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì¡°ì•ˆë‚˜ì…ë‹ˆë‹¤. ì§€ë‚œ 6ì›” ASCOì—ì„œ ASCENT-04 ë°ì´í„°ë¥¼ ë°œí‘œí•œ ì´í›„ë¶€í„° ì‹¤ì œë¡œ íŠ¸ë¡œë¸ë¹„ì˜ ìë°œì  ì‚¬ìš©ì´ ì¡°ê¸ˆì”© ì¦ê°€í•˜ê¸° ì‹œì‘í–ˆìŠµë‹ˆë‹¤. 1ì°¨ ì¹˜ë£Œ(first-line) ì„¸íŒ…ì—ì„œë„ ê·¸ë ‡ê³ , 2ì°¨ ì¹˜ë£Œ(second-line) ì„¸íŒ…ì—ì„œ ì €í¬ì˜ ë¦¬ë”ì‹­ í¬ì§€ì…˜ì„ ë”ìš± ê°•í™”í•˜ëŠ” ì¸¡ë©´ì—ì„œë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ì´ëŸ° íë¦„ì´ ê³„ì† í˜•ì„±ë˜ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ì´ê²ƒì€ ìë°œì  ì‚¬ìš©ì…ë‹ˆë‹¤. 1ì°¨ ì¹˜ë£Œì— ëŒ€í•œ í”„ë¡œëª¨ì…˜ í™œë™ì€ ì—†ìŠµë‹ˆë‹¤. ì €í¬ ë©”ë””ì»¬ íŒ€ê³¼ í•„ë“œ íŒ€ì´ ë‰´ì‰ê¸€ëœë“œ ì˜í•™ì €ë„(New England Journal of Medicine)ì— ê²Œì¬ëœ ë°ì´í„°ì™€ ë§ì”€í•˜ì‹  NCCN ê°€ì´ë“œë¼ì¸ì„ ì¤‘ì‹¬ìœ¼ë¡œ êµìœ¡ í™œë™ë§Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ TrodelvyëŠ” 1ì°¨ ì¹˜ë£Œì—ì„œ PD-L1 ì–‘ì„±ê³¼ PD-L1 ìŒì„± ì „ì´ì„± TNBC ëª¨ë‘ì—ì„œ, ê·¸ë¦¬ê³  2ì°¨ ì¹˜ë£Œ í™˜ê²½ì—ì„œë„ ê¶Œê³ ë˜ëŠ” ìœ ì¼í•œ ADCì…ë‹ˆë‹¤. ì´ ì§ˆí™˜ì´ ë§¤ìš° ê³µê²©ì ì¸ í˜•íƒœì˜ ìœ ë°©ì•”ì´ê¸° ë•Œë¬¸ì—, í™˜ìë“¤ì—ê²Œ ë¯¸ì¹  ìˆ˜ ìˆëŠ” ì˜í–¥ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì‹œì¥ ê¸°íšŒ ì¸¡ë©´ì—ì„œ ë³´ë©´, ê·œëª¨ê°€ ì•½ ë‘ ë°° ì •ë„ì…ë‹ˆë‹¤. 2ì°¨ ì¹˜ë£Œ í™˜ê²½ì—ì„œ 1ì°¨ ì¹˜ë£Œ í™˜ê²½ìœ¼ë¡œ í™•ëŒ€ë˜ëŠ” ê²ƒì„ ìƒê°í•´ë³´ì‹œë©´, 1ì°¨ ì¹˜ë£Œ í™˜ê²½ì—ëŠ” ì•½ 1ë§Œ ëª… ì •ë„ì˜ ì—¬ì„± í™˜ìë“¤ì´ ì¹˜ë£Œë¥¼ í•„ìš”ë¡œ í•˜ê³  ìˆìœ¼ë©°, Trodelvyê°€ PD-L1 ìŒì„±ê³¼ pembrolizumabê³¼ ë³‘ìš©í•˜ëŠ” PD-L1 ì–‘ì„± ëª¨ë‘ì—ì„œ ì˜í–¥ì„ ë¯¸ì¹  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤.<br><br>ë˜ ë‹¤ë¥¸ ê¸°íšŒëŠ” ì¹˜ë£Œ ê¸°ê°„(DOT, duration of treatment) ì¸¡ë©´ì¸ë°, ê¸°ë³¸ì ìœ¼ë¡œ ì¹˜ë£Œ ê¸°ê°„ì´ ë‘ ë°°ë¡œ ëŠ˜ì–´ë‚˜ê²Œ ë©ë‹ˆë‹¤. 2ì°¨ ì¹˜ë£Œ í™˜ê²½ì—ì„œëŠ” ì§ˆë³‘ì˜ ê³µê²©ì„± ë•Œë¬¸ì— 4~5ê°œì›” ì •ë„ì…ë‹ˆë‹¤. ë”°ë¼ì„œ 1ì°¨ ì¹˜ë£Œë¥¼ ìƒê°í•´ë³´ë©´ ì•½ ë‘ ë°°ì¸ 9~10ê°œì›” ì •ë„ë¡œ, ì´ëŠ” í™˜ìë¶„ë“¤ì—ê²Œ ì¡°ê¸ˆ ë” í¬ë§ì„ ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ Trodelvyë¥¼ ì„ ë‘ë¡œ í•œ ì‚¼ì¤‘ìŒì„± ìœ ë°©ì•” ì¹˜ë£Œì—ì„œ ë¶„ëª…íˆ ì¤‘ìš”í•œ ì§„ì „ì´ë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Our last question comes from Courtney Breen at Bernstein.</td><td>**Operator:** ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ ë²ˆìŠ¤íƒ€ì¸ì˜ ì½”íŠ¸ë‹ˆ ë¸Œë¦°ìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Courtney Breen: Bernstein Institutional Services LLC, Research Division I'm going to point us back to Yeztugo again and just kind of really trying to get our arms around the 2026 guide. By our calculations, you have to believe that there's no growth in new patient starts compared to what we've seen kind of through January for the rest of this year, and a more than 10% price cut year-on-year to kind of get to that $800 million guide for 2026. Given that, should we be thinking about the $800 million as a floor or as kind of a guide for 2026?</td><td>**Courtney Breen:** ì˜ˆì¦ˆíˆ¬ê³ ë¡œ ë‹¤ì‹œ ëŒì•„ê°€ì„œ 2026ë…„ ê°€ì´ë˜ìŠ¤ë¥¼ ì •í™•íˆ ì´í•´í•˜ê³ ì í•©ë‹ˆë‹¤. ì €í¬ ê³„ì‚°ìœ¼ë¡œëŠ”, ì˜¬í•´ ë‚˜ë¨¸ì§€ ê¸°ê°„ ë™ì•ˆ 1ì›”ê¹Œì§€ í™•ì¸ëœ ìˆ˜ì¤€ ëŒ€ë¹„ ì‹ ê·œ í™˜ì ì¦ê°€ê°€ ì „í˜€ ì—†ê³ , ì „ë…„ ëŒ€ë¹„ 10% ì´ìƒì˜ ê°€ê²© ì¸í•˜ê°€ ìˆì–´ì•¼ 2026ë…„ 8ì–µ ë‹¬ëŸ¬ ê°€ì´ë˜ìŠ¤ì— ë„ë‹¬í•  ìˆ˜ ìˆëŠ” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ë¥¼ ê°ì•ˆí•  ë•Œ, 8ì–µ ë‹¬ëŸ¬ë¥¼ ìµœì €ì„ (floor)ìœ¼ë¡œ ë´ì•¼ í• ê¹Œìš”, ì•„ë‹ˆë©´ 2026ë…„ ê°€ì´ë˜ìŠ¤ë¡œ ë´ì•¼ í• ê¹Œìš”?</td></tr>
<tr><td>Johanna Mercier: Chief Commercial & Corporate Affairs Officer Thanks, Courtney, for your question. I'm not sure I'm tracking your modeling because we are definitely assuming continued strong momentum for Yeztugo. I know all of you are looking at weekly. We're obviously looking at weekly, but we're also looking at monthly and making sure that we're creating new growth numbers month-to-month. And so we do see that as an acceleration of our growth as we go into 2026. A lot of those pieces are supported by making sure that we're adding new patients on Yeztugo, new individuals on Yeztugo and also bringing back people for their second injection. So those two pieces are considered in that guidance. And I think we're excited thus far about where we stand today with Yeztugo and all the pieces are coming together. We are just making sure that as much as the access is strong right now, and I'm really proud of the team that pulled that through. We also need to pull it through at an account level. So we're doing that account by account and making sure people are navigating the logistics of an injectable in the oral market and all of that takes a little bit of time. But the intent is we expect strong, consistent durable growth for the long term for Yeztugo. So we're excited about what's to come. And I guess DTC will also have a pretty big impact, we believe, to bring people in, asking and talking about Yeztugo.</td><td>**Johanna Mercier:** ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤, Courtney. ëª¨ë¸ë§ ë¶€ë¶„ì´ ì •í™•íˆ ì–´ë–¤ ë¶€ë¶„ì¸ì§€ ì˜ íŒŒì•…ì´ ì•ˆ ë˜ëŠ”ë°ìš”, ì €í¬ëŠ” ë¶„ëª…íˆ Yeztugoì˜ ê°•ë ¥í•œ ëª¨ë©˜í…€ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ëŸ¬ë¶„ ëª¨ë‘ ì£¼ê°„ ë°ì´í„°ë¥¼ ë³´ê³  ê³„ì‹  ê±¸ ì•Œê³  ìˆê³ , ì €í¬ë„ ë‹¹ì—°íˆ ì£¼ê°„ìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤ë§Œ, ë™ì‹œì— ì›”ê°„ ë°ì´í„°ë„ ë³´ë©´ì„œ ë§¤ì›” ìƒˆë¡œìš´ ì„±ì¥ ìˆ˜ì¹˜ë¥¼ ë§Œë“¤ì–´ë‚´ê³  ìˆëŠ”ì§€ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ 2026ë…„ìœ¼ë¡œ ê°€ë©´ì„œ ì„±ì¥ì´ ê°€ì†í™”ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ì¥ì˜ ë§ì€ ë¶€ë¶„ì€ Yeztugoì— ì‹ ê·œ í™˜ìë¥¼ ì¶”ê°€í•˜ê³ , ìƒˆë¡œìš´ ì‚¬ìš©ìë¥¼ í™•ë³´í•˜ë©°, ë‘ ë²ˆì§¸ íˆ¬ì—¬ë¥¼ ìœ„í•´ ì¬ë°©ë¬¸í•˜ëŠ” í™˜ìë“¤ì„ í™•ë³´í•˜ëŠ” ê²ƒìœ¼ë¡œ ë’·ë°›ì¹¨ë©ë‹ˆë‹¤. ì´ ë‘ ê°€ì§€ ìš”ì†Œê°€ ëª¨ë‘ ê°€ì´ë˜ìŠ¤ì— ë°˜ì˜ë˜ì–´ ìˆìŠµë‹ˆë‹¤. í˜„ì¬ê¹Œì§€ Yeztugoì˜ ìƒí™©ê³¼ ëª¨ë“  ìš”ì†Œë“¤ì´ ì˜ ë§ë¬¼ë ¤ ê°€ê³  ìˆëŠ” ê²ƒì— ëŒ€í•´ ë§¤ìš° ê³ ë¬´ì ìœ¼ë¡œ ìƒê°í•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì ‘ê·¼ì„±ì´ ë§¤ìš° ê°•ë ¥í•œ ìƒí™©ì´ê³ , ì´ë¥¼ ì„±ê³µì ìœ¼ë¡œ ì´ëŒì–´ë‚¸ íŒ€ì— ëŒ€í•´ ì •ë§ ìë‘ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì´ì œ ìš°ë¦¬ëŠ” ì´ê²ƒì„ ê³„ì • ë‹¨ìœ„ì—ì„œë„ í™•ì‹¤íˆ ì‹¤í˜„í•´ì•¼ í•©ë‹ˆë‹¤. ê·¸ë˜ì„œ ê³„ì •ë³„ë¡œ í•˜ë‚˜í•˜ë‚˜ ì§„í–‰í•˜ë©´ì„œ, ê²½êµ¬ìš© ì‹œì¥ì—ì„œ ì£¼ì‚¬ì œì˜ ë¬¼ë¥˜ë¥¼ ì˜ ì²˜ë¦¬í•  ìˆ˜ ìˆë„ë¡ í•˜ê³  ìˆìœ¼ë©°, ì´ ëª¨ë“  ê²ƒì—ëŠ” ì•½ê°„ì˜ ì‹œê°„ì´ í•„ìš”í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ìš°ë¦¬ì˜ ì˜ë„ëŠ” ëª…í™•í•©ë‹ˆë‹¤. Yeztugoê°€ ì¥ê¸°ì ìœ¼ë¡œ ê°•ë ¥í•˜ê³  ì¼ê´€ë˜ë©° ì§€ì† ê°€ëŠ¥í•œ ì„±ì¥ì„ ì´ë£° ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì•ìœ¼ë¡œì˜ ì „ë§ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  DTC(ì†Œë¹„ì ì§ì ‘ ê´‘ê³ )ë„ ì‚¬ëŒë“¤ì´ Yeztugoì— ëŒ€í•´ ë¬¸ì˜í•˜ê³  ì´ì•¼ê¸°í•˜ë„ë¡ ìœ ë„í•˜ëŠ” ë° ìƒë‹¹íˆ í° ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ë¯¿ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: That completes the time that we have for questions. I'll now invite Dan to share any closing remarks.</td><td>**Operator:** ì§ˆì˜ì‘ë‹µ ì‹œê°„ì´ ëª¨ë‘ ì¢…ë£Œë˜ì—ˆìŠµë‹ˆë‹¤. ì´ì œ Danê»˜ì„œ ë§ˆë¬´ë¦¬ ë§ì”€ì„ í•´ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Chairman & CEO: Thanks, everybody. First of all, let me thank the Gilead teams again. It's such a pleasure to work with them, and to see them deliver these really strong full year performance measures, and reinforcing that this is a time of impact and growth for the company. Our performance from last year gives us a really strong foundation for the coming year where we have a lot to deliver for the patients and communities we serve. Coming off of a year where we had just a really strong Yeztugo launch, as Johanna mentioned several key launch indicators have exceeded our expectations. We are firmly committed to continuing to drive that launch. But in addition, we have 4 potential launches this year and 5 pivotal Phase III readouts across all 3 therapeutic areas, HIV, oncology, liver disease. So you can expect us to show the same strong commercial and clinical execution you've seen in the past and disciplined focus on expense management, as you've seen from us quarter after quarter. And with no major LOEs until 2036, the next 10 years and a really proactive approach to business development. Gilead's business is secure, growing and with the potential for much more to come. So thanks again for your time today. We look forward to keeping you informed on our progress. And as usual, if you have any follow-up questions, our Investor Relations team is very happy to support you with the answers to your questions. Thank you, everybody. Have a good rest of your day.</td><td>**Chairman & CEO:** ê°ì‚¬í•©ë‹ˆë‹¤. ìš°ì„  ê¸¸ë¦¬ì–´ë“œ íŒ€ë“¤ì—ê²Œ ë‹¤ì‹œ í•œë²ˆ ê°ì‚¬ì˜ ë§ì”€ì„ ë“œë¦½ë‹ˆë‹¤. ì´ë“¤ê³¼ í•¨ê»˜ ì¼í•˜ëŠ” ê²ƒì€ ì •ë§ í° ê¸°ì¨ì´ë©°, ì´ë ‡ê²Œ ê°•ë ¥í•œ ì—°ê°„ ì‹¤ì ì„ ë‹¬ì„±í•˜ëŠ” ëª¨ìŠµì„ ë³´ëŠ” ê²ƒ, ê·¸ë¦¬ê³  ì´ê²ƒì´ íšŒì‚¬ì˜ ì„íŒ©íŠ¸ì™€ ì„±ì¥ì˜ ì‹œê¸°ì„ì„ ì¬í™•ì¸í•˜ëŠ” ê²ƒì€ ë§¤ìš° ëœ»ê¹ŠìŠµë‹ˆë‹¤. ì‘ë…„ì˜ ì‹¤ì ì€ ì˜¬í•´ë¥¼ ìœ„í•œ íƒ„íƒ„í•œ ê¸°ë°˜ì´ ë˜ì–´ì£¼ê³  ìˆìœ¼ë©°, ìš°ë¦¬ê°€ ì„œë¹„ìŠ¤ë¥¼ ì œê³µí•˜ëŠ” í™˜ìë“¤ê³¼ ì§€ì—­ì‚¬íšŒë¥¼ ìœ„í•´ ë§ì€ ê²ƒë“¤ì„ ì‹¤í˜„í•´ì•¼ í•  í•œ í•´ê°€ ë  ê²ƒì…ë‹ˆë‹¤. ì‘ë…„ì— ì˜ˆì¦ˆíˆ¬ê³ ì˜ ë§¤ìš° ì„±ê³µì ì¸ ì¶œì‹œê°€ ìˆì—ˆê³ , ìš”í•œë‚˜ê°€ ì–¸ê¸‰í–ˆë“¯ì´ ì—¬ëŸ¬ í•µì‹¬ ì¶œì‹œ ì§€í‘œë“¤ì´ ìš°ë¦¬ì˜ ê¸°ëŒ€ì¹˜ë¥¼ ë›°ì–´ë„˜ì—ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ ì¶œì‹œë¥¼ ì§€ì†ì ìœ¼ë¡œ ì¶”ì§„í•˜ëŠ” ë° í™•ê³ íˆ ì „ë…í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ì— ë”í•´, ì˜¬í•´ëŠ” 4ê°œì˜ ì ì¬ì  ì‹ ì œí’ˆ ì¶œì‹œì™€ HIV, ì¢…ì–‘í•™, ê°„ì§ˆí™˜ ë“± 3ê°œ ì¹˜ë£Œ ì˜ì—­ ì „ë°˜ì— ê±¸ì³ 5ê°œì˜ ì¤‘ì¶”ì ì¸ 3ìƒ ì„ìƒì‹œí—˜ ê²°ê³¼ ë°œí‘œê°€ ì˜ˆì •ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì—¬ëŸ¬ë¶„ê»˜ì„œëŠ” ì €í¬ê°€ ê³¼ê±°ì— ë³´ì—¬ë“œë ¸ë˜ ê²ƒê³¼ ë™ì¼í•œ ê°•ë ¥í•œ ì˜ì—… ë° ì„ìƒ ì‹¤í–‰ë ¥, ê·¸ë¦¬ê³  ë¶„ê¸°ë§ˆë‹¤ ë³´ì—¬ë“œë¦° ë°” ìˆëŠ” ì² ì €í•œ ë¹„ìš© ê´€ë¦¬ë¥¼ ê¸°ëŒ€í•˜ì…”ë„ ì¢‹ìŠµë‹ˆë‹¤. 2036ë…„ê¹Œì§€ ì£¼ìš” íŠ¹í—ˆ ë§Œë£Œê°€ ì—†ëŠ” í–¥í›„ 10ë…„, ê·¸ë¦¬ê³  ë§¤ìš° ì ê·¹ì ì¸ ì‚¬ì—… ê°œë°œ ì ‘ê·¼ ë°©ì‹ì„ í†µí•´ ê¸¸ë¦¬ì–´ë“œì˜ ì‚¬ì—…ì€ ì•ˆì •ì ì´ê³  ì„±ì¥í•˜ê³  ìˆìœ¼ë©°, ì•ìœ¼ë¡œ í›¨ì”¬ ë” ë§ì€ ê°€ëŠ¥ì„±ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì‹œê°„ ë‚´ì£¼ì…”ì„œ ë‹¤ì‹œ í•œë²ˆ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. ì €í¬ì˜ ì§„í–‰ ìƒí™©ì„ ê³„ì†í•´ì„œ ì•Œë ¤ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í‰ì†Œì™€ ê°™ì´ ì¶”ê°€ ì§ˆë¬¸ì´ ìˆìœ¼ì‹œë©´ íˆ¬ìì ê´€ê³„íŒ€ì´ ê¸°êº¼ì´ ë‹µë³€ì„ ë„ì™€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê°ì‚¬í•©ë‹ˆë‹¤. ì¢‹ì€ í•˜ë£¨ ë³´ë‚´ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># Gilead Sciences ì‹¤ì  ë°œí‘œ ì£¼ìš” ìš”ì•½<br><br>## í•µì‹¬ ë‚´ìš©<br><br>â€¢ **Yeztugo ì¶œì‹œ ì„±ê³¼**: HIV ì˜ˆë°©ì œ Yeztugoì˜ 2026ë…„ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ $800M ì œì‹œ. 90% ë³´í—˜ ì»¤ë²„ë¦¬ì§€ ë‹¬ì„±(ëŒ€ë¶€ë¶„ $0 ë³¸ì¸ë¶€ë‹´), ì£¼ìš” ì¶œì‹œ ì§€í‘œë“¤ì´ ì˜ˆìƒì¹˜ ì¶©ì¡± ë˜ëŠ” ì´ˆê³¼. 6ê°œì›” íˆ¬ì—¬ ì œí˜•ì˜ ì°¨ë³„í™”ëœ í”„ë¡œí•„ë¡œ ì¥ê¸°ì ìœ¼ë¡œ ì‹œì¥ ë¦¬ë”ì‹­ í™•ë³´ ëª©í‘œ. ë‹¤ë§Œ ì£¼ì‚¬ì œë¥¼ ê²½êµ¬ì œ ì¤‘ì‹¬ ì‹œì¥ì— ë„ì…í•˜ëŠ” ë¬¼ë¥˜ì  ê³¼ì œë¡œ ê³„ì •ë³„ ì „í™˜ì— ì‹œê°„ ì†Œìš” ì¤‘<br><br>â€¢ **íŒŒì´í”„ë¼ì¸ ëª¨ë©˜í…€**: 2027ë…„ê¹Œì§€ ìµœëŒ€ 10ê°œ ì‹ ì œí’ˆ ì¶œì‹œ ì˜ˆì •(2026ë…„ 4ê°œ í¬í•¨), 5ê°œ Phase III ì„ìƒê²°ê³¼ ë°œí‘œ ì˜ˆì •. HIV, ì¢…ì–‘í•™, ê°„ì§ˆí™˜ ì „ ì˜ì—­ì—ì„œ ê°•ë ¥í•œ íŒŒì´í”„ë¼ì¸ ë³´ìœ . íŠ¹íˆ anito-cel(4ì°¨ ë‹¤ë°œì„±ê³¨ìˆ˜ì¢…, 2026ë…„ í•˜ë°˜ê¸° ì¶œì‹œ ì˜ˆìƒ, $3.5B ì‹œì¥), Trodelvy(ìê¶ë‚´ë§‰ì•” 2ì°¨ ì¹˜ë£Œ Phase III ê²°ê³¼ 2026ë…„ í•˜ë°˜ê¸° ì˜ˆìƒ), ì—° 1íšŒ íˆ¬ì—¬ lenacapavir PrEP(2028ë…„ ì¶œì‹œ ê°€ëŠ¥) ë“±ì´ ì£¼ëª©<br><br>â€¢ **ì¬ë¬´ ê±´ì „ì„± ë° ì „ëµ**: 2036ë…„ê¹Œì§€ ì£¼ìš” íŠ¹í—ˆë§Œë£Œ ì—†ëŠ” ì•ˆì •ì  ì‚¬ì—… ê¸°ë°˜ í™•ë³´. ì—°ê°„ ì•½ $1B ê·œëª¨ì˜ ì´ˆê¸°ë‹¨ê³„ íŒŒíŠ¸ë„ˆì‹­ ì§€ì† ì¶”ì§„</p>
    <hr style="margin:50px 0;">
    
</body></html>